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ABSTRACT 
 
 Skeletal muscle is composed of post-mitotic multinucleated myofibers. During 
embryonic skeletal myogenesis, cells in somites commit to myogenic lineage and differentiate 
into myoblasts, which then fuse to form multinucleated myofibers. Post-natal growth, repair, and 
maintenance of skeletal muscle are dependent on muscle satellite cells, which in response to 
stimuli differentiate and fuse to form new myofibers. Developmental or post-natal failure of 
skeletal myogenesis results in diverse muscular dystrophies and atrophies, largely impairing life 
quality and sometimes directly causing death. The myogenic process is guided by various 
environmental cues and regulated by distinct signaling pathways, resulting in the activation of 
specific transcription factors and subsequent reprogramming of gene expression. The mammalian 
target of rapamycin (mTOR) is a Ser/Thr kinase that controls a wide spectrum of cellular and 
developmental processes including regulation of skeletal myogenesis. In my dissertation work, I 
investigate the mechanisms of myogenic regulation, with a focus on the signaling network 
assembled by mTOR. 
Various processes of skeletal muscle differentiation and remodeling were known to be 
inhibited by the mTOR-specific inhibitor, rapamycin. In cultured myoblasts, the target of 
rapamycin – mTOR – had been reported to regulate differentiation at different stages through 
distinct mechanisms, including one that is independent of mTOR kinase activity. However, there 
had been no in vivo evidence to validate those mTOR myogenic mechanisms in vitro. In Chapter 
II, I show that rapamycin impairs injury-induced muscle regeneration. To validate the role of 
mTOR with genetic evidence and to probe the mechanism of mTOR function, I have generated 
and characterized transgenic mice expressing two mutants of mTOR under the control of human 
skeletal actin (HSA) promoter – rapamycin-resistant (RR) and RR/kinase-inactive (RR/KI) 
mTOR. My results show that muscle regeneration in rapamycin-administered mice is restored by 
RR-mTOR expression. In the RR/KI-mTOR mice, nascent myofiber formation during the early 
phase of regeneration proceeds in the presence of rapamycin, but growth of the regenerating 
myofibers is blocked by rapamycin. Igf2 mRNA levels increase drastically during early 
regeneration, which is sensitive to rapamycin in WT muscles but partially resistant to rapamycin 
in both RR- and RR/KI-mTOR muscles, consistent with mTOR regulation of Igf2 expression in a 
kinase-independent manner. Furthermore, systemic ablation of S6K1, a target of mTOR kinase, 
results in impaired muscle growth but normal nascent myofiber formation during regeneration. 
Therefore, mTOR regulates muscle regeneration through kinase-independent and kinase-
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dependent mechanisms at the stages of nascent myofiber formation and myofiber growth, 
respectively. 
MicroRNAs have emerged as key regulators of skeletal myogenesis, but our knowledge 
of the identity of the myogenic miRNAs and their targets remains limited. In Chapter III, I 
describe the identification and characterization of a novel myogenic microRNA – miR-125b. I 
find that the levels of miR-125b decline during myogenesis, and that miR-125b negatively 
modulates myoblast differentiation in culture and muscle regeneration in mice. My results 
identify the insulin-like growth factor 2 (Igf2), a critical regulator of skeletal myogenesis, as a 
direct and major target of miR-125b in both myocytes and regenerating muscles, revealing for the 
first time a microRNA mechanism controlling IGF-II expression. In addition, I provide evidence 
suggesting that miR-125b biogenesis is negatively controlled by kinase-independent mTOR 
signaling both in vitro and in vivo, as a part of a dual mechanism by which mTOR regulates the 
production of IGF-II – a master switch governing the initiation of skeletal myogenesis.  
In Chapter IV, in collaboration with a former graduate student in the lab, Dr. Yuting Sun, 
I find that expression of another microRNA, miR-1, is regulated by mTOR both in differentiating 
myoblasts and in mouse regenerating skeletal muscle. We have found that mTOR controls 
MyoD-dependent transcription of miR-1 through its upstream enhancer, most likely by regulating 
MyoD protein stability. Moreover, a functional pathway downstream of mTOR and miR-1 is 
delineated, in which miR-1 suppression of HDAC4 results in production of follistatin and 
subsequent myocyte fusion. Collective evidence strongly suggests that follistatin is the long-
sought mTOR-regulated fusion factor. In summary, these findings unravel yet another link 
between mTOR and microRNA biogenesis, and identify an mTOR-miR-1-HDAC4-follistatin 
pathway that regulates myocyte fusion during myoblast differentiation in vitro and skeletal 
muscle regeneration in vivo. 
The importance of the canonical mTOR complex 1 signaling components, including 
raptor, S6K1, and Rheb, had been suggested in muscle maintenance, growth, and metabolism. 
However, the role of those components in myogenic differentiation is not entirely clear. In 
Chapter V, I report the investigation of the functions of raptor, S6K1, and Rheb in the 
differentiation of C2C12 mouse myoblasts. I find that although mTOR knockdown severely 
impairs myogenic differentiation as expected, the knockdown of raptor, as well as Rheb, 
enhances differentiation. Consistent with a negative role for these proteins in myogenesis, over-
expression of raptor or Rheb inhibits C2C12 differentiation. On the other hand, neither 
knockdown nor overexpression of S6K1 has any effect. Moreover, the enhanced differentiation 
elicited by raptor or Rheb knockdown is accompanied by increased Akt activation, elevated IRS1 
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protein levels, and decreased Ser307 (human Ser312) phosphorylation on IRS1. Finally, IRS1 
knockdown eliminated the enhancement in differentiation elicited by raptor or Rheb knockdown, 
suggesting that IRS1 is a critical mediator of the myogenic functions of raptor and Rheb. In 
conclusion, the Rheb-mTOR/raptor pathway negatively regulates myogenic differentiation by 
suppressing IRS1-PI3K-Akt signaling. These findings underscore the versatility of mTOR 
signaling in biological regulations and implicate the existence of novel mTOR complexes and/or 
signaling mechanism in skeletal myogenesis. 
Lastly in Appendix B, I document the effort of an RNAi screening to search for novel 
myogenic regulators among secreted factors. A few distinct groups of cytokines and chemokines 
are found to either enhance or suppress myoblast differentiation and fusion when knocked down, 
suggesting that they may regulate myogenesis. Future characterization of these candidates will 
include assessing knockdown efficiency, identifying the exact processes that they regulate, and 
dissecting their regulatory pathways. 
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CHAPTER I. INTRODUCTION 
 
I.1. Skeletal Myogenesis 
 
I.1.1. Embryonic skeletal myogenesis and myogenic transcription program 
During embryonic skeletal myogenesis, cells in somites commit to myogenic lineage and 
differentiate into myoblasts, which then fuse to form multinucleated myofibers (Buckingham, 
2001). In response to signals from the notochord and the neural tube, the somites differentiate and 
subdivide to give rise to the dermomyotome, which is subdivided into the hypaxial and the 
epaxial dermomyotome, becoming the source of cells for the lateral trunk musculature and deep 
back musculature, respectively (Parker et al., 2003). It is a highly coordinated process where 
various environmental cues and signaling pathways integrate to regulate the formation of skeletal 
muscle (Lassar and Munsterberg, 1994; Naya and Olson, 1999). The basic helix-loop-helix 
myogenic regulatory factors (MRFs) have critical roles in skeletal muscle development. The 
primary MRFs, MyoD and Myf5, are required at the determination step for commitment of the 
proliferating somatic cells to the myogenic lineage. The committed cells (myoblasts) can 
proliferate and further differentiate into myocytes and mature into myofibers under the action of 
the secondary MRFs, myogenin and MRF4 (Berkes and Tapscott, 2005). The myocyte enhancer 
factor-2 (MEF2) family of transcription factors is also involved in the activation of muscle-
specific gene expression. Together with the MRFs, these transcription factors are responsible for 
coordinating muscle-specific gene expression in the developing embryo (Berkes and Tapscott, 
2005).  
 
I.1.2. Muscle regeneration and mouse models 
One of the adult skeletal muscle remodeling processes – regeneration after muscle 
damage – largely recapitulates embryonic myogenesis. Satellite cells, the stem cells of adult 
skeletal muscle, reside beneath the basal lamina of adult skeletal muscle, closely juxtaposed 
against the muscle fibers. Satellite cells arise around 17dpc during mouse embryogenesis, and 
make up 2-7% of the nuclei associated with a particular myofiber (Hawke and Garry, 2001). 
Satellite cells are normally mitotically quiescent but are activated and re-enter the cell cycle in 
response to stress induced by weight-bearing exercise or trauma, including injury. The activated 
satellite cells, or, myogenic precursor cells (mpcs), undergo multiple rounds of division prior to 
fusion with the existing or to form new myofibers (Hawke and Garry, 2001). Skeletal muscle 
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regeneration in mouse serves as a nice model to study skeletal myogenesis in vivo, as it shares a 
large extent of regulatory mechanisms with embryonic myogenesis. 
 
I.1.3. Myoblast differentiation and culture models 
Cultured myoblasts undergo differentiation into multinucleated myotubes upon growth 
factor withdrawal, providing an in vitro system that has been powerful for the delineation of 
molecular mechanisms regulating skeletal myogenesis. The muscle satellite cells can be isolated 
and cultured in vitro, serving as a useful tool to study physiologically relevant functions of 
muscle in vitro. Also, the well-established mouse C2C12 myoblast cell line is one of the most 
commonly used systems for in vitro myoblast differentiation study. 
 
I.2. Mammalian Target of Rapamycin (mTOR) 
mTOR, the mammalian target of rapamycin, is a Ser/Thr kinase that belongs to the 
phosphoinositide 3-kinase (PI3K)-related protein kinases (PIKK) family, which comprises large 
proteins that enable organisms to cope with metabolic, environmental and genetic stresses (Zoncu 
et al., 2011). As its name indicated, TOR was first discovered in yeast as the specific cellular 
target of rapamycin, a macrolide isolated from the soil bacterium Streptomyces hygroscopicus. 
Rapamycin acts by forming an inhibitory complex with its intracellular receptor, the FK506-
binding protein, FKBP12, which binds a region in the C terminus of TOR proteins termed FRB 
(FKB12–rapamycin binding) domain, thereby inhibiting TOR activity (Chen et al., 1995; Choi et 
al., 1996).  
The TOR protein is highly conserved from yeast to mammals (Schmelzle and Hall, 
2000). Shortly after discovery of yeast TOR, its mammalian ortholog was independently cloned 
and identified by four groups and named FRAP (FKBP–rapamycin-associated protein; (Brown et 
al., 1994)), RAFT1 (rapamycin and FKBP target (Sabatini et al., 1994)), RAPT1 (rapamycin 
target; (Chiu et al., 1994)) and mTOR (Sabers et al., 1995). mTOR deletion is mice caused early 
embryonic lethality (Gangloff et al., 2004; Murakami et al., 2004), unarguably demonstrating its 
essentiality. It is now known that mTOR senses cellular nutrients and energy levels and 
orchestrates a wide spectrum of cellular processes, including cell growth, differentiation, 
proliferation, apoptosis, autophage, etc (Zoncu et al., 2011). Its inhibitor rapamycin has been 
demonstrated with potent immunosuppressive and anti-proliferative properties and has since been 
shown to prolong life of mice and might also be useful in the treatment of certain cancers. 
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I.2.1. mTORC1 
mTOR nucleates two distinct complexes, mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2) (Fig. I.1). mTORC1 is uniquely defined by its scaffolding protein 
regulatory-associated protein of mTOR (raptor). It also includes negative regulators 40 kDa Pro-
rich Akt substrate (PRAS40) and DEP domain-containing mTOR-interacting protein (Deptor), as 
well as a positive regulator mammalian lethal with SEC13 protein 8 (mLST8). mTORC1 is the 
rapamycin sensitive complex (Kim et al., 2002) that phospohrylates S6 kinase 1 (S6K1) and 
eIF4E-binding protein 1 (4E-BP1) to control translation. It integrates nutrient signals that are 
generated by amino acids, growth factors such as insulin and insulin-like growth factors (IGFs), 
energy signals that act through AMP-activated kinase (AMPK) and various stressors including 
hypoxia and DNA damage. Many of these signals integrate at tuberous sclerosis 1 (TSC1)/TSC2 
complex, which is the GAP towards Ras homologue enriched in brain (Rheb) required for 
mTORC1 activation (Zoncu et al., 2011). 
 
I.2.2. mTORC2 
mTORC2 contains its specific scaffold rapamycin-insensitive companion of mTOR 
(rictor), positive regulators protein observed with rictor (Protor) which helps complex assembly, 
and mammalian stress-activated map kinase-interacting protein 1 (mSIN1) which may help 
membrane targeting. It also shares Deptor and mLST8 with mTORC1. mTORC2 is sensitive to 
prolonged rapamycin treatment in a subset of tissues and cell types (Sarbassov et al., 2006; 
Sarbassov et al., 2005). Growth factor receptors activate mTORC2 near the plasma membrane, 
where mTORC2 may be recruited through binding of mSIN1. Because of its role in 
phosphorylating and activating Akt, mTORC2 forms a core component of the phosphoinositide 3-
kinase (PI3K) pathway and regulates cell cytoskeleton organization among other functions 
(Zoncu et al., 2011). 
 
I.3. mTOR as a Master Regulator of Skeletal Myogenesis 
 Besides regulating various aspects of skeletal muscle physiology including metabolic 
homeostasis, muscle hypertrophy and atrophy (Frost and Lang, 2011; Glass, 2010; Hornberger, 
2011; Rivas et al., 2009), mTOR is also a master regulator of skeletal myogenesis. 
 
I.3.1. Rapamycin sensitivity of myoblast differentiation 
It has been widely reported that rapamycin blocks myoblast differentiation in mouse 
C2C12 cells (Conejo et al., 2002; Conejo et al., 2001; Cuenda and Cohen, 1999; Erbay and Chen, 
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2001; Hribal et al., 2003; Shu et al., 2002; Sumitani et al., 2002) and rat L6 cells (Apostolova et 
al., 2000; Coolican et al., 1997), although conflicting observations also exist (Canicio et al., 1998; 
Jayaraman and Marks, 1993). Convincing evidence came from our and others’ characterizations 
of C2C12 cells that stably express the mTOR mutant, RR (rapamycin-resistant)-mTOR: RR were 
able to fully differentiate in the presence of rapamycin (Erbay and Chen, 2001; Shu et al., 2002). 
This confirms the specificity of rapamycin, further solidifying the essential function of mTOR in 
myoblast differentiation.  
 
I.3.2. mTOR targets IGF-II during myogenic initiation and a secreted factor(s) during 
myocyte maturation.  
Interestingly, we further found that unlike RR-mTOR cells, the differentiation of C2C12 
cells stably expressing the RR/kinase-inactive (RR/KI)-mTOR stalled at the nascent myotube 
stage in the presence of rapamycin (Erbay and Chen, 2001). This suggests that mTOR kinase 
activity is dispensable for nascent myotube formation during myogenesis initiation, but is 
required for myotube maturation. This key observation reveals for the first time a surprisingly 
kinase-independent function for mTOR, and also suggests a biochemically separable two-stage 
fusion model for myoblast differentiation. Indeed, we found that IGF-II (insulin-like growth 
factor-II), a critical myogenic initiator, mediates mTOR’s kinase-independent function: mTOR 
regulates myogenesis initiation by controlling IGF-II transcription via a muscle enhancer (Erbay 
et al., 2003) (Fig. I.2).  
During the study of the second stage myocyte maturation where mTOR kinase activity is 
required, we found that conditional culture medium from mature myotubes was able to support 
the arrested RR/KI cells to differentiate into mature myotubes, suggesting that some mTOR 
kinase-regulated secreted factor(s) is responsible for second-stage fusion (Park and Chen, 2005) 
(Fig. I.2). These studies provide great insight into mTOR regulation of skeletal myogenesis, but 
immediately pose the following questions: is this elaborate two-stage regulatory mechanism only 
applicable to myoblast culture, or is it also true during in vivo myogenesis? What’s the mTOR 
regulated secreted factor(s) for myocyte maturation? My thesis chapter II and IV will describe the 
answers to these questions. 
 
I.3.3. The canonical mTOR signaling components in myogenesis and homeostasis regulation 
With the established functions of mTOR in myogenesis as well as the well-characterized 
mTOR signaling pathways regarding cell growth, one would wonder whether the same players 
are employed in the two systems. 
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Raptor. Skeletal muscle-specific inactivation of raptor, the mTORC1 specific component, 
revealed its critical role in the muscle homeostasis maintenance (Bentzinger et al., 2008). Raptor 
deleted muscle showed impaired oxidative capacity, increased glycogen stores, and decreased 
mitochondrial biogenesis, all of which are essential for life (Bentzinger et al., 2008). Not 
surprisingly, mice with skeletal muscle-specific deletion of mTOR showed severe myopathy, 
resulting in premature death (Risson et al., 2009). mTOR depletion also resulted in impaired 
oxidative metabolism, altered mitochondrial regulation and glycogen accumulation, and 
exacerbates the myopathic features in both slow oxidative and fast glycolytic muscles (Risson et 
al., 2009). This reinforced the essential role of mTOR in skeletal muscle development and 
metabolic homeostasis. Interestingly, mTOR was suggested to control dystrophin transcription in 
a cell-autonomous, rapamycin-resistant, and kinase-independent manner, where neither raptor nor 
rictor was required (Risson et al., 2009). Nevertheless, the consistent metabolic phenotype from 
mTOR and raptor depletion suggests mTORC1 as a critical regulator of muscle homeostasis.    
However, raptor’s function in skeletal myogenesis seems controversial. Raptor 
knockdown facilitated the inhibitory effect of myostatin on human myoblast differentiation 
(Trendelenburg et al., 2009), suggesting a positive function for raptor in myogenesis. However, 
no effect on differentiation was observed in this study by removing raptor only (Trendelenburg et 
al., 2009). Similar conclusion was made from an independent study that raptor depletion does not 
affect differentiation (Shu and Houghton, 2009). In contrast, other groups found that raptor 
negatively regulates differentiation through suppression of rictor in L6 differentiation (Jaafar et 
al., 2011). 
S6K1 and 4E-BP1. mTOR downstream of PI3K/Akt (Bodine et al., 2001; Reynolds et 
al., 2002; Rommel et al., 2001), or independent of PI3K/Akt downstream of Rheb (Goodman et 
al., 2010), is known to be important for skeletal muscle hypertrophy and atrophy. The immediate 
mTORC1 effector, S6K1 has also been extensively studied for its role in atrophy (Ohanna et al., 
2005) and hypertrophy (Park et al., 2005). Indeed, s6k1-/- skeletal muscle cells exhibited atrophic 
phenotype (Ohanna et al., 2005).  
In terms of muscle differentiation, numerous studies have reported the tight correlation of 
S6K1 activity with myogenic differentiation (Conejo et al., 2002; Coolican et al., 1997; Cuenda 
and Cohen, 1999; Sarker and Lee, 2004). Although it has been reported that overexpression of 
S6K1 decreases myogenin and troponin, two myogenic markers (Jaafar et al., 2011), an absolute 
requirement of S6K1 in myogenesis has not been widely observed (Erbay and Chen, 2001; Shu et 
al., 2002). Instead, a dispensability of S6K1 in skeletal myogenesis would be in line with the fact 
that there is no myogenesis defect was observed in s6k1-/- skeletal muscle (Ohanna et al., 2005).  
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The other immediate effector of mTORC1, 4E-BP1, has been implicated in myogenesis 
under mTOR regulation as rapamycin caused dephosphorylation of 4E-BP1 (Shu et al., 2002). 
However, by the same group, mTORC1 was ruled out as the rapamycin-sensitive complex 
regulating myogenesis (Shu and Houghton, 2009), thus disqualifying 4E-BP1 as a mediator of 
myogenic differentiation. Indeed, we and others did not observe a similar change in p4E-BP1 in 
response to rapamycin (Erbay and Chen, 2001; Willett et al., 2009).  
 PLD1. mTOR senses mitogenic signals through its upstream regulator phospholipase D1 
(PLD1) (Fang et al., 2003; Fang et al., 2001). Indeed, PLD1 is required for myogenic 
differentiation. It activates mTOR and subsequently IGF-II transcription in an amino acid 
sensitive fashion (Yoon and Chen, 2008) (Fig. I.3). PLD1 has also been found to coordinate actin 
organization, which is required for differentiation (Mebarek et al., 2007), although mTOR does 
not seem to affect differentiation through actin filament (Yoon and Chen, 2008). Recently, PLD1 
has been proposed to regulate myogenic differentiation through both mTORC1 and mTORC2 
(Jaafar et al., 2011). The mechanism of how PLD1 promotes myogenesis could be complicated 
and might be variable in different cellular contexts, but its activation of mTOR and the two 
functioning in the same positive regulatory arm are conserved between cell growth and 
differentiation regulation. The characterization of muscle specific pld1-/- mice during muscle 
regeneration would be very informative in proving myogenic function of PLD1 in vivo. 
Rictor. Whereas the initial observations of rapamycin inhibition of myogenesis implied 
the involvement of mTORC1, the rapamycin sensitive complex, as the candidate regulatory 
pathway, later recognition that prolonged rapamycin treatment also affects the assembly of 
mTORC2 raised the distinct possibility that rapamycin could exert its inhibitory effect on 
differentiation by modulating mTORC2. Indeed, rictor has been widely implicated as a positive 
regulator of myoblast differentiation (Jaafar et al., 2011; Shu and Houghton, 2009; Trendelenburg 
et al., 2009), although the downstream mechanisms proposed by different groups are quite 
different. Houghton and colleagues propose Akt as the mediator of mTORC2 function, as 
constitutively active Akt rescues differentiation of cells depleted with rictor and of cells treated 
by rapamycin, although the latter rescue is delayed and incomplete (Shu and Houghton, 2009). 
Further, ROCK1 is assigned downstream of Akt: inhibition of ROCK1, whose down-regulation is 
prerequisite for myoblast differentiation (Nishiyama et al., 2004), again rescued the 
differentiation inhibition by either rictor knockdown or rapamycin treatment (Shu and Houghton, 
2009). The Nemoz group, however, rules out a major role for Akt in myogenic regulation, and 
instead proposes PKCα as the mediator of mTORC2’s myogenic function (Jaafar et al., 2011). 
Note that these two studies used different cell models and focused on different markers for 
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differentiation. It will be interesting to find out the more physiologically relevant pathway(s) 
around mTORC2 in myogenesis in vivo.  
Interestingly, the positive myogenic function of rictor is in contrast to the in vivo 
observation that rictor is dispensable for skeletal muscle development (Bentzinger et al., 2008), 
unlike the previously discussed positive roles for mTOR and raptor in muscle homeostasis. This 
probably indicates different functions of rictor in myogenic differentiation and muscle 
maintenance.  
Other mTOR signaling components. Other mTOR signaling components are less studied 
in myogenic differentiation. Skeletal muscle specific overexpression of TSC1, the upstream GAP 
for Rheb protein, results in atrophy (Wan et al., 2006); muscle specific deletion of AMPK, the 
activator of TSC1/2 under energy stress, increased muscle size (Lantier et al., 2010). These are 
consistent with the notion that mTORC1 is a positive regulator of muscle growth. The function of 
these proteins in muscle differentiation, however, has not been investigated.  
Knockdown of PRAS40, a negative regulator of mTORC1, impaired protein synthesis, 
increased G1 retention and decreased proliferation of C2C12 myoblast (Kazi and Lang, 2010). A 
decreased rate of differentiation was observed in PRAS40 depleted cells, although the 
knockdown cells were already at disadvantage upon differentiation in terms of myoblasts number, 
thus what was observed might not be a direct differentiation defect (Kazi and Lang, 2010).  
 
I.3.4. Other pathways that intersect with mTOR in myogenesis 
Considering the central role of mTOR in myogenesis, it is not surprising that it could be 
widely affected by or exhibits impact on other myogenic pathways. NET39 (nuclear envelope 
transmembrane protein 39) is a nuclear lamina-associated nuclear envelope protein, strongly up-
regulated during myoblast differentiation (Liu et al., 2009). Knockdown of NET39 enhanced 
differentiation whereas overexpression suppressed it, at the same time diminished mTOR activity 
and IGF-II production during myogenesis (Liu et al., 2009). mTOR was found to be an 
interacting partner of NET39 in myotubes, thus it is suggested that NET39 negatively regulates 
myogenesis at least partially through mTOR-IGF-II (Liu et al., 2009). 
FoxO1 (Forkhead box protein O1) is a downstream target of PI3K/Akt signaling known 
to suppress skeletal myocyte differentiation (Hribal et al., 2003; Wu et al., 2008). It was found 
that overexpression of FoxO1 induced proteasome-dependent degradation of a subset of mTOR 
signaling components including mTOR itself (Wu et al., 2008) (Fig. I.3). FoxO1 inhibited IGF-II 
expression at the transcriptional activation level through the modulation of mTOR protein levels, 
and exogenous IGF-II fully rescued myocyte differentiation from FoxO inhibition (Wu et al., 
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2008). Therefore, mTOR-IGF-II pathway is suggested as a major mediator of FoxO's inhibitory 
function in skeletal myogenesis (Wu et al., 2008). 
Myostatin belongs to TGFβ superfamily and is known to inhibit myogenesis through 
ALK receptor and Smad2/3 phosphorylation (Langley et al., 2002; McFarlane et al., 2006; Yang 
et al., 2007). It is proposed that IGF-I and myostatin converge on Akt, through PI3K and Samd2/3 
respectively, in the regulation of myogenesis (Trendelenburg et al., 2009). Interestingly, either 
depletion of raptor (presumably downstream of Akt), or that of rictor (presumably upstream of 
Akt), facilitated the inhibition of myogenic differentiation by myostatin (Trendelenburg et al., 
2009), suggesting that mTOR signaling might impact on myostatin pathway in myogenesis. 
The MAPK p38 is a well-known myogenic kinase, as its inhibitor SB203580 potently 
suppresses myoblast differentiation (Cuenda and Cohen, 1999). Interestingly, it has been 
observed that the slow activation of S6K1 during differentiation was not only prevented by 
rapamycin but also by SB203580, and the activation of MAPKAP kinase-2 (an in vivo substrate 
of p38) was not only prevented by SB203580 but also by rapamycin (Cuenda and Cohen, 1999). 
These observations suggest a tight correlation between mTOR and p38 pathways. In L6 
differentiation, rapamycin, as potent as LY294002 (PI3K inhibitor) and dominant-negative Akt, 
inhibited Cdk5 activation (Sarker and Lee, 2004), which is required for myogenic differentiation 
(Philpott et al., 1997). Although these inhibitions could be attributed to a concurring 
differentiation blockage therefore secondary effect, a possibly direct interaction between these 
major myogenic pathways can not be ruled out. 
 
I.4. Regulation of Skeletal Myogenesis by MicroRNAs 
MicroRNAs (miRNAs) are a class of evolutionally conserved non-coding RNAs of ~22 
nucleotides, which regulate gene expression predominantly at the post-transcriptional level 
(Bartel, 2004). Eight years after the initial discovery of lin-4 in C. elegans in 1993 (Lee et al., 
1993; Wightman et al., 1993), dozens of miRNAs were reported simultaneously by several 
groups (Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001), thus beginning the 
miRNA era. Over the last decade, hundreds of miRNAs were identified or predicted across a 
wide spectrum of species (Berezikov et al., 2006). The prevalence and importance of this small 
RNA family in modulating gene expression has become increasingly clear. 
Mammalian miRNAs are encoded in the intergenic or intragenic (both intronic and 
exonic) regions of the genome, their genes often found clustered (Olena and Patton, 2010). 
MiRNA genes are transcribed as long primary transcripts (pri-miRNAs), mainly by RNA 
polymerase II (Kim et al., 2009), although polymerase III-dependent transcription has also been 
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described (Borchert et al., 2006). Pri-miRNAs are processed co-transcriptionally by the nuclear 
RNase III Drosha/DGCR8 to generate ~70bp pre-miRNAs, which are then exported by Exportin-
5 to the cytoplasm in a Ran-GTP dependent manner. In the cytoplasm, pre-miRNAs are further 
processed by the RNase III Dicer to yield ~22nt mature miRNAs (reviewed in (Kim et al., 2009)). 
The miRNA biogenesis paradigm has recently been expanded to include “mirtrons” that bypass 
Drosha processing (Berezikov et al., 2007; Okamura et al., 2008), and miRNAs (or miRNA-like 
small RNAs) that are generated independently of Dicer (Cifuentes et al., 2010; Lee et al., 2010; 
Yang and Lai, 2010; Yang et al., 2010). In addition, recent discoveries of secreted miRNAs in 
microvehicles communicating between cells further widen the scope of miRNA biogenesis and 
function (Zhang et al., 2010). 
Through partial sequence complementarity, miRNAs exert their functions by binding to 
the 3’UTR of the target mRNAs (Bartel, 2009) and subsequently directing them for translational 
inhibition and mRNA decay (Filipowicz et al., 2008), although translational activation by 
miRNAs has also been reported (Vasudevan and Steitz, 2007; Vasudevan et al., 2008). A most 
recent study has revealed that mammalian miRNAs inhibit gene expression predominantly 
through decreasing target mRNA levels (Guo et al., 2010). It has been estimated that over 60% of 
the human protein-coding genes are under selective pressure to maintain miRNA sites (Friedman 
et al., 2009). With this enormous target repertoire, it is not surprising that miRNAs have emerged 
as key regulators for myriads of cellular and developmental processes. The early embryonic 
lethality of Dicer deficient mice, and severe phenotypes from conditional Dicer knockout during 
different development stages and in various adult tissues (Bernstein et al., 2003; Kanellopoulou et 
al., 2005; Murchison et al., 2007; Tang et al., 2007), attest to the pivotal roles of miRNAs.  
 
I.4.1. Regulation of miRNA expression in skeletal muscle 
Modulation of myogenic gene expression by miRNAs has emerged as a new level of 
control for myogenesis. Mice with Dicer deleted in muscle die perinatally and display decreased 
skeletal muscle mass, increased apoptosis of the muscle cells, accompanied by abnormal 
myofiber morphology (O'Rourke et al., 2007). It is important to note that Dicer is also responsible 
for the production of other types of small RNAs, whereas DGCR8, the binding partner of Drosha, 
is specific to the miRNA biogenesis pathway (Kim et al., 2009). Of significance, striated muscle-
specific Dgcr8 knockout mice display severe dilated cardiomyopathy and heart failure (Rao et al., 
2009), although characterization of skeletal muscle in those mice has not been reported. Below 
we survey the expression of miRNAs with reported myogenic functions in skeletal muscle (Table 
1.1). 
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MiR-1/miR-133/miR-206. The best-studied myogenic miRNAs are the miR-1/miR-206 
and miR-133a/miR-133b families, consisting of four mature miRNAs expressed from three 
chromosomal loci as bicistronic transcripts (Williams et al., 2009a). These miRNAs are 
specifically expressed in cardiac and skeletal muscles under the control of the myogenic 
transcription factors SRF, MyoD and MEF2 (Liu et al., 2007; Rao et al., 2006; Rosenberg et al., 
2006; Zhao et al., 2005), and they regulate the fundamental processes of skeletal myogenesis 
including myoblast/satellite cell proliferation and differentiation (reviewed in (Williams et al., 
2009a)). Among many miRNAs profiled, miR-1, miR-133, and miR-206 levels are most 
dramatically increased during myoblast differentiation (Chen et al., 2006; Wong and Tellam, 
2008). 
Adding to the complexity of regulation, miR-1, miR-133 and miR-206 have also been 
suggested to be controlled at the level of pri-miRNA processing. The RNA binding protein KSRP 
is a component of both Drosha and Dicer complexes and it promotes the maturation of a subset of 
miRNA precursors through binding to their terminal loops (Trabucchi et al., 2009). MiR-1, miR-
133, and miR-206 appear to belong to this subgroup of miRNAs. Future studies to examine the 
commonality of this regulatory mechanism in myogenic miRNAs should be illuminating. 
The expression of these three well-studied myogenic miRNAs has also been examined in 
vivo. MiR-1 (Jeng et al., 2009), miR-133 (Jeng et al., 2009), and miR-206 (Greco et al., 2009; 
Jeng et al., 2009; McCarthy et al., 2007; Yuasa et al., 2008) have all been reported to be up-
regulated during muscle regeneration in animals after injury. Interestingly, a transient drop in 
these miRNA levels has also been observed immediately after muscle injury (Chen et al., 2010a; 
Greco et al., 2009; Jeng et al., 2009; Yuasa et al., 2008). Whereas this decrease may be a 
consequence of muscle damage and induction of fibrosis independent of muscle regeneration 
(Greco et al., 2009), a recent report correlated this early phase of miR-1 and miR-206 suppression 
with their anti-proliferation effect on satellite cells (Chen et al., 2010a). miR-1 and miR-133a 
levels were also found decreased in skeletal muscles 7 days after functional overload, 
accompanied by an increase in the corresponding pri-miRNAs (McCarthy and Esser, 2007), 
implicating regulation at a miRNA maturation step. As the authors speculated, potential targets of 
these miRNAs may be involved in muscle growth regulation (McCarthy and Esser, 2007). 
Alternatively, it is reasonable to suggest, based on the recent report (Chen et al., 2010a), that 
satellite cell activation and proliferation in response to the overload stimulus may require 
suppression of miR-1. 
MiR-208/miR-499. Also displaying a muscle-restricted expression pattern is a family of 
intronic miRNAs named “MyomiRs” (van Rooij et al., 2009), consisting of miR-208a, miR-208b, 
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and miR-499. Whereas miR-208a is restricted to cardiac muscle, miR-208b and miR-499 are 
expressed in both cardiac and skeletal muscles. These miRNAs are encoded by introns of their 
host myosin genes, α-MHC, β-MHC and Myh7β, respectively, regulating myofiber type 
specification (van Rooij et al., 2009). Interestingly, miR-499 was found to be the most 
dramatically decreased miRNA in a hind limb suspension-induced atrophy model, suggesting its 
potential importance in muscle maintenance (McCarthy et al., 2009). 
MiR-486. Another muscle-enriched miRNA is miR-486. Encoded in the gene Ankrin-1, 
the expression of miR-486 is activated by myocardin-related transcription factor-A (MRTF-A), 
SRF, and MyoD (Small et al., 2010). Most recently, miR-486 is reported to be highly induced 
during myoblast differentiation, and to exert a myogenic function (Dey et al., 2010). 
Ubiquitously expressed miRNAs with myogenic functions. In addition to the muscle-
restricted and muscle-enriched miRNAs described above, some ubiquitously expressed miRNAs 
also have myogenic functions, and their expression levels typically change during myoblast 
differentiation. MiR-214 expression is de-repressed from the polycomb protein Ezh2 and 
stimulated by MyoD and myogenin during differentiation (Juan et al., 2009). Similarly, miR-
29b/c expression is suppressed in myoblasts by the repressive transcription factor YY1; during 
myoblast differentiation and muscle regeneration, release from YY1 and stimulation by SRF and 
MEF2 lead to the up-regulation of miR-29 levels (Wang et al., 2008). MiR-24 transcription is 
also up-regulated during myoblast differentiation, upon de-repression from TGF-b-Smad 
signaling (Sun et al., 2008). De-repression from suppressive signals appears to be a common 
theme within this subset of myogenic miRNAs, the up-regulation of which correlates with 
myogenic differentiation.  
Several other miRNAs with myogenic functions are also up-regulated during skeletal 
myogenesis, but the upstream regulators are yet to be identified. MiR-181 is highly expressed in 
neurons and bone marrow but barely detectable in mature myofibers (Chen et al., 2004; Sempere 
et al., 2004). However, miR-181 levels are drastically increased during myoblast differentiation 
and muscle regeneration (Naguibneva et al., 2006). Other ubiquitously expressed myogenic 
miRNAs found to be up-regulated during myogenic differentiation include miR-26a (Wong and 
Tellam, 2008), miR-27b (Crist et al., 2009), miR-322/424 and miR-503 (Sarkar et al., 2010). 
MiRNAs down-regulated during myogenic differentiation. Compared to myogenic 
miRNAs that are up-regulated, fewer miRNAs with demonstrated myogenic functions are down-
regulated during myogenic differentiation. MiR-221 and miR-222, which share sequence 
similarity and are clustered on chromosome X, are found to be highly expressed in quail 
myoblasts, and down-regulated during differentiation (Cardinali et al., 2009). A similar 
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expression pattern is found in mouse C2C12 myocytes, although the change is to a lesser degree 
(Cardinali et al., 2009). It has been suggested that the expression of miR-221/222 is under the 
control of Ras-MAPK signaling (Cardinali et al., 2009), consistent with a negative role that this 
pathway plays in myogenic differentiation (Ciuffini et al., 2008; Perry et al., 2001). MiR-222 
expression has also been correlated with the presence of infiltrating inflammatory cells in injured 
muscles (Greco et al., 2009), and it is highly up-regulated in several muscular dystrophies 
(Eisenberg et al., 2007).  
MiRNA expression during skeletal myogenesis has been profiled extensively by 
numerous groups. Many miRNAs not mentioned above have been found to be differentially 
expressed during myoblast differentiation in vitro (Chen et al., 2006; Chen et al., 2010a; Chen et 
al., 2010b; Dey et al., 2010; Wong and Tellam, 2008) and muscle development or disease in vivo 
(Chen et al., 2010a; Eisenberg et al., 2007; Greco et al., 2009; Panguluri et al., 2010). Future 
characterization of those miRNAs will likely lead to the identification of novel myogenic 
regulators.  
 
I.4.2. Gene targets and functions of myogenic miRNAs 
Manipulation of miRNA levels in vitro and in vivo, by genetic and biochemical methods, 
has become a standard approach to interrogating miRNA functions. Ultimately, revealing the 
gene targets of a miRNA is key to understanding its function. Identification of biologically 
important targets remains a major challenge in miRNA studies, as most metazoan miRNAs pair 
with their targets imperfectly. Pairing of miRNA “seed” region (nucleotide 2-8) to the 3’UTR of 
the target gene is believed to be one of the most important parameters that determine efficient 
miRNA targeting (Krek et al., 2005; Lewis et al., 2005; Stark et al., 2003), yet “seedless” 
targeting has also been well documented (Lal et al., 2009; Shin et al., 2010). Although 
computational prediction has become a powerful tool in facilitating miRNA target identification 
(Bartel, 2009; Rajewsky, 2006; Sethupathy et al., 2006), the current algorithms remain far from 
accurate, with high false-positive and false-negative rates (Ritchie et al., 2009). Experimental 
approaches to identifying miRNA targets continue to be developed and refined, but extracting 
biologically important information from typically very large data sets from such methods can be 
daunting. The reader is referred to Thomas et al (Thomas et al., 2010) for an excellent review on 
current approaches to miRNA target identification. 
Despite the technical challenges, in recent years numerous biological targets for 
myogenic miRNAs has been revealed, representing a wide range of genes in the myogenic 
program, from transcription regulators, signaling molecules, to structural proteins. Here we 
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survey the myogenic miRNAs for which gene targets have been identified or reasonably 
predicted (Table I.1).  
MiR-1 and miR-206. miR-1 and miR-206 differ by only 4 nucleotides outside the seed 
region, and they are believed to share gene targets although not all reported targets have been 
experimentally validated for both miRNAs. The gap junction protein connexin43 (Cx43) is a 
target of miR-1/miR-206 (Anderson et al., 2006; Kim et al., 2006), the down-regulation of which 
is necessary for myoblast fusion (Anderson et al., 2006). The receptor tyrosine kinase c-Met is 
also targeted by miR-1/miR-206, identified in a rhabdomyosarcoma cell line; miR-1/miR-206 
could function as a potent tumor suppressor in c-Met-overexpressing tumors with aberrant 
proliferation and cell migration (Taulli et al., 2009; Yan et al., 2009). Another target of miR-
1/miR-206 is histone deacetylase 4 (HDAC4) (Chen et al., 2006; Williams et al., 2009b), a 
transcriptional repressor of muscle gene expression (McKinsey et al., 2000). HDAC4 partly 
mediates the effects of miR-206 in promoting regeneration of neuromuscular synapses and 
delaying amyotrophic lateral sclerosis (ALS) in a mouse model (Williams et al., 2009b). 
Moreover, miR-1 and miR-206 have recently been reported to target Pax7 and, as a consequence, 
inhibit satellite cell proliferation and promoting myogenic differentiation (Cacchiarelli et al., 
2010; Chen et al., 2010a; Dey et al., 2010). Interestingly, miR-1 and miR-206 levels undergo a 
temporary drop during the early phase of muscle regeneration in animals (Chen et al., 2010a;  
Greco et al., 2009; Yuasa et al., 2008), which correlates well with active satellite cell proliferation 
at that stage. 
Several more gene targets have been reported for miR-206, although it remains to be 
determined whether they are also shared by miR-1. Examining the effect of miR-206 
overexpression on mRNA expression profiles in C2C12 myoblasts led to the identification of 
DNA polymerase alpha as a bona fide target of miR-206 (Kim et al., 2006), the downregulation 
of which may be involved in the suppression of DNA synthesis upon myogenic differentiation. 
Butyrate-induced transcript 1 (B-ind1), monocyte-to-macrophage differentiation-associated 
protein (Mmd), and Cx43 were also implicated as miR-206 targets in the same study (Kim et al., 
2006). As discussed earlier, Cx43 has been identified as a target for both miR-1 and miR-206 in 
another study (Anderson et al., 2006). More targets of miR-206 have been computationally 
predicted and experimentally confirmed, including follistatin-like 1 (Fstl1) (Rosenberg et al., 
2006), utrophin (Utrn) (Rosenberg et al., 2006), and tissue inhibitor of metalloproteinase 3 
(TIMP3) (Liu et al., 2010a). Glucose-6-phosphate dehydrogenase (G6PD) has been reported to be 
a miR-1 target; in Duchenne muscular dystrophy the dystrophic phenotype is partially caused by 
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HDAC2 suppression of miR-1 expression and subsequent G6PD over-production (Cacchiarelli et 
al., 2010). 
MiR-133. Its genes clustering with those of miR-1 and miR-206, miR-133 targets SRF, 
thus enhancing myoblast proliferation and inhibiting myogenic differentiation (Chen et al., 2006). 
Interestingly, miR-133 has also been shown to directly promote differentiation by targeting the 
alternative splicing factor neuronal polypyrimidine tract-binding protein (nPTB), the down-
regulation of which is necessary for the production of muscle-specific transcripts during 
myogenic differentiation (Boutz et al., 2007). MiR-133 is also reported to target uncoupling 
protein 2 (UCP2) known to regulate energy expenditure and thermogenesis in various organisms 
and to negatively impact myoblast differentiation (Chen et al., 2009). 
MiR-24. Found to be suppressed by TGF-b signaling, miR-24 promotes myoblast 
differentiation (Sun et al., 2008). The targets of miR-24 in myogenesis have not been reported. 
Interestingly, in non-myogenic cells miR-24 has been found to target a cohort of cell cycle 
regulators, including Myc and E2F (Lal et al., 2009). Hence, it is conceivable that miR-24 may 
target these same genes in myoblasts and support cell cycle exit necessary for myogenic 
differentiation. 
MiR-26a. Up-regulated during myoblast differentiation, miR-26a has been shown to 
promote differentiation (Wong and Tellam, 2008). The histone methyltransferase Ezh2, a 
polycomb group protein known to negatively regulate skeletal myogenesis (Caretti et al., 2004), 
is found to be a target of miR-26a (Wong and Tellam, 2008). Ezh2 binds to chromatin via its 
association with the transcription factor YY1, and subsequently silences muscle gene expression 
through its histone methyltransferase activity (Caretti et al., 2004). Hence, miR-26a suppression 
of Ezh2 may be necessary for myogenic differentiation. Dysregulated expression of miR-26a and 
Ezh2 has been found in rhabdomyosarcoma, implicating their involvement in the pathogenesis of 
this malignant tumor (Ciarapica et al., 2009). 
MiR-27b. In a search for miRNAs that target Pax3, miR-27b emerged as a strong 
candidate predicted by multiple computational algorithms, and a direct targeting was confirmed 
experimentally (Crist et al., 2009). Pax3 is required for muscle stem cell maintenance and 
migration, but its removal is necessary for myogenic differentiation (Boutet et al., 2007; 
Buckingham and Relaix, 2007). MiR-27b promotes entry into the differentiation program both in 
vitro and in regenerating muscles by down-regulating Pax3 (Crist et al., 2009). 
MiR-29. MiR-29 targets the polycomb group protein associated transcription factor YY1 
(Wang et al., 2008). YY1 recruits PcG proteins to suppress muscle gene expression, and is down-
regulated by NF-kB transcriptionally (Wang et al., 2007) and by miR-29 post-transcriptionally 
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(Wang et al., 2008) to allow myogenic differentiation. In addition, miR-29 targets collagen 
(COL1A1) and elastin (ELN) in the extracellular matrix in cardiac myocytes (van Rooij et al., 
2008), and the same targeting has been suggested to mediate the fibrosis phenotype in Duchenne 
muscular dystrophy due to suppression of miR-29 (Cacchiarelli et al., 2010). 
MiR-181. The homeobox protein Hox-A11, reported to repress transcription of MyoD 
(Yamamoto and Kuroiwa, 2003), is found to be a target for miR-181 (Naguibneva et al., 2006). 
The transient expression of miR-181 during myoblast differentiation and muscle regeneration, 
and the lack of its detection in adult muscles, suggest that this microRNA is involved in muscle 
formation but not maintenance (Naguibneva et al., 2006). 
MiR-208b and miR-499. Produced from introns of two myosin genes – β-MHC and 
Myh7β, miR-208b and miR-499 share the same seed sequence and presumably the same set of 
targets. These two miRNAs function redundantly to target the transcriptional repressors of slow 
myofiber genes, including Sox6, Purβ, Sp3, and HP-1β, thus governing myofiber type switch 
(van Rooij et al., 2009). 
MiR-214. Like miR-26a, miR-214 also targets Ezh2 (Juan et al., 2009), a repressor of 
muscle gene expression. In addition, N-Ras has been found to be a target of miR-214 through 
transcriptional profiling of miR-214-overexpressing C2C12 myoblasts (Liu et al., 2010b). Since 
Ras promotes cell cycle entry and inhibits differentiation, miR-214 suppression of N-Ras 
facilitates cell cycle exit and subsequent myogenic differentiation (Liu et al., 2010b). In zebrafish, 
miR-214 is involved in muscle fate determination by modulating Hedgehog signaling (Flynt et 
al., 2007). It will be interesting to see whether this function is conserved in mammals. 
MiR-221 and miR-222. MiR-221 and miR-222 target the cell cycle inhibitor p27Kip in 
cancer cells (Gillies and Lorimer, 2007; Pineau et al., 2009). The same targeting has been 
implicated in myoblasts, and miR-221/miR-222 inhibits myogenic differentiation possibly 
through interfering with cell cycle withdrawal involving p27 (Cardinali et al., 2009). It has been 
suggested that p27 may also control myoblast differentiation through other cellular targets beyond 
cell cycle regulation (Messina et al., 2005). 
MiR-322/424 and miR-503. MiR-322/424 (miR-424 is the human ortholog of mouse 
miR-322) and miR-503 have very similar seed sequences, and their genes are clustered.  These 
two miRNAs are reported to target Cdc25A (Sarkar et al., 2010), a phosphatase responsible for 
removing inhibitory phosphorylation of Cdk2 (Sarkar et al., 2010). Up-regulation of miR-322/424 
and miR-503 in differentiating C2C12 cells leads to cell cycle withdrawal through down-
regulation of Cdc25A, thus promoting myogenesis (Sarkar et al., 2010). 
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MiR-486. Found to be enriched in cardiac and skeletal muscles, miR-486 was reported to 
target two negative regulators in the PI3K pathway – PTEN and FoxO1a – in rat cardiomyocytes 
(Small et al., 2010). Given the essential role of PI3K signaling in skeletal myogenesis (Jiang et 
al., 1998), it was a reasonable prediction that miR-486 would be required therein. Indeed, miR-
486 has recently been shown to positively regulate myoblast differentiation (Dey et al., 2010). 
However, in that study Pax7 is identified as the direct target of miR-486 (Dey et al., 2010), along 
with miR-206 (discussed earlier). 
As summarized above, the regulatory roles of miRNA have been established in almost 
every aspect of skeletal muscle development, with a dozen or so myogenic miRNAs identified 
and their targets revealed (Table I.1). However, this is unlikely to be a complete list. Following 
up investigations, partly inspired by the sizable number of miRNAs found to be differentially 
expressed during skeletal myogenesis and powered by recent advances in miRNA targets 
prediction will likely expand the family of myogenic miRNAs significantly. My thesis Chapter III 
and IV will describe the identification of novel miRNAs and their regulatory mechanisms in 
skeletal myogenesis. 
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I.5. Figures and Tables 
 
 
 
 
 
 
Figure I.1. mTOR complex in cell growth regulation. mTOR nucleates two distinct complexes, 
mTORC1 and mTORC2. mTORC1 senses cellular nutrients and energy levels, regulating protein 
synthesis through S6K1 and 4E-BP1 among other functions, whereas mTORC2 regulates actin 
cytoskeletal  remodeling through Akt. 
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Figure I.2. mTOR is a master regulator of skeletal myogenesis. mTOR regulates myogenic 
initiation through IGF-II in a kinase-independent manner, and myocyte maturation through an 
unknown secreted factor(s) in a kinase-dependent fashion. 
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Figure I.3. mTOR signaling in skeletal myogenesis. PLD1 mediates amino acids sensing and 
activates mTOR-IGF-II, which then regulates myogenesis through PI3K/Akt. Akt phosphorylates 
and inhibits FoxO, which is a negative regulator of myogenesis by degrading mTOR and its 
signaling components.  
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microRNA Tissue distribution 
Expression upon 
myoblast 
differentiation 
Targets in skeletal muscles 
miR-1a muscle-specific Increase 
HDAC4 (Chen et al., 2006), 
Cx43 (Anderson et al., 2006), 
Pax7 (Chen et al., 2010a), c-
Met (Yan et al., 2009), G6PD 
(Cacchiarelli et al., 2010) 
miR-24 ubiquitous Increase unknown 
miR-26a ubiquitous Increase Ezh2 (Wong and Tellam, 2008) 
miR-27b ubiquitous Increase Pax3 (Crist et al., 2009) 
miR-29b/c ubiquitous Increase 
YY1 (Wang et al., 2008), 
COL1A1 (Cacchiarelli et al., 
2010; van Rooij et al., 2008), 
ELN (Cacchiarelli et al., 2010; 
van Rooij et al., 2008) 
miR-133 muscle-specific Increase 
SRF (Chen et al., 2006), nPTB 
(Boutz et al., 2007), UCP2 
(Chen et al., 2009) 
miR-181 ubiquitous Increase Hox-A11 (Naguibneva et al., 2006) 
miR-206a skeletal muscle-specific Increase 
DNA pol α (Kim et al., 2006), 
Fstl1 (Rosenberg et al., 2006), 
Utrn (Rosenberg et al., 2006), 
Cx43 (Anderson et al., 2006), 
TIMP3 (Liu et al., 2010a), 
Pax7 (Cacchiarelli et al., 2010; 
Chen et al., 2010a; Dey et al., 
2010), c-Met (Taulli et al., 
2009; Yan et al., 2009), 
HDAC4 (Williams et al., 
2009b) 
miR-208b/499 muscle-specific Unknown 
Sox6 (van Rooij et al., 2009), 
Purβ (van Rooij et al., 2009), 
Sp3 (van Rooij et al., 2009), 
HP-1β (van Rooij et al., 2009) 
miR-214 ubiquitous Increase Ezh2 (Juan et al., 2009), N-Ras (Liu et al., 2010b) 
miR-221/222 ubiquitous Decrease p27 (Cardinali et al., 2009) 
miR-322/424 ubiquitous Increase Cdc25A (Sarkar et al., 2010) 
miR-486 muscle-enriched Increase 
FoxO1 (Small et al., 2010), 
PTEN (Small et al., 2010), 
Pax7 (Dey et al., 2010) 
miR-503 ubiquitous Increase Cdc25A (Sarkar et al., 2010) 
amiR-1 and miR-206 presumably share the same targets. Here we list the targets separately based on 
published experimental evidence. 
 
Table I.1. Expression and targets of miRNAs known to function in skeletal myogenesis. See 
text for details.
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CHAPTER II. MTOR REGULATES SKELETAL MUSCLE REGENERATION IN VIVO 
THROUGH KINASE-DEPENDENT AND KINASE-INDEPENDENT MECHANISMS 
 
II.1. Introduction 
 During development, cells in the somites undergo myogenic lineage commitment, 
myoblast proliferation and terminal differentiation to form multinucleated myofibers. Skeletal 
myogenesis is guided by various environmental cues and regulated by distinct signal transduction 
pathways, which result in the activation of specific transcription factors and subsequent 
reprogramming of gene expression (Naya and Olson, 1999; Weintraub, 1993). One of the adult 
skeletal muscle remodeling processes – regeneration after muscle damage – recapitulates 
embryonic myogenesis to a certain degree. Upon muscle injury, quiescent muscle precursor cells, 
or satellite cells, positioned between the basal lamina and the plasma membrane of muscle fibers 
become activated, proliferate, and differentiate to form new myofibers or repair existing 
myofibers (Hawke and Garry, 2001). 
 The Ser/Thr kinase mTOR is a master regulator of a wide range of biological processes 
including cell growth, various types of cellular differentiation, and metabolism (Erbay et al., 
2005; Sarbassov et al., 2005; Wullschleger et al., 2006). As the cellular target of the bacteria 
macrolide rapamycin in complex with the ubiquitous protein FKBP12 (Abraham and 
Wiederrecht, 1996), mTOR transduces signaling in response to nutrient availability, cellular 
energy sufficiency, mitogenic signals, and various types of stress signals. The best-known 
function of mTOR is regulation of protein synthesis through phosphorylation of the downstream 
targets S6K1 and 4E-BP1, which target ribosomal protein S6 and the cap binding complex, 
respectively (Fumagalli and Thomas, 2000; Gingras et al., 1999; Ma and Blenis, 2009). mTOR 
assembles two biochemically and functionally distinct protein complexes – the rapamycin- 
sensitive mTORC1 and the rapamycin-insensitive mTORC2, containing raptor and rictor, 
respectively  (Sarbassov et al., 2005).  
 Rapamycin-sensitive mTOR signaling has emerged as a key regulator of skeletal muscle 
differentiation and remodeling. Rapamycin had been known for some time to inhibit 
differentiation of several types of myoblasts in culture (Conejo et al., 2001; Coolican et al., 1997; 
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Cuenda and Cohen, 1999; Erbay and Chen, 2001). mTORC1 regulates myoblast differentiation at 
different stages via distinct molecular mechanisms. The initial stage of differentiation resulting in 
nascent myotube formation is controlled by mTOR through its regulation of IGF-II expression in 
a nutrient-dependent manner (Erbay and Chen, 2001; Erbay et al., 2003), whereas a late-stage 
fusion leading to myotube maturation is regulated by mTOR through a yet-to-be-identified 
secreted factor (Park and Chen, 2005). While the kinase activity of mTOR is required for 
myotube maturation, mTOR initiates myoblast differentiation via an unexpected pathway that is 
independent of its kinase activity and independent of the previously established downstream 
effectors S6K1 and 4E-BP1 (Erbay and Chen, 2001; Erbay et al., 2003). However, the kinase-
independent myogenic function of mTOR has been disputed by data obtained in the same 
myoblast cell line – C2C12 (Shu et al., 2002). This discrepancy may be attributed to clonal and 
sub-culture variation, a common pitfall of cell culture systems. Ultimately, in vivo evidence will 
be required to validate any regulatory mechanisms discovered in vitro.  
 Several lines of evidence suggest a critical involvement of mTOR in adult muscle 
remodeling. For instance, rapamycin inhibits IGF-induced myotube hypertrophy in vitro (Park et 
al., 2005; Rommel et al., 2001). Compensatory myofiber hypertrophy in vivo and re-growth of 
myofibers after denervation-induced atrophy are also sensitive to rapamycin (Bodine et al., 2001). 
Furthermore, mTORC1 regulates protein synthesis in response to mechanical stimulation of 
skeletal muscle ex vivo (Hornberger et al., 2004; Hornberger et al., 2006). Mice with systemic 
s6k1 knockout have smaller myofibers, suggesting that S6K1 is required for muscle growth 
(Ohanna et al., 2005). Although S6K1 serves as a reliable readout of mTORC1 signaling, it is not 
the sole target of mTOR’s rapamycin-sensitive functions. Given that our in vitro studies have 
established an S6K1-independent role of mTOR in myoblast differentiation, direct examination of 
the function of mTOR and its kinase activity in an in vivo model would be highly desirable.  
 In this chapter, I investigate the regulation of skeletal muscle regeneration by mTOR in a 
mouse muscle injury model. My studies reveal that rapamycin impairs both new fiber formation 
and myofiber growth during regeneration. Although rapamycin is considered a highly specific 
inhibitor for mTOR in cell culture when used at nanomolar concentrations, its direct targeting of 
FKBP12 (Abraham and Wiederrecht, 1996) can potentially lead to disruption of a myriad of 
mTOR-independent functions at higher drug concentrations. As it is not feasible to control, nor 
measure, the concentration of rapamycin in tissues or cells in the intact animal, the effect of 
rapamycin in vivo cannot be presumed to be exclusively through inhibition of mTOR. To confirm 
mTOR’s role in the rapamycin-sensitive processes of regeneration, I have generated transgenic 
mice expressing a rapamycin-resistant mutant of mTOR (Erbay and Chen, 2001) in skeletal 
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muscle. To probe the requirement of mTOR kinase activity for its myogenic functions, I have 
also generated transgenic mice with muscle-specific expression of a rapamycin-resistant/kinase 
inactive (RR/KI) mTOR (Erbay and Chen, 2001). Characterization of the regeneration potential 
of these transgenic mice has revealed kinase-independent regulation of new myofiber formation 
by mTOR and a requirement for mTOR kinase activity during the myofiber growth phase. These 
results provide genetic and in vivo evidence for the distinct regulatory mechanisms of mTOR in 
myogenesis as originally unraveled by in vitro studies. 
 
II.2. Materials and Methods 
II.2.1. Antibodies and other reagents. Antibodies against mTOR and phospho-Ser235/236-S6 
were purchased from Cell Signaling Technology. Anti-tubulin was from Abcam. All secondary 
antibodies were from Jackson ImmunoResearch Laboratories, Inc. Anti-embryonic MHC 
(F1.652) was obtained from the Developmental Studies Hybridoma Bank developed under the 
auspices of the NICHD, National Institutes of Health and maintained by The University of Iowa, 
Department of Biological Sciences. Rapamycin was from LC Labs. All other chemicals were 
from Sigma Aldrich. 
II.2.2. Plasmids. The pSA3 vector containing the 2.2 kb promoter of the human α-skeletal actin 
(HSA) gene (a generous gift from Dr. Karyn Esser, University of Kentucky) was used to 
construct the mTOR transgene expression plasmids. Human mTOR cDNA containing a sequence 
encoding the FLAG epitope at the 5’ end and Ser2035Thr (RR) or Ser2035Thr/Asp2357Glu 
(RR/KI) mutations was inserted into pSA3 downstream of the HSA promoter via Not I sites.  The 
polyA signal from the BGH gene was inserted at the 3’ end of mTOR cDNA via the Not I site. 
Nru I and PstZ17 I were used to generate a 10.1 kb transgene fragment for pronuclear injection 
(see Fig. II.3A). 
II.2.3. Generation of transgenic and knockout mice. All animal experiments in this study 
followed protocols approved by the Animal Care and Use Committee at the University of Illinois 
at Urbana-Champaign. HSA-driven RR-mTOR and RR/KI-mTOR transgenic mice were 
produced by pronuclear injection of FVB zygotes, at the Gene Targeting and Transgenic Facility 
at the University of Connecticut Health Center. Transgene integration in the founder lines was 
confirmed by PCR and Southern analysis (strategy depicted in Fig. II.3A), and breeding was 
performed using wild-type FVB mice. All transgenic mice were maintained as hemizygotes. 
 S6k1 knockout mice in a C57BL/6 background were generated by blastocyst injection of 
previously reported embryonic stem cells with targeted disruption of the s6k1 gene (Kawasome et 
al., 1998) followed by back-crossing with C57BL/6 mice for eight generations. The mice were 
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maintained as heterozygotes, which were bred to yield S6k1-/- and S6k1+/- mice for experiments. 
Genotyping was performed by PCR. 
II.2.4. BaCl2 induced muscle injury and regeneration. An established method of muscle injury 
by intramuscular injection of BaCl2 (Caldwell et al., 1990; McArdle et al., 1994) was employed in 
this study. The choice of BaCl2 among myotoxins was based on its low cost and easy 
accessibility. BaCl2 induces muscle fiber necrosis while completely preserving the basement 
membrane (Caldwell et al., 1990), and the subsequent muscle regeneration follows a process and 
timeline comparable to those induced by snake venoms or freezing (Deponti et al., 2007; Fink et 
al., 2003; Horsley et al., 2003; Jansen and Pavlath, 2006; McArdle et al., 1994; Richard-Bulteau 
et al., 2008). Ten-week-old male mice were used in all the regeneration experiments. The 
following strains and/or genotypes of mice were characterized as described in the Results and 
Figure Legends: wild-type (FVB and C57BL/6 as controls for mTOR transgenics and s6k1 
knockouts, respectively), RR-mTOR, RR/KI-mTOR, s6k1+/-, and s6k1-/-. For each experimental 
condition (including controls), 3 to 10 mice were used to obtain the mean ± SD data presented 
here. The animals were anesthetized by intraperitoneal injection of 300-400 µL of 2.5% avertin 
(100% avertin was made by mixing 10g of tribromoethyl alcohol with 10ml of tertiary amyl 
alcohol). BaCl2 (50 µL of 1.2% w/v in saline) was injected into the tibialis anterior (TA) or 
gastrocnemius muscle of a hind limb. As controls, saline (50 µL) was injected similarly. Injected 
animals were caged singly throughout the duration of the experiments and monitored for their 
general levels of physical activity, and any signs of health problems. Rapamycin was 
administered by intraperitoneal injection once daily at 1 mg per kg weight (100 µL in 5% Tween 
80, 5% PEG-400, and 4% ethanol). The control mice received intraperitoneal injection of the 
vehicle. Food intake was measured using Rodent Cafe Type M feeder (OYC international). On 
days 1, 3, 7, 14, 21, and 28 after injury, the mice were euthanized and the TA muscles were 
collected, followed by cryosection and staining as described below. In some instances as detailed 
in the Results and Figure Legends, mice were characterized 8 weeks after injury. All mice were 
housed in a 12 h light/12 h dark cycle mouse facility, with the room temperature tightly 
controlled at 72 0F. All the BaCl2 injections and muscle collection were performed around 10 am. 
II.2.5. Muscle tissue cryosection and analysis. TA muscles were isolated by dissection, frozen 
in liquid nitrogen-cooled 2-methylbutane, and embedded in TBS tissue freezing medium (Fisher 
Scientific). Sections of 10 µm thickness were made with a Microm HM550 cryostat at -20 0C, 
placed on uncoated slides, and stained with hematoxylin and eosin (H&E). The stained slides 
were examined with a Leica DMI 4000B microscope, and the images were captured with a 20x 
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dry objective (Leica Fluotar, numerical aperture 0.4) using a RETIGA EXi camera. The images 
were then processed as 24-bit colored images using Adobe Photoshop CS2. An area of 614,400 
µm2 at the center of degenerated region of each TA muscle was selected for scoring centrally 
nucleated regenerating myofiber numbers and cross-section area (CSA). CSA was measured 
using the Qcapture Pro51 software (QImagingTM). 
II.2.6. Muscle tissue homogenization and Western blotting. Mouse TA muscles were isolated, 
ground into powder in liquid nitrogen, and then lysed in a buffer containing 2% Triton X-100, 
200 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 2.5 mM sodium 
pyrophosphate, 1 mM ß-glycerol phosphate, 1 mM sodium orthovanadate, and a protease 
inhibitor cocktail (Sigma). After micro-centrifugation at 14,000 rpm, the supernatant was mixed 
with 2x SDS sample buffer. The samples were boiled, run on SDS-PAGE, and transferred onto 
PVDF membrane (Millipore) followed by incubation with various antibodies according to the 
manufacturers’ recommendations. Detection of horseradish peroxidase-conjugated secondary 
antibodies was performed with Western LightningTM Chemiluminescence Reagent Plus (Perkin 
Elmer Life Sciences). 
II.2.7. Statistical analysis. All data are presented as means ± standard deviation (SD). Statistical 
significance of the data was analyzed, when necessary, by performing paired two-tailed t-tests or 
two-way repeated measures analysis of variance (ANOVA) with Bonferroni’s post-test as 
indicated in the figure legends, using GraphPad Prism 4.0. P values, whenever applicable, are 
indicated in the figure legends. 
 
II.3. Results 
II.3.1. Rapamycin inhibits skeletal muscle regeneration. 
 Mice were injected with BaCl2 in the tibialis anterior (TA) muscle, which was dissected 
and cryosectioned on various days up to 28 days after injury (AI). The injected muscle underwent 
pronounced necrosis on Day 1 AI (Fig. II.1A), followed by extensive immune cell infiltration and 
satellite cell proliferation by Day 3 AI (data not shown), consistent with previously reported 
effects of both BaCl2 and snake venoms on mouse muscles (Caldwell et al., 1990; Lefaucheur and 
Sebille, 1995; McArdle et al., 1994). Formation of regenerating myofibers, identified by the 
presence of central myonuclei, was clearly evident by Day 7 AI (Fig. II.1A), and by Day 21 the 
regeneration was typically complete and regenerated myofibers reached the size of undamaged 
mature fibers (Fig. II.1A upper panels; also see Fig. II.1B below). Embryonic myosin heavy chain 
(eMHC) expression was detected in all the centrally nucleated myofibers on Day 7 (data not 
shown), confirming their nascent myofiber nature. This time course of regeneration is consistent 
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with those previously reported by others examining muscle regeneration post injury by BaCl2 
(Casar et al., 2004; Jansen and Pavlath, 2006; McArdle et al., 1994), snake venoms (Deponti et 
al., 2007; Lefaucheur and Sebille, 1995), or freezing (Horsley et al., 2003). Systemic rapamycin 
administration (daily at 1 mg per kg body weight) drastically impaired the regeneration process, 
evidenced by the abnormal muscle architecture, the presence of necrotic fibers, and infiltration of 
mononucleated cells even at Day 28 AI (Fig. II.1A, lower panels). When BaCl2 was injected into 
the gastrocnemius muscle, the regeneration process and rapamycin inhibition were 
indistinguishable from those of TA muscles (data not shown). 
 The average cross section areas (CSA) of the regenerating myofibers were measured. By 
Day 21 AI, regenerating myofibers had average CSA comparable to undamaged fibers (Fig. 
II.1B, black bars).  Impairment of regeneration by rapamycin was clearly reflected by the smaller 
average CSA of the regenerating myofibers throughout the time course examined (Fig. II.1B, 
gray bars). The rapamycin dosage administered was sufficient to inhibit mTORC1 signaling in 
muscles, as indicated by a dramatic decrease of S6 phosphorylation (see Fig. II.4B). Even after 8 
weeks, the regenerating myofibers in animals continually treated with rapamycin did not grow to 
the normal size (Fig. II.1B), although the overall muscle structure did improve (Fig. II.1A). 
Animals injected with rapamycin for up to 8 weeks did not display any visible symptoms, and 
rapamycin by itself did not affect myofiber size or structure (Fig. II.1A&B), consistent with 
previously reported observations (Bodine et al., 2001). In addition, food intake by the animals 
after injury was not affected by rapamycin injection (data not shown). There was also no visibly 
detectable change in physical activities of the mice after injury, or with rapamycin injection. 
Taken together, my observations suggest that rapamycin-sensitive mTOR signaling may be 
required for skeletal muscle regeneration. 
 
II.3.2. Rapamycin inhibits both nascent myofiber formation and myofiber growth during 
regeneration. 
 Since rapamycin did not completely block muscle regeneration (Fig. II.1A&B), I 
questioned whether rapamycin had any effect on the initial formation of regenerating myofibers. 
To this end, I quantified the number of regenerating myofibers on H&E stained muscle sections. 
On both Day 7 and Day 14 AI, rapamycin-injected mice had significantly fewer regenerating 
myofibers in their injured TA muscles (Fig. II.1C), suggesting that mTOR is at least partially 
responsible for the initial formation of new myofibers during regeneration. 
 The observations described in Fig. II.1 implied that rapamycin might also block the 
growth of myofibers during a later stage of regeneration, a process that may be molecularly 
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separable from the initial myofiber formation. To directly examine this possibility, I started 
administering rapamycin to BaCl2-injured mice on Day 7 AI, when new myofiber formation had 
already completed (see regenerating myofiber number comparison between Day 7 and Day 14 AI 
in Fig. II.1C) but the regenerating myofibers were still significantly smaller than mature 
myofibers (see Fig. II.1B). Indeed, in the presence of rapamycin, regenerating myofibers did not 
grow to normal size (Fig. II.2A, compared to Fig. II.1A upper panels). In fact, muscle maturation 
appeared to be blocked, rather than delayed, by rapamycin administration, as the average fiber 
size was still ~25% smaller than normal when examined 8 weeks after injury with continued daily 
rapamycin injection (Fig. II.2B). Hence, mTOR appears to be required for myofiber growth 
during regeneration. 
 
II.3.3. Generation and characterization of transgenic mice expressing mTOR mutants 
 To seek genetic validation for the involvement of mTOR in the rapamycin-sensitive 
processes and to probe the role of mTOR kinase activity, I established transgenic mice expressing 
rapamycin-resistant mTOR with (RR) or without (RR/KI) its kinase activity in the skeletal 
muscle. Both RR- and RR/KI-mTOR were tagged with the FLAG epitope at the N-terminus. 
Transgene expression was driven by the human skeletal muscle actin (HSA) promoter (Fig. 
II.3A). Transgene integration for both mTOR mutants was confirmed by Southern analysis (Fig. 
II.3B) and PCR (data not shown). Both the HSA-RR and HSA-RR/KI lines were confirmed to 
express FLAG-tagged recombinant mTOR protein in skeletal muscle (Fig. II.3C); no transgene 
expression was detected in the liver (data not shown). The level of recombinant protein 
expression was approximately 2 to 3-fold of that of the endogenous mTOR (Fig. II.3C, mTOR 
blot). 
 No obvious phenotype was observed from birth up to 8 months of age in either RR or 
RR/KI transgenic mice. The weight and size of the transgenic animals and their limb muscles 
were indistinguishable from those of WT animals when age-matched comparisons were made 
(data not shown). Examination of the TA muscle revealed no difference in the average myofiber 
cross-section area between RR-mTOR, RR/KI-mTOR and WT mice (Fig. II.4A). Despite the 
higher levels of transgene expression compared to the endogenous protein, the kinase-inactive 
mTOR did not behave as a dominant negative mutant, consistent with what we had observed with 
this mutant in cell culture with a similar degree of overexpession (our unpublished observations). 
To confirm the biochemical nature of the mTOR transgene products, I analyzed the homogenates 
of limb muscles from RR and RR/KI mice injected with rapamycin. As shown in Fig. II.4B, 
rapamycin injection drastically inhibited S6 phosphorylation, a common readout of mTORC1 
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activity, in both WT and RR/KI muscles, whereas RR muscles displayed complete rapamycin-
resistance in S6 phosphorylation. The inability of RR/KI-mTOR to support S6 phosphorylation in 
the presence of rapamycin is expected as S6K1 activation requires mTOR kinase activity. 
 
II.3.4. Muscle regeneration in RR-mTOR transgenic mice in the presence of rapamycin 
With the transgenic lines in hand, I first asked whether the expression of the recombinant 
RR-mTOR in skeletal muscle was able to reverse the rapamycin inhibitory effect on muscle 
regeneration. The RR-mTOR mice were subjected to BaCl2-induced injury in the TA muscle. In 
the absence of rapamycin, muscle regeneration in these mice was indistinguishable to that in WT 
mice (Fig. II.5A top panels, compared to Fig. II.1A top panels). When they were compared in the 
presence of rapamycin (administered from day 1 AI), the RR-mTOR muscles regenerated 
significantly better than WT muscles, as the overall muscle structure was completely restored by 
Day 21 AI (Fig. II.5A lower panels, compared to Fig. II.1A lower panels). The rapamycin-
resistant regeneration of the RR-mTOR muscles was also evidenced by a higher number of 
nascent regenerating myofibers (Fig. II.5B) and larger cross-section areas of the regenerating 
myofibers (Fig. II.5C) when compared to WT muscles. It was apparent, however, that both the 
formation of regenerating myofibers and their growth were delayed by rapamycin injection in the 
RR-mTOR mice, although eventually these muscles regenerated to the full extent (Fig. II.5B, Day 
14; Fig. II.5C, Day 28) (to be discussed in Discussion). 
 
II.3.5. The kinase activity of mTOR is dispensable for nascent myofiber formation but 
required for myofiber growth in muscle regeneration. 
To probe the requirement of mTOR kinase activity in muscle regeneration in vivo, I took 
advantage of the rapamycin-resistant mutation in mTOR, which allowed me to study the function 
of any mTOR mutants (in this case, the kinase-inactive mutant) while suppressing endogenous 
mTOR function with rapamycin. I subjected the RR/KI-mTOR mice to BaCl2-induced muscle 
injury, and characterized muscle regeneration in the presence or absence of systemic rapamycin 
administration. In the absence of rapamycin, regeneration of the RR/KI muscles was identical to 
that of WT muscles in the recovery of muscle structure (Fig. II.6A, upper panels), regenerating 
myofiber number (Fig. II.6B, black bars), and myofiber size (Fig. II.7A, black bars). This 
confirmed that RR/KI-mTOR transgene expression did not exert any dominant negative effect. 
When rapamycin had been administered from Day 1 AI, the regeneration of RR/KI muscles was 
much improved compared to WT muscles as indicated by the overall recovery of muscle structure 
by Day 21 AI (Fig. II.6A lower panels, compared to Fig. II.1A lower panels). Quantification of 
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myofiber numbers revealed that RR/KI muscles formed more regenerating myofibers than WT 
muscles in the presence of rapamycin (Fig. II.6B). Although the RR/KI muscles were partially 
sensitive to rapamycin (to be discussed later), it is important to note that the rate and degree of 
myofiber formation in the presence of rapamycin were indistinguishable between RR/KI and RR 
mice (compare Fig. II.6B to Fig. II.5B). These observations strongly suggest that the kinase 
activity of mTOR is dispensable for the initial formation of regenerating myofibers.  
Previously we had reported that mTOR regulates the initiation of C2C12 differentiation 
by controlling Igf2 mRNA expression in an mTOR kinase-independent manner (Erbay et al., 
2003). To investigate whether the same mechanism was involved in muscle regeneration in vivo, 
I examined the level of Igf2 mRNA in regenerating muscles by quantitative PCR. Igf2 levels in 
injured WT TA muscle peaked around Day 7 AI (data not shown) as reported by others (Paoni et 
al., 2002). This 13-fold increase of Igf2 was drastically inhibited by rapamycin administration 
(Fig. II.6C, black bars). In RR- and RR/KI-mTOR muscles, a similar degree of increase in Igf2 
mRNA was observed on Day 7 AI, but it was clear that this increase was partially resistant to 
rapamycin treatment (Fig. II.6C, compare grey and white bars to black bars). The RR and RR/KI 
muscles behaved indistinguishably in this case. These observations are in full agreement with 
mTOR regulation of Igf2 expression in the absence of mTOR kinase activity during the early 
phase of muscle regeneration. 
Although RR and RR/KI muscles displayed equal capacity in forming regenerating 
myofibers in the presence of rapamycin, the average myofiber size was affected by the genotype. 
As shown in Fig. II.7A, rapamycin treatment severely diminished the average CSA of the 
regenerating fibers in RR/KI-mTOR muscles, to a similar degree as that of the fibers in WT 
muscles, suggesting that mTOR kinase activity might be necessary for the growth of regenerating 
myofibers. To directly investigate the requirement of mTOR kinase activity for myofiber growth, 
I administered rapamycin beginning on Day 7 AI, when nascent myofibers had mostly formed but 
the average fiber size was significantly smaller than mature fibers (see Fig. II.1B&C). As shown 
in Fig. II.7B, while regenerating myofibers in RR/KI mice continued to grow from Day 7 to Day 
28 AI at a rate comparable to the growth of WT myofibers under normal conditions, rapamycin 
administration completely blocked RR/KI muscle growth. This block appeared to be permanent 
as no growth was evident even at 8 weeks AI with continued daily rapamycin injection (data not 
shown). On the other hand, RR-mTOR myofibers underwent full rapamycin-resistant growth 
(Fig. II.7B). Therefore, the kinase activity of mTOR is required for myofiber growth and 
maturation. 
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II.3.6. S6K1 is dispensable for nascent myofiber formation but required for myofiber 
growth in muscle regeneration. 
 S6K1 is a major downstream effector of mTORC1 signaling. To assess S6K1’s role in 
muscle regeneration, I created and examined s6k1 knockout mice. Previously reported embryonic 
stem cells with targeted deletion of s6k1 (Kawasome et al., 1998) were used to generate systemic 
knockout animals, which were viable and fertile but smaller in size (data not shown), consistent 
with the report by Thomas and colleagues (Um et al., 2004). The limb muscle weight (data not 
shown) and TA myofiber size (Fig. II.8B “uninjured”) in the s6k1-/- mice were also reduced 
compared to those in WT or heterozygous animals, in full agreement with the observations by 
Ohanna et al (Ohanna et al., 2005).  
 s6k1-/-, s6k1+/-, and WT mice were subjected to BaCl2-induced TA muscle injury, and 
muscle regeneration was examined on various days after injury. The formation of regenerating 
myofibers, indicated by the number of centrally nucleated myofibers on Day 7 and Day 14 AI, 
was indistinguishable among the three types of muscles (Fig. II.8A), suggesting that S6K1 is 
dispensable for the initial myofiber formation during regeneration.  
 Measurements of the cross section area of the regenerating myofibers, however, revealed 
a significant difference between s6k1-/- and WT or the heterozygous animals. While WT and 
s6k1+/- myofibers grew at a similar rate and reached the size of their uninjured counterparts by 
Day 28 AI, the s6k1-/- myofibers appeared to be arrested at a size significantly smaller than the 
uninjured myofibers (Fig. II.8B). Thus, in addition to the smaller average size of their myofibers 
before injury, the s6k1-/- muscles were impaired in the growth of regenerating myofibers. Taken 
together, I conclude that S6K1 plays a role in muscle growth but is not involved in the formation 
of nascent myofibers during regeneration. 
 
II.4. Discussion 
 Based on observations made in cell culture, we previously proposed that rapamycin-
sensitive mTOR signaling regulates myoblast differentiation at two different stages by distinct 
mechanisms (Erbay and Chen, 2001; Erbay et al., 2003; Park and Chen, 2005): the initiation of 
differentiation and nascent myotube formation are controlled by mTOR independent of its kinase 
activity and its target S6K1, whereas myotube growth and maturation require mTOR kinase 
activity. The current study was designed to examine mTOR function in muscle regeneration in 
vivo, and to validate the molecular mechanisms of mTOR signaling previously discovered in 
vitro in a physiological setting. In a mouse model of BaCl2-induced muscle 
degeneration/regeneration, I have found that rapamycin inhibits both the formation of 
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regenerating myofibers and the maturation of myofibers. This inhibitory effect of rapamycin is 
consistent with previously reported rapamycin inhibition of muscle re-growth after denervation-
induced atrophy (Bodine et al., 2001), and suggests the involvement of mTOR. To provide 
genetic evidence for mTOR function in the rapamycin-sensitive processes, I have generated and 
characterized transgenic mice with muscle-specific expression of rapamycin-resistant mTOR – 
RR-mTOR and its kinase-inactive counterpart RR/KI-mTOR. Rapamycin-resistant regeneration 
in the RR-mTOR muscles has provided definitive evidence for the function of mTOR in 
regeneration. 
 I have observed that regeneration of the RR-mTOR muscles is partially sensitive to 
rapamycin, especially at earlier time points of regeneration. This delay may be explained by the 
nature of the HSA promoter that drives the mTOR transgene expression, which is highly active in 
differentiated myofibers but has low basal activity in satellite cells or myoblasts (Nicole et al., 
2003). Although I cannot definitively rule out the possibility that the RR-mTOR recombinant 
protein is only partially active, or that rapamycin has some mTOR-independent effect, my 
observations indicate that RR-mTOR can significantly overcome rapamycin inhibition in both 
regenerating myofiber formation and myofiber growth. Due to its delayed activation, the HSA 
promoter would not be suitable for driving transgene expression for the purpose of studying 
satellite cell activation and proliferation. Future efforts to generate transgenic mice expressing 
mTOR mutants under the control of satellite cell-specific promoters, such as that of Pax7, would 
allow investigation into mTOR’s role in earlier events of muscle regeneration.  
 Although the kinase activity of mTOR is essential for almost all reported mTOR 
functions, we previously observed that mTOR regulation of the initiation of C2C12 myoblast 
differentiation was independent of its kinase activity, and that this myogenic function is mediated 
by IGF-II (Erbay and Chen, 2001; Erbay et al., 2003), which is critically involved in both satellite 
cell proliferation and differentiation (Hawke and Garry, 2001). In the current study, I have found 
that the kinase-inactive RR/KI-mTOR supports myofiber formation in the presence of rapamycin 
as effectively as RR-mTOR. Furthermore, Igf2 mRNA expression during regeneration is 
inhibited by rapamycin and partially rescued by both RR- and RR/KI-mTOR transgene 
expression. Taken together, these in vivo observations faithfully recapitulate our in vitro findings, 
and are consistent with a kinase-independent function of mTOR in the initial formation of 
myofibers during regeneration.  
 Rapamycin inhibits the continued growth of regenerating myofibers. Due to technical 
difficulties in quantifying nuclei numbers in centrally nucleated myofibers, I are not able to assess 
whether the myofiber growth examined in my study requires further addition of nuclei (i.e. 
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fusion) or is only a result of mass increase. In any event, this growth requires mTOR in its kinase-
active form, as it is supported by RR-mTOR, but not RR/KI-mTOR, in the presence of 
rapamycin. These observations fully corroborate our previous findings in vitro, that rapamycin-
sensitive mTOR signaling is required for myotube maturation and hypertrophy (Park et al., 2005; 
Rommel et al., 2001). I have also characterized s6k1-/- mice, and found that growth of 
regenerating myofibers is impaired in these mice but the number of regenerating fibers is 
comparable to that in WT mice. These findings confirm the requirement of S6K1 for muscle 
growth (Ohanna et al., 2005), and provide in vivo validation for the S6K1-independent initiation 
of myoblast differentiation in vitro (Erbay and Chen, 2001; Erbay et al., 2003). They are also in 
full agreement with the kinase-independent role of mTOR in regeneration since S6K1 is a major 
substrate of the mTOR kinase. 
 Most recently, it has been reported that muscle-specific ablation of raptor – the factor that 
defines the rapamycin-sensitive mTORC1, but not rictor, leads to a down-shift of myofiber size 
distribution in skeletal muscles, and signs of progressive muscle dystrophy (Bentzinger et al., 
2008). The effect of raptor knockout on myofiber size mirrors the effect of s6k1 knockout 
(Ohanna et al., 2005), confirming mTORC1’s role in muscle size control. It would be reasonable 
to speculate that raptor-/- muscles would be able to form nascent myofibers upon injury like 
rapamycin-treated RR/KI-mTOR muscles and s6k1-/- muscles, since raptor function is tightly 
associated with mTOR kinase activity by recruiting substrates (such as S6K1) for mTOR (Choi et 
al., 2003; Nojima et al., 2003; Schalm et al., 2003). Of significance, daily rapamycin 
administration up to 2 months in mice does not induce any detectable changes in muscle size, or 
signs of muscle dystrophy (our unpublished observation) (Bodine et al., 2001), even though the 
effect of rapamycin on regeneration upon muscle injury is quite dramatic. The discrepancy 
between pharmacological and genetic inhibition of mTORC1 can potentially be explained by the 
fact that gene deletions in animals, even when induced by Cre under the control of a muscle-
specific promoter (HSA in the case of raptor deletion), often have developmental effects. As 
such, the mTOR transgenic mice combined with rapamycin treatment offer an experimental 
system that allows more precise probing of mTOR function in adult muscle remodeling and 
function without the complication of developmental influences. The comparison between RR- 
and RR/KI-mTOR transgenics also enables direct assessment of the functionality of the mTOR 
kinase activity. These mouse models created here provide useful tools for future investigation of 
mTOR function and signaling mechanisms in various aspects of muscle biology. 
 In conclusion, I have demonstrated that mTOR controls myofiber formation and myofiber 
growth during muscle regeneration via kinase-independent and kinase-dependent mechanisms, 
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respectively. The expression of Igf2 during the early phase of regeneration is sensitive to 
rapamycin in an mTOR kinase-independent manner, whereas S6K1 is required for the mTOR 
kinase-dependent myofiber growth. My results provide in vivo validation for the myogenic 
mechanisms of mTOR previously discovered in vitro. Of particular significance is the kinase-
independent mechanism of mTOR at the initial stage of myogenesis, which has not been reported 
for any other functions of mTOR. 
 
II.5. Contributions of Co-Worker  
This project is a collaboration work with Ai-Luen Wu. Wu established the RR- and 
RRKI-mTOR transgenic lines and contributed to Fig. II.3B.
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II.6. Figures 
 
 
 
 
Figure II.1. Muscle regeneration is impaired by rapamycin. Injury of the hind limb TA 
muscle was induced by BaCl2 injection in 10-week-old male mice. The “no injury” control 
muscles received saline injection. Where indicated, rapamycin (1 mg/kg) was administered daily 
via intraperitoneal injection starting on Day 1 AI. Vehicle was injected in all mice not receiving 
rapamycin. On various days AI, the animals were sacrificed and TA muscles were isolated and 
cryosectioned. (A) TA muscle cross-sections were stained with H&E. Scale bar represents 50 µm. 
Two representative images are shown for Day 21 and Day 28 to demonstrate the abnormal 
muscle structure as well as smaller regenerating myofibers. (B) CSAs of regenerating myofibers, 
identified by their central nuclei on H&E stained sections, were quantified. At least 100 
regenerating myofibers were measured for each muscle section. (C) The number of regenerating 
myofibers was counted in an area of 614,400 µm2 for each sample. For all the data, the average 
results (n=7 mice for each data point) are shown, with error bars representing SD. Paired two-
tailed t-tests were performed to compare data from control and rapamycin-treated samples at each 
time point in (C). *P<0.01. 
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Figure II.2. Rapamycin suppresses regenerating myofiber growth. Mouse TA muscles were 
injured by BaCl2 injection, followed by daily intraperitoneal injection of rapamycin (1 mg/kg) 
starting on Day 7 AI. On the days indicated, the animals were sacrificed and TA muscles were 
isolated and cryosectioned. (A) TA muscle cross-sections were stained with H&E. Scale bar 
represents 50 µm. (B) CSAs of regenerating myofibers were quantified. At least 100 regenerating 
myofibers were measured for each muscle section. The average results (n=7 mice for each data 
point) are shown, with error bars representing SD. The control data (black bars) are from Fig. 
II.1B. 
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Figure II.3. Generation of transgenic mice expressing mTOR mutants. (A) A diagram of the 
mTOR transgene expression vector is shown. FLAG-tagged mTOR (RR or RR/KI) was under the 
control of the human skeletal muscle actin (HSA) promoter. The NruI—BstZ17I fragment was 
used for pronuclear injection. BamHI sites and the probe used for Southern analysis of the 
transgene integration are shown. (B) A representative Southern blot for genomic DNA isolated 
from RR and RR/KI mice tails is shown. (C) Transgene expression was examined by Western 
analysis of limb muscle homogenates, using anti-FLAG and anti-mTOR antibodies. Anti-tubulin 
blot served as a loading control. 
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Figure II.4. Characterization of mTOR transgenic mice. (A) TA muscles from 10-week-old 
WT, RR and RR/KI mice were isolated, cryosectioned and stained with H&E. The average CSAs 
with SD are shown below the images (n=4-8 mice). Scale bar represents 50 µm. (B) Limb muscle 
homogenates were isolated from mice injected with rapamycin (1 mg/kg) or vehicle, and 
subjected to Western analysis for phospho-S6, a read-out for mTORC1 signaling activity. Anti-
tubulin blot served as a loading control. 
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Figure II.5. RR-mTOR supports rapamycin-resistant muscle regeneration. RR-mTOR mice 
were subjected to TA muscle injury, rapamycin injection, and muscle isolation as described in 
Fig. II.1 legend. (A) TA muscle cross-sections generated on various days AI were stained with 
H&E. Scale bar represents 50 µm. (B) The number of regenerating myofibers was counted within 
an area of 614,400 µm2 for each sample. (C) CSAs of regenerating myofibers were quantified. At 
least 100 regenerating myofibers were measured for each muscle section. For all the 
quantification data, the average results (n=7 mice for each data point) are shown with error bars 
representing SD. The WT data are from Fig. II.1B&C. In (B), paired two-tailed t-tests were 
performed to compare RR to WT samples under the same conditions (same day and same 
treatment), *P<0.05. In (C), two-way repeated measures ANOVA was performed to analyze 
regeneration in the presence of rapamycin over the time course, and between WT and RR 
genotypes. Overall analysis: time, P<0.0001; genotype, P<0.0001; interaction, P<0.0001. 
Significant difference between WT and RR at each time point: **P<0.001. 
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Figure II.6. Defective muscle regeneration in RR/KI-mTOR transgenic mice in the presence 
of rapamycin. RR/KI-mTOR mice were subjected to TA muscle injury, rapamycin injection, and 
muscle isolation as described in Fig. II.1 legend. (A) TA muscle cross-sections generated on 
various days AI were stained with H&E. Scale bar represents 50 µm. (B) The number of 
regenerating myofibers was counted within an area of 614,400 µm2 for each sample. The average 
results (n=7 mice for each data point) are shown with error bars representing SD. Paired two-
tailed t-tests were performed to compare RR/KI to WT samples under the same conditions (same 
day and same treatment). **P<0.001. (C) WT, RR-, and RR/KI-mTOR mice were subjected to 
muscle injury, rapamycin injection, and muscle isolation as indicated.  Total RNA was extracted, 
and Igf2 mRNA was measured by qRT-PCR. Relative levels compared to those of Day 1 AI are 
shown with error bars representing SD (n=3). 
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Figure II.7. Kinase activity of mTOR is dispensable for nascent myofiber formation but 
required for myofiber growth in muscle regeneration. (A) WT and RR/KI mice were 
subjected to TA muscle injury, and rapamycin injection starting on Day 1 AI, followed by muscle 
isolation and cryosection on Day 7, 14, 21, 28 AI. (B) WT, RR, and RR/KI mice were subjected 
to TA muscle injury, and rapamycin injection starting on Day 7 AI, followed by muscle isolation 
and cryosection on Day 14, 21, 28 AI. CSAs of regenerating myofibers were quantified. At least 
100 regenerating myofibers were measured for each muscle section. The average results (n=7 
mice for each data point) are shown, with error bars representing SD. The WT data are from Figs. 
1B and 2B. In (B), two-way repeated measures ANOVA was performed to analyze regeneration 
in the presence of rapamycin over the time course and between different genotypes. Overall 
analysis: time, P<0.0001; genotype, P<0.0001; interaction, P=0.001. Significant difference 
between WT and transgenics at each time point: **P<0.001. 
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Figure II.8. S6K1 is dispensable for nascent myofiber formation but required for myofiber 
growth in muscle regeneration. WT, s6k1+/-, and s6k1-/- mice were subjected to TA muscle 
injury, muscle isolation, and H&E staining as described in Fig. II.1 legend. (A) The number of 
regenerating myofibers was counted within an area of 614,400 µm2 for each sample. No 
statistically significant difference was found when comparing muscles of three genotypes at each 
time point. (B) CSAs of regenerating myofibers were quantified. At least 100 regenerating 
myofibers were measured for each muscle section. The average results (n=4 mice for each data 
point) are shown, with error bars representing SD. Two-way repeated measures ANOVA was 
performed to analyze CSA data over regeneration time and between different genotypes. Overall 
analysis: time, P<0.0001; genotype, P<0.0001; interaction, P=0.26. Significant difference 
between genotypes at each time point: *P<0.05, **P<0.001. Significant difference between Day 
28 AI and uninjured: †P<0.05. 
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CHAPTER III. IGF-II IS REGULATED BY MICRORNA-125B IN  
SKELETAL MYOGENESIS 
 
III.1. Introduction 
During skeletal muscle development, cells from the somites commit to myogenic lineage 
and progress along the myogenic pathway by proliferation, terminal differentiation, and 
formation of multinucleated myofibers (Buckingham, 2001). The entire process is guided by 
various environmental cues and regulated by distinct signaling pathways, resulting in the 
activation of specific transcription factors, and subsequent reprogramming of gene expression 
(Lassar and Munsterberg, 1994; Naya and Olson, 1999; Perry and Rudnicki, 2000; Weintraub, 
1993). Skeletal muscle regeneration is one of the adult muscle remodeling processes, which 
involves satellite cell (or other types of muscle stem cell) activation, proliferation, and 
differentiation to form new myofibers (Wagers and Conboy, 2005). Muscle regeneration shares a 
high extent of regulatory mechanisms with embryonic myogenesis (Parker et al., 2003), and 
serves as an experimental model to study the regulation of skeletal myogenesis in vivo. 
Myogenesis is also largely recapitulated by in vitro culture of myoblasts which, in response to 
serum withdrawal, exit cell cycle, differentiate, and fuse to form myotubes. 
The insulin-like growth factors (IGFs) have long been established to play critical roles in 
skeletal myogenesis both during development and in adult muscle remodeling (Florini et al., 
1996; Florini et al., 1991a). IGF-II, an embryonic regulator of myogenesis and an autocrine factor 
that initiates myoblast differentiation in vitro (Florini et al., 1991b), is regulated at the 
transcriptional level through a muscle-specific enhancer by mammalian target of rapamycin 
(mTOR) signaling (Erbay et al., 2003). IGF-II translation has also been shown to be regulated by 
a RNA binding protein, LIN-28, during skeletal myogenesis (Polesskaya et al., 2007). Given its 
critical role in the initiation of myogenesis, it would not be surprising if the production of IGF-II 
during myogenesis were under additional modes of regulation yet to be discovered.  
 
MicroRNAs (miRNAs), ~22-nt non-coding RNAs regulating gene expression at post-
transcriptional levels, have emerged as key regulators for many developmental processes (Bartel, 
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2009; Bushati and Cohen, 2007), including skeletal myogenesis. The central role of miRNAs in 
skeletal muscle development has been demonstrated by the detrimental consequence of Dicer 
deletion in embryonic skeletal muscle (O'Rourke et al., 2007). Several muscle-specific miRNAs 
that control various aspects of myogenesis have been identified and characterized (Callis et al., 
2008; Williams et al., 2009). The best-studied are the miR-1/206 and miR-133 families, which 
regulate fundamental processes of myogenesis including myoblast/satellite cell proliferation and 
differentiation under the control of myogenic transcription factors (Williams et al., 2009 and 
references therein). Additional miRNAs reported to function in skeletal myogenesis include miR-
24 (Sun et al., 2008), miR-26a (Wong and Tellam, 2008), miR-27b (Crist et al., 2009), miR-29 
(Wang et al., 2008), miR-181 (Naguibneva et al., 2006b), miR-214 (Juan et al., 2009), miR-
221/222 (Cardinali et al., 2009), miR-486 (Small et al., 2010), and miR-499 (van Rooij et al., 
2009). Direct targets in muscles have been identified for some of these miRNAs, but not others. It 
would be reasonable to speculate that more myogenic miRNAs are yet to be discovered.  
miR-125b, as well as its paralog miR-125a, is the homolog of C. elegans lin-4, the first 
miRNA reported (Lee et al., 1993). Both miR-125a and miR-125b are highly expressed in mouse 
brains, but only miR-125b is easily detectable in several other tissues including heart, lung, 
spleen, and skeletal muscle (Lagos-Quintana et al., 2002). miR-125 has been implicated in 
neuronal differentiation of mouse P19 cells by targeting the RNA binding protein LIN-28 (Wu 
and Belasco, 2005), and it also promotes neuronal differentiation in human cells by suppressing 
multiple targets (Le et al., 2009b). Moreover, it has been demonstrated that miR-125b targets p53 
in stress-induced apoptosis (Le et al., 2009a). However, a function for miR-125b in skeletal 
muscle has never been reported despite its notable expression in the muscle. Here I find that miR-
125b negatively modulates myoblast differentiation in vitro and muscle regeneration in vivo. I 
identify IGF-II as the molecular target of miR-125b in skeletal myogenesis. Furthermore, my 
results suggest that mTOR signaling controls the levels of miR-125b during myogenesis both in 
vitro and in vivo. 
 
III.2. Materials and Methods 
III.2.1. Antibodies and other reagents. Anti-MHC (MF20) and anti-myogenin (F5D) were 
obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the 
NICHD, National Institutes of Health and maintained by The University of Iowa, Department of 
Biological Sciences. Anti-tubulin was from Abcam. Anti-BrdU was from Sigma-Aldrich. All 
secondary antibodies were obtained from Jackson ImmunoResearch Laboratories, Inc. 
Rapamycin was from LC Labs. All other reagents were from Sigma-Aldrich. 
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III.2.2. Cell culture and transfection. C2C12 myoblasts were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 1 g/L glucose with 10% fetal bovine serum at 
37°C with 7.5% CO2. Primary myoblasts were maintained in F-10 medium supplied with 25 
ng/ml bFGF and 20% fetal bovine serum at 37°C with 7.5% CO2. To induce differentiation, cells 
were plated on tissue culture plates coated with 0.2% gelatin and grown to 100% confluence for 
C2C12 and 60-70% confluence for primary myoblasts, changed into differentiation medium 
(DMEM containing 2% horse serum), and replenished with fresh medium daily for 3 days 
(C2C12) or 2 days (primary myocytes). C2C12 myoblasts and myocytes were transfected using 
Lipofectamine 2000 (Invitrogen) for RNA duplexes. Introduction of LNAs and luciferase 
reporters into C2C12 cells was performed using Amaxa Nucleofector (Solution V, program B-
032) following the manufacturer’s recommendations. HEK293 cells were maintained in DMEM 
containing 4.5 g/L glucose with 10% fetal bovine serum at 37°C with 5% CO2, and transfected 
using Polyfect (Qiagen). 
III.2.3. Mouse primary myoblast isolation. All animal experiments in this study followed 
protocols approved by the Animal Care and Use Committee at the University of Illinois at 
Urbana-Champaign. Five- to 7-day-old neonates were euthanized by cervical dislocation, and 
rinsed in 70% ethanol and penicillin/streptomycin/fugizone antibiotic solution.  Hind leg muscles 
were isolated and minced in HBSS, digested in dispase II (2.4 U/mL, Roche) and collagenase D 
(1.5 U/mL, Roche) solution containing 2.5 mM CaCl2 at 37°C for 2hr. Upon sequential filtering 
through 70 µm and 40 µm cell strainers (BD biosciences), the cells were collected by 
centrifugation at 350 g, and resuspended in F-10 culture medium. Serial plating was performed to 
enrich myoblasts and eliminate fibroblasts. 
III.2.4. Mouse muscle injury and regeneration. Ten-week-old male FVB mice were used in all 
the regeneration experiments. Muscle injury was induced by injection of BaCl2 (50 µL of 1.2% 
w/v in saline) into TA muscles as previously described (Ge et al., 2009). On various days after 
injury, the mice were euthanized and the TA muscles were collected, followed by cryosection and 
staining as described below. 
III.2.5. Muscle tissue cryosection and analysis. TA muscles were isolated by dissection, frozen 
in liquid nitrogen-cooled 2-methylbutane, and embedded in TBS tissue freezing medium (Fisher 
Scientific). Sections of 10 μm thickness were made with a Microm HM550 cryostat at -20°C, 
placed on uncoated slides, and stained with hematoxylin and eosin (H&E). The stained slides 
were examined with a Leica DMI 4000B microscope with a 10x dry objective (Leica Fluotar, 
numerical aperture 0.4), and the phase contrast images were captured at 24-bit at room 
temperature using a RETIGA EXi camera equipped with Qcapture Pro51 software (QImagingTM). 
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The images were then processed in Adobe Photoshop CS2, where brightness and contrast were 
adjusted. An area of 614,400 µm2 at the center of degenerated region of each TA muscle was 
selected for scoring centrally nucleated regenerating myofiber numbers and their cross-section 
area (CSA). 
III.2.6. Plasmids and oligonucleotides. The Igf2 3’UTR reporter was generated by inserting the 
entire 3’UTR of mouse Igf2 gene into the pMIR-REPORTER vector (Applied Biosystems) 
downstream of luciferase gene through Mlu I and Pme I sites. The mutant Igf2 3’UTR reporters 
were created by mutating the seed region of the predicted miR-125b site (UCAGGG to 
AGUCCC) or miR-150 site (GUUGGGAG to CAACCCUC) by nested PCR. RNA duplexes for 
miRNAs and siEGFP (siRNA against EGFP) and LNA-containing oligonucleotides were custom-
synthesized by Integrated DNA Technology. The sequences of the LNA oligonucleotides are as 
follows, with LNA-modified nucleotides indicated by capital letters. Anti-miR-125b: 
tcacaagTTAGGGTCtcaggga (distinguishable from miR-125a by two LNA-modified nucleotides).  
Scramble: catgtcaTGTGTCACatctctt. miRIDIAN miR-125b mimic and a negative control (cel-
miR-67, which has minimal sequence identity with miRNAs in human, mouse and rat) were 
purchased from Dharmacon. Dy547-cel-miR-67 and FAMTM-anti-miR negative control were 
from Dharmacon and Ambion, respectively. 
III.2.7. Northern blotting. Antisense DNA oligonucleotides for miR-125b and let-7a were end-
labeled with γ-[32P]ATP. The RNA Decade Maker (Applied Biosystems) was similarly 
radiolabeled as size markers. RNA (20 μg per sample) was separated on 12% denaturing 
polyacrylamide gels, transferred to nylon membranes (GE Healthcare), and UV cross-linked. 
Prehybridization and hybridization with probe were performed in ULTRAhyb hybridization 
buffer (Applied Biosystems) at 42°C for 2 h and overnight, respectively. The membranes were 
then washed with 2× SSC and 0.1% SDS at 42°C, followed by exposure to x-ray films. 
III.2.8. BrdU labeling. Subconfluent C2C12 myoblasts were incubated in BrdU (final 
concentration 10 µM) under growth condition for 2 hrs, and then fixed with 3.7% formaldehyde. 
After treatment by 4N HCl, immunostaining with anti-BrdU antibody and FITC-labeled anti-
mouse IgG was carried out, and fluorescence microscopy was performed as described in the 
“Immunofluorescence microscopy and quantitative analysis of myocytes” section below. 
III.2.9. Western blotting. Cells were lysed in a buffer containing 50 mM Tris-HCl, pH 7.2, 150 
mM NaCl, 1% NP-40, and 1% protease inhibitor cocktail (Sigma). The lysates were cleared by 
micro-centrifugation at 14,000 rpm, and then mixed with SDS sample buffer. Proteins were 
resolved on SDS-PAGE and transferred onto PVDF membrane (Millipore), and incubated with 
various antibodies following the manufacturer’s recommendations. Detection of horseradish 
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peroxidase-conjugated secondary antibodies was performed with Western LightningTM 
Chemiluminescence Reagent Plus (Perkin Elmer Life Sciences, Inc.), and images were developed 
on X-ray films. Quantification of Western band intensities was performed by densitometry of X-
ray images using the software Image J. 
III.2.10. Immunofluorescence microscopy and quantitative analysis of myocytes. C2C12 
cells differentiated in 12-well plates were fixed and stained for MHC and DAPI as previously 
described (Park and Chen, 2005). The secondary antibody for MHC immunostaining was FITC-
labeled anti-mouse IgG. The stained cells were examined with a Leica DMI 4000B microscope 
with a 10x dry objective (Leica Fluotar, numerical aperture 0.4), and the fluorescent images were 
captured using a RETIGA EXi camera at 8-bit at room temperature using a RETIGA EXi camera 
equipped with Qcapture Pro51 software (QImagingTM). The images were then pseudo-colored in 
Adobe Photoshop CS2, where brightness and contrast were adjusted. The differentiation and 
fusion indexes were calculated as the percentage of nuclei in MHC-positive myocytes and 
myotubes with ≥2 nuclei, respectively. Each data point was generated from at least 200 randomly 
chosen MHC-positive cells or myotubes. 
III.2.11. Real-time quantitative PCR. Mouse TA muscles were isolated, ground into powder in 
liquid nitrogen, and lysed in Trizol (Invitrogen). C2C12 cells or mouse primary myoblasts were 
lysed directly in Trizol. RNA was isolated following the manufacturer’s protocol. qRT-PCR for 
Igf2 mRNA was performed as previously described (Yoon and Chen, 2008). miR-125b levels 
were quantified using a qPCR-based Taqman assay kit (Applied Biosystems) specifically 
designed for miR-125b (not miR-125a). SnoRNA-202, a commonly employed mouse internal 
reference, was used as the internal control for normalization. We confirmed that Ct values of 
snoRNA-202 did not change from sample to sample in any systematic manner under all 
conditions (data not shown). 
III.2.12. Lentivirus-mediated RNAi. shRNAs in the pLKO.1-puro vector for knocking down 
mTOR and S6K1 were purchased from Sigma-Aldrich (MISSION® TRC). Lentivirus packaging 
and testing were performed as previously described (Yoon and Chen, 2008). The Sigma clone ID 
for the shRNA constructs used in this study are:  mTOR #1, NM_020009.1-7569s1c1; mTOR #2, 
NM_020009.1-5493s1c1; S6K1 #1, NM_028259.1-264s1c1; S6K1 #2, NM_028259.1-616s1c1. 
C2C12 cells were transduced with lentiviruses in growth medium containing 8 μg/ml polybrene, 
selected in 2 μg/ml puromycin for one day, followed by plating into 12-well plates for 
differentiation. 
III.2.13. Luciferase assays. C2C12 or HEK293 cells transfected with wide type or mutant Ig2 
3’UTR reporter were lysed in Passive Lysis Buffer (Promega), and luciferase assays were 
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performed using the Luciferase Assay Systems kit (Promega) following the manufacturer’s 
protocol. 
III.2.14. Measurement of secreted IGF-II. Media were collected from differentiating C2C12 
cultures, and subjected to measurement of secreted IGF-II using the DuoSet ELISA Development 
System for mouse IGF-II (R&D Systems) following the manufacturer’s protocol. 
III.2.15. Statistical analysis. All data are presented as mean ± standard deviation (SD). 
Whenever necessary, statistical significance of the data was analyzed by performing one-sample 
t-tests or paired t-tests. The specific types of tests and the P values, when applicable, are indicated 
in figure legends. 
 
III.3. Results 
III.3.1. miR-125b is down-regulated during myoblast differentiation in vitro and muscle 
regeneration in vivo.  
 In a microRNA profiling that we had previously performed (Sun et al., 2010), miR-125b 
was found to be down-regulated during C2C12 myoblast differentiation. The closely related miR-
125a was detected at a much lower level, consistent with the findings from other reports (Chen et 
al., 2006; Inose et al., 2009), and unchanged upon differentiation (Sun et al., 2010). To confirm 
the down-regulation of miR-125b observed in our microarray experiments, I examined miR-125b 
levels by quantitative RT-PCR in C2C12 cells induced to differentiate by serum withdrawal, 
which formed mature myotubes by day 3 as we had previously reported (Erbay et al., 2003). 
Indeed, miR-125b levels decreased by approximately 30% and 50% by Day 2 and 3 of 
differentiation, respectively (Fig. III.1A). A similar decrease of miR-125b levels was observed 
during differentiation of mouse primary myoblasts (Fig. III.1B). This decrease of miR-125b 
during myoblast differentiation was observed by others as well (Polesskaya et al., 2007), although 
its functional significance remained unknown. A recent report suggested that cell-cell contact 
could activate miRNA biogenesis globally (Hwang et al., 2009). Unlike primary myoblasts, 
which were differentiated at sub-confluence, C2C12 cell differentiation was typically initiated at 
100% confluence in our experiments. To assess any potential change in miR-125b levels due to 
cell-cell contact, I compared confluent culture (differentiation day 0) and proliferating myoblasts 
at ~60% confluence, and found no difference in miR-125b levels (Fig. III.1A). Thus, miR-125b 
biogenesis did not seem to be influenced by cell density under my experimental conditions. 
 Next, I assessed miR-125b expression during skeletal muscle regeneration in vivo in a 
mouse muscle injury model. I have recently shown that barium chloride (BaCl2) injection into the 
tibialis anterior (TA) muscle induces acute and severe myofiber degeneration on day 1 after 
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injury (AI), followed by myofiber regeneration that reaches completion by day 21-28 AI (Ge et 
al., 2009), consistent with previous reports by others (Caldwell et al., 1990; McArdle et al., 
1994). The levels of miR-1 and miR-206, two of the best-studied myogenic miRNAs, decreased 
on Day 3 AI and then increased during the regeneration time course (Fig. III.11), in full 
agreement with reported observations (Chen et al., 2010; Greco et al., 2009). As shown in Fig. 
III.1C, miR-125b levels declined on day 5 to day 7 AI – a period of active new myofiber 
formation (Ge et al., 2009), and returned to the basal level after that. This temporary decrease of 
miR-125b expression during regeneration in vivo is in line with the pattern of miR-125b 
expression during myoblast differentiation, which suggests a potentially negative role of miR-
125b in myogenesis. 
 
III.3.2. MiR-125b negatively regulates myoblast differentiation and muscle regeneration. 
To investigate a potential role of miR-125b in myoblast differentiation, I introduced a 
synthetic RNA duplex of miR-125b into C2C12 myoblasts, which were then induced to 
differentiate. As shown in Fig. III.2A, delivery of this duplex was highly effective, increasing 
cellular miR-125b levels by over 10-fold. This exogenous miR-125b dampened C2C12 
differentiation, as indicated by decreased myotube formation (Fig. III.2B). Quantification of the 
myotubes revealed significant decreases in both differentiation index (percentage of nuclei in 
MHC-positive cells) and fusion index (percentage of nuclei in myocytes with ≥2 nuclei) as shown 
in Fig. III.2C. I also introduced a locked nucleic acid (LNA)-containing anti-sense miR-125b 
oligonucleotide – anti-miR-125b (Naguibneva et al., 2006a) – into C2C12 cells to antagonize 
endogenous miR-125b. An LNA-containing oligonucleotide of a scrambled sequence with no 
complementarity to any known miRNAs served as a negative control. Anti-miR-125b reduced the 
cellular level of miR-125b by ~50% before the natural decline of miR-125b to a similar extent 
(Fig. III.2D), and this was accompanied by enhanced myotube formation (Fig. III.2B) as 
confirmed by increased differentiation and fusion indexes (Fig. III.2E). Anti-miR-125b did not 
change the cellular level of miR-125a (Fig. III.2F), validating the specificity of the anti-sense 
oligonucleotide. Two myogenic differentiation markers, myogenin (early) and MHC (late), were 
both expressed at levels correlated well with morphological differentiation upon miR-125b or 
anti-miR-125b expression (Fig. III.2G). The milder effect of anti-miR-125b on differentiation, 
compared to miR-125b, is consistent with its moderate impact on cellular miR-125b levels. 
Delivery of these oligonucleotides into C2C12 cells by transfection was assessed using the 
fluorescently labeled Dy547-cel-miR-67 (RNA duplex) and FAMTM-anti-miR (single stranded 
RNA), and the efficiency was ~90% and ~75%, respectively (Fig. III.12A). The degree of 
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oligonucleotide up-take varied among the transfected cells for both types of probes (Fig. III.12A), 
and it is possible that maximal manipulation of miR-125b did not occur in all transfected cells. 
Nevertheless, the inverse relationship between miR-125b levels and degrees of myoblast 
differentiation clearly evident from my data suggests that miR-125b negatively regulates 
myogenic differentiation. 
To probe a possible role of miR-125b in myoblast proliferation, I examined 
bromodeoxyuridine incorporation in C2C12 cells transfected with synthetic miR-125b or anti-
miR-125b. As shown in Fig. III.12B, manipulation of miR-125b levels had no effect on the 
proliferation of myoblasts. Furthermore, introduction of miR-125b or anti-miR-125b did not 
change the cell number by the end of differentiation (Fig. III.12C). Thus, miR-125b does not 
appear to regulate myoblast proliferation or survival, but rather has a specific role in myoblast 
differentiation. 
To probe the function of miR-125b in muscle regeneration in vivo, I introduced miR-
125b duplex and, separately, LNA-containing anti-miR-125b into the muscle injury site by co-
injecting the oligonucleotides with BaCl2. Muscle regeneration was then examined on Days 5, 7, 
and 14 AI. Representative cross sections of regenerating muscle on Day 7 AI are shown in Fig. 
III.3A; exogenous miR-125b impaired regeneration as indicated by the incomplete restoration of 
muscular structure at the injury site. Injection of any of the oligonucleotides in the absence of 
BaCl2 had no detectable effect on the muscles (Fig. III.3A “saline” panels). Regenerating 
myofibers, characterized by their centrally localized nuclei, were quantified, and the results 
revealed a reduction in the number of regenerating myofibers as well as a smaller average 
myofiber size upon injection of miR-125b duplex on Days 5, 7, and 14 AI (Fig. III.3B). On the 
other hand, anti-miR-125b injection enhanced muscle regeneration as evidenced by the modest – 
nonetheless statistically significant – increase in regenerating myofiber size on Days 5, 7 and 14 
AI (Fig. III.3C). The regenerating myofiber number was not further increased by anti-miR-125b 
at any time during regeneration (Fig. III.3C), likely because the natural decline of miR-125b (see 
Fig. III.1C) was sufficient to allow new myofiber formation to reach saturation at this time point 
(Ge et al., 2009). Injection of the two negative control oligonucleotides (siEGFP and LNA-
scramble) did not have any effect on the normal regenerating myofiber number and size (data not 
shown). The more modest effects of anti-miR-125b compared to duplex miR-125b could also be 
attributed to the difference in delivery efficiency and/or stability of the two types of 
oligonucleotides in muscles. Indeed, after a dramatic change of miR-125b levels in both miR-
125b- and anti-miR-125b-injected muscles on Day 1 AI, miR-125b remained elevated to a similar 
level as in non-injured muscles even on Day 7 AI, whereas anti-miR-125b injection no longer had 
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an effect on miR-125b levels by Day 5 AI (Fig. III.3D). I did not measure miR-125b levels 
beyond Day 7 AI since it was unlikely that the injected oligonucleotides would remain stable in 
vivo for extended time. Nevertheless, it is conceivable that a difference in myofiber formation 
could be observed at later time points even when the miR-125b level was no longer detectably 
changed, as an impact on the early stage of regeneration could change the entire time course of 
regeneration. In conclusion, consistent with its role in myoblast differentiation, miR-125b 
negatively impacts skeletal muscle regeneration in vivo. This is the first time that miR-125b is 
assigned a function in skeletal myogenesis. 
 
III.3.3. MiR-125b regulates IGF-II expression during myogenesis. 
I next asked what the molecular target(s) of miR-125b in myogenesis might be. 
MicroRNAs are believed to exert their function mostly by imperfect pairing with the 3’UTR of 
target mRNAs. A “seed region” at the 5’ end of the mature miRNA (starting at nucleotide 2, up to 
nucleotide 9) in the miRNA-mRNA duplex has been found to be largely responsible for effective 
miRNA targeting (Krek et al., 2005; Lewis et al., 2005; Stark et al., 2003), although “seedless” 
targeting has also been reported (Juan et al., 2009; Lal et al., 2009; Shin et al., 2010). 
Computational target prediction using miRanda, TargetScan, and PicTar yielded over a thousand 
potential gene targets for miR-125b. Because microRNAs are known to induce target mRNA 
degradation (Baek et al., 2008; Guo et al., 2010), I looked for predicted miR-125b targets that 
were up-regulated at the mRNA level during myoblast differentiation, taking advantage of gene 
expression profiles in differentiating C2C12 cells that we had previously generated (Park and 
Chen, 2005). This yielded a list of 11 predicted genes (Table III.1). Among them, IGF-II emerged 
as the most attractive candidate, as it has well-established roles in skeletal myogenesis (Florini et 
al., 1996; Florini et al., 1991a). It is noted that while the predicted miR-125b targeting sequence 
is identical in rat and mouse Igf2 genes, the human gene is different by two nucleotides in the 
seed region (Fig. III.13). However, the overall sequence conservation in the miR-125b target 
region between rodent and human Igf2 is high, and the human gene has potentially two more 
base-pairings with miR-125b outside of the 6-mer seed region (Fig. III.13). Seedless targeting of 
human Igf2 by miR-125b is possible, although it cannot be reliably predicted. I decided to focus 
on the mouse gene in the current study as the relevant experimental systems, both in vitro and in 
vivo, were readily available. 
To examine the possibility of miR-125b targeting IGF-II, I asked whether miR-125b 
regulated IGF-II expression. Both mRNA and protein levels of IGF-II increased during C2C12 
differentiation (Fig. III.4A, black bars) as previously reported (Erbay et al., 2003; Florini et al., 
 64 
1991b), which correlated well with the drop of miR-125b levels at the same time (compare Fig. 
III.4A and Fig. III.1A). More importantly, both mRNA and protein levels of IGF-II were reduced 
by 60-70% on day 2 and day 3 of differentiation when a chemically modified miR-125b mimic 
(miRIDIAN, Dharmacon) was transfected into the cells (Fig. III.4A). Native miR-125b duplex 
exerted a similar, but less pronounced, effect on IGF-II levels (data not shown). Conversely, anti-
miR-125b enhanced IGF-II expression at both mRNA and protein levels (Fig. III.4B). The degree 
of enhancement (1.3- to 2-fold) was quite remarkable considering that IGF-II was already up-
regulated drastically during normal differentiation. The inhibition of IGF-II by miR-125b is 
unlikely due to a secondary effect of miR-125b suppression of differentiation, as miR-125b 
duplex transfected into day-2 differentiated C2C12 myotubes potently inhibited IGF-II levels 
only after 12 hrs (Fig. III.4C).  
If IGF-II were a major functional target of miR-125b, exogenous IGF-II would be 
expected to override the negative effect of miR-125b on differentiation. Indeed, differentiation of 
C2C12 cells, measured by differentiation and fusion indexes, was no longer sensitive to miR-
125b duplex when the cell medium was supplemented with recombinant IGF-II (Fig. III.4D). 
This suggests that IGF-II may mediate a significant portion of miR-125b’s negative function in 
myogenesis, even if Igf2 is not the sole target of miR-125b.  
IGF-II expression increases acutely during injury-induced muscle regeneration and it 
peaks around 5-7 days AI before declining (Ge et al., 2009; Paoni et al., 2002), which inversely 
correlates with the expression pattern of miR-125b in regenerating muscles (Fig. III.1C). Co-
injection of miR-125b duplex with the injury-inducing BaCl2 lowered Igf2 mRNA levels by 
~45% on day 7 AI and, conversely, co-injection of anti-miR-125b increased Igf2 mRNA by 
~35% (Fig. III.5). Injection of those oligonucleotides in the absence of BaCl2 did not affect Igf2 
levels (Fig. III.5, non-injured). The efficacy of delivering oligonucleotides into muscles might not 
be optimal (see Fig. III.3D), but the observed effects are significant and fully consistent with 
miR-125b targeting IGF-II during muscle regeneration in vivo. 
 
III.3.4. The 3’UTR of Igf2 is targeted by miR-125b. 
 The 3’UTR of Igf2 was predicted to contain a single miR-125b target site with complete 
complementarity in the seed region (Fig. III.6A), starting at nucleotide 2670 of the 3048 bp 
3’UTR. It is important to note that the major isoforms of Igf2 mRNA in C2C12 cells, as well as 
in embryonic skeletal muscles, all have 3’UTR containing this putative miR-125b target site 
(Rosen et al., 1993). To directly examine the possibility of miR-125b targeting Igf2 3’UTR, I 
constructed a reporter with the entire Igf2 3’UTR inserted at the 3’ end of the luciferase gene. I 
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first tested the effect of miR-125b on this reporter in HEK293 cells, a non-myogenic cell line that 
has undetectable levels of miR-125b (Wu et al., 2006 and our unpublished observation). As 
shown in Fig. III.6B, transfected miR-125b duplex drastically inhibited the reporter activity, 
whereas it had no effect on the control reporter without the 3’UTR (“vector”). Most importantly, 
when the predicted miR-125b seed region in the 3’UTR was mutated, the mutant reporter no 
longer responded to miR-125b (Fig. III.6B), strongly suggesting that the predicted site is a bona 
fide target of miR-125b and it is solely responsible for miR-125b targeting of Igf2 3’UTR. 
 I also examined the reporters in C2C12 cells, and found that activity of the wild-type 
reporter increased steadily during differentiation (Fig. III.6C, black bars), which is consistent with 
activation of IGF-II expression through de-suppression of its 3’UTR. The miR-125b-site mutant 
reporter displayed a constant activity unchanged by the differentiation status of the cells (Fig. 
III.6C, gray bars), suggesting that miR-125b is most likely a major, if not the only, suppressor of 
the Igf2 3’UTR. Interestingly, the mutant reporter activity was at the same level as the wild-type 
reporter on Day 3 of differentiation, even though ~50% miR-125b remained in the cell (Fig. 
III.1A). This might suggest that the decreased miR-125b level had reached below a threshold for 
reporter inhibition. However, comparison of the absolute activities of the two reporters might not 
be reliable. The most important information derived from these data is the distinct trends the two 
reporters displayed during differentiation. Furthermore, synthetic miR-125b duplex completely 
suppressed the wild-type reporter activation during differentiation (Fig. III.6D). Collectively, 
these observations are in full agreement with miR-125b targeting the 3’UTR of Igf2 via a seed-
containing site during myoblast differentiation. 
 It has become increasingly evident that an mRNA can often be targeted by multiple 
miRNAs in its 3’UTR. To assess whether the 3’UTR of Igf2 may be targeted by other miRNAs in 
addition to miR-125b, I considered all miRNAs found in our miRNA profiling study (Sun et al., 
2010) to be down-regulated during C2C12 differentiation (a total of 12). Other than miR-125b, 
miR-150, miR-326 and miR-805 were also predicted by miRanda to target Igf2 3’UTR, each at a 
single site (Fig. III.14A and data not shown). However, unlike miR-125b, which was highly 
expressed in myoblasts, the other three miRNAs were all detected at very low levels in myoblasts 
based on our microarray data (data not shown). Furthermore, whereas miR-125b target site is 
located close to the 3’ end of the 3’UTR, the predicted miR-150, miR-326 and miR-805 target 
sites are all located in the middle of the 3’UTR, making them less likely to be true target sites 
(Grimson et al., 2007). Indeed, introduction of synthetic miR-150 duplex into HEK293 cells had 
no effect on the Igf2 3’UTR reporter (Fig. III.14B). Furthermore, when the putative miR-150 
target site was mutated in its seed region (Fig. III.14A), the mutant reporter behaved identically to 
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the wild-type reporter during C2C12 differentiation (Fig. III.14C). These results suggest that 
miR-150 is unlikely to regulate Igf2, and they also serve as negative controls that validate the 
reporter assays (Fig. III.6) identifying miR-125b as a bona fide Igf2 regulator. Although my 
observations do not definitively eliminate the possibility of other miRNAs and/or target sites 
being involved in regulating Igf2 3’UTR, taken together they strongly support the notion that 
miR-125b plays a predominant role in the regulation of IGF-II during skeletal myogenesis. 
 
III.3.5. MiR-125b expression during myogenesis is controlled by mTOR in a kinase-
independent manner. 
 Previously we had reported that mTOR regulates the expression of IGF-II at the 
transcriptional level during initiation of myoblast differentiation (Erbay et al., 2003). I wondered 
whether the miRNA regulation of IGF-II expression could also be controlled by mTOR. To that 
end, I first examined the effect of rapamycin, a specific inhibitor of mTOR. The results of qPCR 
assays indicated that rapamycin treatment completely prevented the decline of mature miR-125b 
during differentiation in both C2C12 cells and primary myocytes (Fig. III.7A). The natural 
decline of miR-125b during C2C12 differentiation and the effect of rapamycin to sustain miR-
125b levels were also confirmed by Northern blotting (Fig. III.7B). To further confirm the 
involvement of mTOR in the regulation of miR-125b expression, I knocked down mTOR in 
C2C12 cells by lentivirus-delivered shRNA. As shown in Fig. III.7C, knockdown of mTOR 
prevented the decline of miR-125b during differentiation; two shRNAs with independent target 
sequences yielded similar results, thus excluding off-target effects of RNAi. Furthermore, 
rapamycin treatment abolished the increase of Igf2 3’UTR reporter activity during differentiation 
(Fig. III.7D), as would be expected for mTOR control of miR-125b. 
 To gain further insight into the regulation of miR-125b biogenesis during myoblast 
differentiation, I measured the levels of miR-125b primary transcripts (pri-miR-125b). Two genes 
encode miR-125b at distinct chromosomal loci: mir-125b-1 and mir-125b-2. While I were unable 
to detect pri-miR-125b-2 by qRT-PCR, I observed a decrease of pri-miR-125b-1 during 
differentiation that mirrored the decline of mature miR-125b and was prevented by rapamycin 
treatment (Fig. III.7E). These data, together with the fact that precursor miR-125b (pre-miR-
125b) was not detectable by Northern analysis at any point of the differentiation (Fig. III.7B), 
imply that miR-125b biogenesis during myogenic differentiation is unlikely to be regulated at pri-
miR-125b or pre-miR-125b processing. Instead, my observations suggest that miR-125b is 
regulated at the transcriptional level under the control of mTOR signaling. 
 Since mTOR signaling regulates IGF-II transcription in a non-canonical manner that is 
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independent of mTOR kinase activity (Erbay et al., 2003), I decided to probe the kinase-
dependence of mTOR regulation of miR-125b in myoblast differentiation, taking advantage of 
C2C12 cell lines stably expressing rapamycin-resistant (RR) and rapamycin-resistant/kinase-
inactive (RR/KI) mTOR (Erbay et al., 2003). In contrast to parental C2C12 cells, in which 
rapamycin treatment prevented miR-125b down-regulation during differentiation (Fig. III.7A), 
RR-mTOR cells displayed miR-125b down-regulation resistant to rapamycin (Fig. III.8A), 
confirming that the effect of rapamycin was mediated by mTOR. Remarkably, the RR/KI-mTOR 
cells behaved identically to the RR-mTOR cells in preserving miR-125b regulation in the 
presence of rapamycin (Fig. III.8B), indicating that the kinase activity of mTOR is not required. 
S6K1 is a major target of mTOR kinase in the regulation of cell growth (Fingar et al., 2002) but 
has been shown to be dispensable for mTOR regulation of IGF-II expression during myogenesis 
(Erbay et al., 2003). I found that knockdown of S6K1 had no effect on the regulation of miR-
125b during differentiation (Fig. III.8C), consistent with kinase-independent mTOR regulation of 
miR-125b and IGF-II.  
 To seek in vivo validation of the observations described above, I examined the effect of 
rapamycin on miR-125b levels in regenerating muscles. I found that the transient decrease of 
miR-125b during muscle regeneration in wild-type mice (day 5 and day 7 AI) was prevented by 
rapamycin administration (Fig. III.9A). This rapamycin sensitivity was absent in transgenic mice 
expressing muscle-specific RR-mTOR (Fig. III.9B), which displayed rapamycin-resistant muscle 
regeneration (Ge et al., 2009), validating that rapamycin specifically targets mTOR in the 
regenerating muscle. Strikingly, RR/KI-mTOR transgenic muscles, which I had previously shown 
to have normal myofiber formation but impaired fiber growth during regeneration in the presence 
of rapamycin (Ge et al., 2009),  also displayed rapamycin-resistant miR-125b down-regulation 
during regeneration (Fig. III.9C), indistinguishable from RR-mTOR muscles. Therefore, I 
conclude that kinase-independent mTOR signaling is upstream of miR-125b biogenesis during 
skeletal myogenesis both in vitro and in vivo. 
 
III.4. Discussion 
My study has identified the first miRNA regulator of IGF-II in skeletal myogenesis, and 
revealed a novel function of miR-125b in the negative control of myoblast differentiation in vitro 
and muscle regeneration in vivo. Although it is possible that other miRNAs are yet to be 
identified to target IGF-II in myogenesis, my observation that mutation of the seed region of the 
single predicted miR-125b target site abolished the regulation of the full-length Igf2 3’UTR 
reporter during myoblast differentiation (Fig. III.6C) strongly suggests that miR-125b is a major, 
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if not the only, miRNA regulator of IGF-II through its 3’UTR. Furthermore, I show that the levels 
of miR-125b are controlled by mTOR signaling, shedding light on the myogenic regulation of 
miR-125b biogenesis, and uncovering an additional mechanism by which IGF-II production is 
regulated by mTOR during myogenesis (Fig. III.10). 
The functions of mammalian miR-125b and its targets have been reported in several 
cellular contexts (Le et al., 2009a; Le et al., 2009b; Wu and Belasco, 2005), but my findings 
unravel for the first time a myogenic role for miR-125b, and a new target – IGF-II. LIN-28, an 
RNA binding protein, has been shown to regulate IGF-II translation during myogenesis through 
the recruitment of IGF-II mRNA to polysomes (Polesskaya et al., 2007). Interestingly, Lin-28 is 
targeted by lin-4 (miR-125b homolog) in C. elegans (Moss et al., 1997) and by miR-125 in 
mouse neuronal cells (Wu and Belasco, 2005). It is thus formally possible that miR-125b 
regulation of IGF-II during myogenesis may be through targeting Lin-28 (Fig. III.10). Although 
my results do not rule out this possibility, they provide convincing evidence to support a direct 
miR-125b—IGF-II relationship: (1) miR-125b inhibits Igf2 3’UTR reporter activity through a 
seed-containing target site in HEK293 cells (Fig. III.6B), where Lin-28 is not expressed (Moss 
and Tang, 2003); (2) the mRNA levels of IGF-II is regulated by miR-125b in myocytes and 
muscles (Fig. III.4A-C, Fig. III.5), which cannot be explained by LIN-28 as a mediator, since 
LIN-28 regulates the translation of IGF-II (Polesskaya et al., 2007).  
Coordinate targeting of multiple genes in a functional pathway or protein complex has 
emerged as a common theme for many miRNAs (Tsang et al., 2010). For example, miR-24 
coordinately targets a network of cell cycle regulators to facilitate cell cycle exit upon cellular 
differentiation (Lal et al., 2009); let-7 acts as a tumor suppressor by targeting multiple genes 
involved in cell proliferation (Johnson et al., 2007). In the case of miR-125b regulating 
myogenesis, however, the complete rescue of myoblast differentiation by recombinant IGF-II 
from the inhibitory effect of miR-125b overexpression (Fig. III.4D) is consistent with IGF-II 
being a major, if not the only, target of miR-125b. Although I cannot rule out the possibility of 
miR-125b targeting additional myogenic genes, my current observations collectively suggest that 
the miR-125b-Igf2 relationship is functionally dominant in the regulation of myogenesis.  
As a critical inducer of skeletal myogenesis both in vitro and in vivo, it is not surprising 
that the myogenic production of IGF-II is tightly controlled by multiple mechanisms. The 
transcription of IGF-II is regulated through a muscle-specific enhancer by mTOR signaling 
(Erbay et al., 2003), and the translation of IGF-II during skeletal myogenesis is regulated by Lin-
28 (Polesskaya et al., 2007). My current study adds a new layer of mechanism – through a 
microRNA – that modulates both the mRNA and protein levels of IGF-II. It is generally believed 
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that miRNAs play fine-tuning roles in the control of gene expression; miR-125b targeting of IGF-
II in coordination with transcriptional and translational controls is a perfect example of that 
principle. The strong but incomplete effects of overexpressing or antagonizing miR-125b on IGF-
II expression, myogenic differentiation, and muscle regeneration (Figs. 2-4) are certainly in line 
with the modulating nature of miR-125b. It is reasonable to speculate that miR-125b serves as a 
gatekeeper of IGF-II levels pre-differentiation, and its reduction below a threshold level at the 
initiation of differentiation allows full-blown IGF-II production activated at the transcriptional 
and translational levels.  
Almost all the myogenic miRNAs reported thus far are up-regulated during 
differentiation, with the exception of miR-221/222, which have been reported to be down-
regulated and negatively regulate myogenesis in quail through the previously known target p27 
(Cardinali et al., 2009). Compared to miRNAs that are often drastically up-regulated during 
myogenesis, miR-125b is down-regulated to less dramatic degrees during both myoblast 
differentiation and muscle regeneration (Fig. III.1), similar to the degree of changes of miR-
221/222 upon C2C12 myoblast differentiation (Cardinali et al., 2009). This is consistent with the 
fact that miRNAs are generally very stable (Lee et al., 2003; Lund et al., 2004). Nevertheless, the 
partial reduction of miR-125b is apparently sufficient and necessary to allow IGF-II expression 
and myogenic differentiation.  
My results also raise the distinct possibility of myogenic regulation of miR-125b 
biogenesis at the transcriptional level rather than the maturation steps, under the control of mTOR 
signaling. Further dissection of mechanisms underlying miR-125b biogenesis will require 
identification of the regulatory elements for the two miR-125b genes. Most recently, we have 
discovered a myogenic pathway in which mTOR regulates miR-1 biogenesis through MyoD (Sun 
et al., 2010). mTOR regulation of miR-125b, however, would likely be through a different 
mechanism since it results in the decrease of miR-125b during myogenesis, in contrast to the 
increase of miR-1. Until such a mechanism is delineated, we do not know how remotely or 
proximately mTOR lies from miR-125b in its biogenic pathway. In any event, mTOR clearly 
regulates the biogenesis of these two miRNAs through distinct pathways – one dependent (miR-
1, Sun et al., 2010) and one independent (miR-125b) of its kinase activity. It is interesting that 
this kinase-independent function of mTOR controls myogenic IGF-II production at two levels: 
transcriptional regulation through a muscle-specific enhancer (Erbay et al., 2003) and post-
transcriptional regulation through miR-125b. This dual control underlines the importance of the 
mTOR-IGF-II axis in the regulation of skeletal myogenesis. Whether a single non-canonical 
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mTOR pathway controls both processes or there are two distinct kinase-independent mTOR 
mechanisms will be a fascinating topic for future investigation. 
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III.5. Figures and Tables 
 
 
 
 
 
Figure III.1. miR-125b is down-regulated during myoblast differentiation and muscle 
regeneration. (A, B) C2C12 cells (A) and mouse primary myoblasts (B) were induced to 
differentiate at 100% and 60-70% confluence, respectively. Total RNA was isolated from the 
differentiating cells on various days as indicated (Diff. Day), and subjected to analysis by qRT-
PCR to determine the relative levels of mature miR-125b. Proliferating C2C12 myoblasts (MB) 
at 60% confluence were also examined in (A). (C) Regeneration of TA muscles in mouse was 
induced by BaCl2 injury. On various days after injury (AI), total RNA was isolated from the TA 
muscles and subjected to analysis by qRT-PCR to determine the relative levels of mature miR-
125b. Saline injection into contralateral TA muscles served as “no injury” control. The data in 
(A) and (B) are mean ± SD from 3 to 4 independent experiments. The data in (C) are mean ± SD 
with 4 mice per time point. One-sample t test was performed to compare each data point to the 
control (0 hr or no injury). *P < 0.05, **P < 0.01. 
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Figure III.2. miR-125b negatively regulates myoblast differentiation. C2C12 myoblasts were 
transfected with 50 nM RNA duplexes or LNA-containing oligonucleotides, and then were 
induced to differentiate one day later, for 3 days. An siRNA against EGFP (siEGFP) and an 
LNA-oligonucleotide with scrambled sequence (LNA-scr) served as negative controls for miR-
125b duplex and anti-miR-125b, respectively. (A, D) Relative miR-125b levels were measured by 
qPCR in non-transfected cells (control) and cells transfected with various oligonucleotides as 
indicated, during the course of differentiation. (B) The differentiated cells were fixed, and 
immunostained for MHC (green) and DAPI (red). Scale bar: 100 µm. (C, E) Differentiation 
(“diff.”) and fusion indexes were quantified. (F) Relative miR-125a levels were measured by 
qPCR one day after transfection of LNA-oligonucleotides (same as Diff. Day 0). (G) Western 
analysis of cells treated as described above. In (B) and (G) representative results of at least 3 
independent experiments are shown. All quantitative data are shown as mean ± SD from 3 to 4 
independent experiments. For the qPCR data (A, D, F), one-sample t tests were performed to 
compare each data point against “control” on day 0 (A&D) or between LNA-scr and anti-miR-
125b (F). For the differentiation and fusion index data (C, E), paired t tests were performed to 
compare data within each time point. *P < 0.05, **P <0.01. 
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Figure III.3. miR-125b negatively regulates skeletal muscle regeneration. Mouse TA muscles 
were injured with BaCl2 injection, and oligonucleotides (same RNA duplexes and LNA-modified 
oligonucleotides as in Fig. III.2) were co-injected at 0.2 µg/µl as indicated. On various days after 
injury (AI), the TA muscles were isolated and either cryosectioned or extracted for RNA. As 
controls, saline was injected instead of BaCl2, together with the oligonucleotides, into the 
contralateral limb TA muscles. (A) Cross-sections of TA muscle on Day 7 AI were stained with 
H&E. A portion of the regenerating area is shown to provide a representative view. Scale bar: 50 
µm. (B, C) On various days AI, regenerating myofibers (identified by their central nuclei on 
H&E stained sections) were counted within a 614,400 µm2 view for each sample. Cross-section 
areas (CSA) of regenerating myofibers were quantified. At least 100 regeneration myofibers were 
measured on each muscle section. Note that the regenerating muscle area included for 
quantitative analysis in B and C was ~10 times larger than that shown in A. (D) miR-125b in 
oligonucleotide-injected and injured muscles on various days AI was measured by qPCR. 
Relative miR-125b levels are shown with “no injury” sample set at 1 (see Fig. III.1C). All results 
shown are mean ± SD (n = 5 mice for each data point in B&C; n=3 mice for each data point in 
D). Paired t test was performed to compare each pair of data as indicated. *P < 0.05, **P <0.01. 
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Figure III.4. IGF-II levels are regulated by miR-125b during myoblast differentiation. (A, 
B) C2C12 myoblasts were transfected with 50 nM miRIDIAN miR-125b mimic (A) or LNA-
containing anti-miR-125b (B), and after one day induced to differentiate for up to 3 days. As 
negative controls, miRIDIAN cel-miR-67 and LNA-scramble were transfected side by side with 
miR-125b mimic and anti-miR-125b, respectively. Cells were lysed at various time points for 
RNA isolation, followed by qRT-PCR to measure IGF-II mRNA levels (left panels in A, B).  At 
the same time, cell media were collected, and IGF-II protein levels were measured by ELISA 
(right panels in A, B). (C) On day 2 of differentiation, C2C12 myocytes were transfected with 50 
nM miR-125b duplex or siEGFP (control). Total RNA was extracted 12 hrs later and subjected to 
qPCR analysis for Igf2 mRNA (right panel) and miR-125b (right panel).  (D) C2C12 myoblasts 
were transfected with 50 nM miR-125b duplex or siEGFP (control) as indicated, and induced to 
differentiate for 3 days in the presence of recombinant IGF-II (300 ng/mL). The differentiation 
(“diff.”) and fusion indexes were measured. All data shown are mean ± SD from 3 independent 
experiments. Paired t test was performed to compare each pair of data in A, B and D. One-sample 
t test was performed for data in C. *P < 0.05, **P <0.01. 
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Figure III.5. IGF-II levels are regulated by miR-125b during muscle regeneration. Mouse 
TA muscles were injected with oligonucleotides alone (non-injured) or together with BaCl2 
(injured) as described in Fig. III.3 legend. On Day 7 after injury, the TA muscles were isolated 
for RNA extraction, followed by qRT-PCR assays to measure Igf2 mRNA levels. Data shown are 
mean ± SD with 3 mice per data point. One-sample t test was performed to compare each pair of 
data. **P<0.01. 
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Figure III.6. miR-125b directly regulates Igf2 by targeting its 3’UTR. (A) Predicted miR-
125b target site in the 3’UTR of mouse Igf2. The seed region is in bold, which was changed to its 
complementary sequence on the mutant 3’UTR reporter. Watson-Crick and wobble (G-U) base-
pairings are indicated by solid and dashed vertical lines, respectively. (B) Igf2 3’UTR reporter, its 
miR-125b-site mutant, or vector was co-transfected with miR-125b duplex (siEGFP as negative 
control) into HEK293 cells, followed by cell lysis and luciferase assays 24 hr later. (C) C2C12 
myoblasts were transfected with the Igf2 3’UTR reporter or its miR-125b-site mutant, and then 
induced to differentiate for up to 3 days. The cells were lysed at indicated times and luciferase 
assays were performed. (D) C2C12 myoblasts were transfected with the Igf2 3’UTR reporter 
together with miR-125b duplex (siEGFP as negative control), and then induced to differentiate. 
At the times indicated the cells were lysed and luciferase assays were performed. All data shown 
are mean ± SD from 3 independent experiments. 
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Figure III.7. mTOR controls miR-125b levels during myoblast differentiation. (A) C2C12 
cells and mouse primary myoblasts were induced to differentiate in the absence or presence of 50 
nM rapamycin. Total RNA was isolated from the differentiating cells on various days as indicated 
(Diff. Day), and subjected to analysis by qRT-PCR to determine the relative levels of mature 
miR-125b. (B) RNA samples prepared from C2C12 cells as in (A) were subjected to Northern 
analysis for miR-125b and let-7a as a control. Pre-miR-125b species (71 nt and 77 nt) were not 
detected on the blot. (C) C2C12 cells were transduced with lentiviruses expressing two 
independent mTOR shRNAs and a scrambled (Scr) hairpin sequence as negative control. 
Following puromycin selection, the cells were treated as in (A). The insert shows Western results 
confirming mTOR knockdown. (D) C2C12 cells were transfected with the Igf2 3’UTR reporter, 
and then induced to differentiate in the absence or presence of 50 nM rapamycin. The cells were 
lysed at indicated times and luciferase assays were performed. (E) C2C12 cells were treated as in 
(A), and total RNA was subjected to qRT-PCR analysis for pri-miR-125b-1. All data are mean ± 
SD of three independent experiments. Paired t test was performed to compare control and 
rapamycin-treated samples at each time point in D. For the rest of the data, one-sample t test was 
performed to compare each data point to the control (0 hr). *P < 0.05, **P < 0.01. 
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Figure III.8. mTOR regulates miR-125b levels in myoblasts in a kinase-independent and 
S6K1-independent manner. C2C12 cells stably expressing RR-mTOR (A) or RR/KI-mTOR (B) 
were induced to differentiate in the absence or presence of 50 nM rapamycin. Total RNA was 
isolated from the differentiating cells on various days as indicated (Diff. Day), and subjected to 
analysis by qRT-PCR to determine the relative levels of mature miR-125b. (C) C2C12 cells were 
transduced with lentiviruses expressing two independent S6K1 shRNAs and a scrambled (Scr) 
hairpin sequence as negative control. Following puromycin selection, the cells were treated as in 
(A, B). The insert shows Western results confirming S6K1 knockdown. One-sample t test was 
performed to compare each data point to the control (0 hr). *P < 0.05, **P < 0.01. Paired t tests 
were also performed to compare samples within each time point, i.e., “control” to “rapamycin” on 
each day in (A) and (B); “S6K1 shRNA” to “scramble” in (C). No significant difference was 
found. 
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Figure III.9. mTOR regulates miR-125b levels in regenerating muscles in a kinase-
independent manner. (A) TA muscles of wild-type mice were injected with BaCl2, and the 
contralateral muscles were injected with saline as controls (“no injury”), followed by systemic 
administration of rapamycin daily from Day 1 AI. On various days AI, total RNA was isolated 
from the TA muscles and subjected to analysis by qRT-PCR to determine the relative levels of 
mature miR-125b. (B, C) Transgenic mice expressing RR-mTOR (B) or RR/KI-mTOR (C) in 
skeletal muscle were treated as described in (A). All data shown are mean ± SD (n = 4 mice for 
each condition). One-sample t test was performed to compare each data point to the control (no 
injury). *P < 0.05. 
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Figure III.10. A model for the regulatory network involving IGF-II in myogenesis. Kinase-
independent mTOR signaling regulates IGF-II production at a transcriptional level, as well as a 
post-transcriptional level through miR-125b. MiR-125b control of IGF-II expression may also be 
mediated by Lin-28 at a translational level. 
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Figure III.11. miR-1 and miR-206 levels in regenerating skeletal muscles. Regeneration of 
TA muscles in mouse was induced by BaCl2 injury. On various days after injury (AI), total RNA 
was isolated from the TA muscles and subjected to analysis by qRT-PCR to determine the 
relative levels of miR-125b. Saline injection into contralateral TA muscles served as “no injury” 
control. The data shown are mean ± SD with 3 mice per time point. One-sample t test was 
performed to compare each data point to the control (no injury). *P < 0.05, **P < 0.01. 
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Figure III.12. miR-125b does not affect proliferation of C2C12 cells. (A) Efficiencies for 
delivering double-stranded and single-stranded oligonucleotides into C2C12 cells were assessed 
by transfection of 50 nM Dy547-cel-miR-67 (red) and FAM dye-anti-miR (green), respectively. 
DAPI staining is shown in blue. The granular appearance of transfected oligonucleotides is 
commonly seen with C2C12 cells (Technical Notes, Dharmacon). (B) C2C12 myoblasts were 
transfected with various oligonucleotides as indicated. After 24 hrs, BrdU labeling was performed 
as described in Materials and Methods. The percentage of BrdU-positive cells were quantified. 
(C) Cell density at the end of 3-day differentiation described in Fig. III.2 was assessed by 
counting nuclear number per 614,400 µm2 view. Scale bars: 100 µm. 
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Figure III.13. Sequence alignment of mouse, rat and human Igf2 at the predicted miR-125b 
targeting site. Sequence in red is in the seed region. Mismatched bases among the three Igf2 
sequences are indicated as follows: blue – loss of pairing with miR-125b; green – no effect on 
miR-125b pairing; purple – gain of pairing with miR-125b. miR-125b sequence is identical in all 
species. 
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Figure III.14. miR-150 does not target the 3’UTR of Igf2. (A) Predicted miR-150 target site in 
the 3’UTR of mouse Igf2. The seed region is indicated in red. (B) HEK293 cells were transfected 
with the Igf2 3’UTR reporter together with siEGFP or miR-150 duplex. The cells were lysed 24 
hrs later and subjected to luciferase assays. (C) C2C12 myoblasts were transfected with the Igf2 
3’UTR reporter or its miR-150-site mutant, and then induced to differentiate for up to 3 days. The 
cells were lysed at indicated times and luciferase assays were performed. The average results of 
three independent experiments are shown, with error bars representing standard deviation. 
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Table III.1. Predicted targets of miR-125b. Listed are genes that were predicted to be miR-
125b targets by one of the three algorithms and up-regulated during C2C12 differentiation (Park 
and Chen, 2005). The genes are listed in alphabetical order of gene symbol. Accession numbers 
are available from GenBank/EMBL/DDBJ. The prediction programs used were miRanda 
(http://www.microRNA.org, January 2008 release), TargetScan (mouse 4.2 version, April 2008), 
and PicTar (a single version available). 
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CHAPTER IV. MAMMALIAN TARGET OF RAPAMYCIN REGULATES  
MICRORNA-1 AND FOLLISTATIN IN SKELETAL MYOGENESIS 
 
IV.1. Introduction 
 Skeletal myoblast fusion, which results in the formation of multinucleated myofibers, is 
critical for embryonic muscle development, adult muscle regeneration and maintenance, as well 
as muscle hypertrophy under certain conditions. The molecular mechanisms underlying myoblast 
fusion represent one of the central questions in skeletal muscle biology (Jansen and Pavlath, 
2008; Wakelam, 1985). Two molecularly separable stages of fusion have been identified in 
mammalian muscle cells (Jansen and Pavlath, 2008). Following an early stage of differentiation 
including cell cycle withdrawal, myogenin expression and contractile protein expression, 
mononucleated myoblasts fuse to form nascent myofibers/myotubes. Subsequently, growth and 
maturation of the muscle cells is achieved through a second-stage fusion, which occurs between 
the nascent myofibers/myotubes and myoblasts. While many regulators of these fusion processes 
have been revealed in recent years (Jansen and Pavlath, 2008), a better understanding of the 
regulation is still needed. 
 The Ser/Thr protein kinase mTOR mediates signaling in response to nutrient availability, 
cellular energy sufficiency, mitogenic signals, and various types of stress signals. mTOR 
signaling regulates a wide range of biological processes including cell growth, various types of 
cellular differentiation, and metabolism (Erbay et al., 2005; Sarbassov et al., 2005; Wullschleger 
et al., 2006). mTOR assembles two biochemically and functionally distinct protein complexes, 
mTORC1 and mTORC2, which are sensitive and insensitive to rapamycin, respectively 
(Sarbassov et al., 2005). Rapamycin-sensitive mTORC1 signaling has emerged as a key regulator 
of skeletal muscle differentiation and remodeling. Rapamycin inhibits myoblast differentiation in 
vitro (Coolican et al., 1997; Cuenda and Cohen, 1999; Erbay and Chen, 2001), IGF-induced 
myotube hypertrophy in vitro (Park et al., 2005; Rommel et al., 2001), compensatory myofiber 
hypertrophy in vivo, and re-growth of myofibers after atrophy (Bodine et al., 2001). mTORC1 is 
also involved in the mechanical stimulation of skeletal muscle ex vivo (Hornberger et al., 2006). 
The regulation of skeletal myocyte differentiation by mTORC1 occurs at two stages, via distinct 
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mechanisms. mTORC1 controls the initiation of myoblast differentiation by regulating IGF-II 
expression (Erbay and Chen, 2001; Erbay et al., 2003), whereas a late-stage myocyte fusion 
leading to myotube maturation is regulated by mTORC1 through a yet-to-be-identified secreted 
factor (Park and Chen, 2005). These regulatory mechanisms are also recapitulated by mTOR 
functions in muscle regeneration in vivo (Ge et al., 2009). 
 MicroRNAs are a class of small non-coding RNAs that regulate protein expression 
mainly by targeting the 3’UTR of messenger RNAs (Bartel, 2004; Bartel, 2009). Intensive studies 
in recent years have revealed microRNA as a principal regulatory mechanism of gene expression, 
governing numerous biological processes across the species (Bartel, 2009; Bushati and Cohen, 
2007). Several microRNAs have been recognized as important modulators in the development of 
skeletal and cardiac muscle (van Rooij et al., 2008). Among them, miR-1 is a conserved muscle-
specific microRNA that is essential for myogeneisis. In C elegans, miR-1 regulates synaptic 
functions at the neuromuscular junctions (Simon et al., 2008). In Drosophila, deletion of miR-1 
leads to defects in muscle differentiation or maintenance, presumably by removing the inhibition 
on the Notch ligand Delta (Sokol and Ambros, 2005). In mammals, deletion of miR-1-2 in mice 
causes dysregulation of cardiogenesis (Zhao et al., 2007; Zhao et al., 2005), and inhibiting miR-1 
impairs the differentiation of skeletal myoblasts (Chen et al., 2006).  
 Despite the well-recognized importance of both microRNAs and mTOR in myogenesis, a 
possible connection between the two has never been implicated or examined. In this chapter, I 
present evidence revealing the regulation of another microRNA by mTORC1 signaling. 
Furthermore, I have identified follistatin as the fusion factor regulated by mTORC1 signaling 
through miR-1 and HDAC4 in myoblast differentiation and muscle regeneration. 
 
IV.2. Materials and Methods 
IV.2.1. Antibodies and other reagents. The antibodies were obtained from the following 
sources: anti-tubulin from Abcam; anti-MyoD (5.8A) from Imgenex; antibodies against HDAC4, 
mTOR, phospho-T389-S6K1, MEF2A and MEF2C from Cell Signaling; all secondary antibodies 
and DAPI from Jackson ImmunoResearch Laboratory. The MF20 anti-sarcomeric myosin heavy 
chain (MHC) and F5D anti-myogenin antibodies were obtained from the Developmental Studies 
Hybridoma Bank developed under the auspices of the NICHD, National Institutes of Health and 
maintained by The University of Iowa, Department of Biological Sciences. Rapamycin was from 
LC Labs. Follistatin (mouse FS288) was from R&D. Trichostatin A (TSA), gelatin, polybrene, 
puromycin, MG-132, and custom-designed LNA-oligonucleotides were from Sigma. 
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IV.2.2. Tissue culture. C2C12 and C3H10T1/2 cells were maintained in DMEM (1 g/L glucose) 
with 10% fetal bovine serum. For differentiation, cells were seeded in plates coated with 0.2% 
gelatin. Differentiation was induced by switching to DMEM containing 2% horse serum. 
Transfection of LNA anti-miR-1 and luciferase reporters into C2C12 cells was performed using 
Amaxa nucleofector (Solution V, program B-032) following the manufacturer’s 
recommendations. All other transfections were performed with Trans-IT (Mirus) at 50-60% cell 
density. 
IV.2.3. Microarray analysis. MicroRNA profiling was performed using LNA microRNA arrays 
from Exiqon (Vedbaek, Denmark), which contained capture probes for all microRNAs annoated 
in miRBase 9.2. Samples were prepared using mirVana microRNA isolation kit (Ambion, Austin, 
TX), without enrichment for small RNA. 1 µg of total RNA was labeled with Cy3 or Cy5 
according to the manufacturer's protocols co-hybridized to arrays overnight, washed, and scanned 
with a GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA). Image analysis and editing 
was carried out using GenePix Pro 6.0. Data were analyzed using the Bioconductor Packages 
using R software. For each comparison, F statistics were calculated with results from four 
independent experiments. FDR-adjusted p-value at 0.05 was used as cutoff for statistical 
significance. 
IV.2.4. Muscle regeneration in mice. All animal experiments in this study followed protocols 
approved by the Animal Care and Use Committee at the University of Illinois at Urbana-
Champaign. Ten to 12-week-old male FVB mice were used in all experiments. Muscle injury was 
induced by injection of 50 µl BaCl2 (1.2% w/v) into the TA muscle of the hind limb. As control, 
saline was injected into the TA muscle of the lateral hind limb. Rapamycin (1µg per gram of 
body weight) and/or TSA (0.6 µg per gram of body weight), in a carrier containing 5% Tween-
80, 5% PEG-400, and 4% ethanol, were administrated once daily through intraperitoneal 
injection. Adenovirus (AdexCA-FS288 or AdexCA-GFP) was delivered by one-time injection of 
1x1011 viral particles into the TA muscle. 
IV.2.5. Plasmids. pCDNA3-Flag-MyoD was created in a modified pCDNA3 vector containing 
the FLAG epitope followed by Not I and Xba I restriction sites, in which MyoD cDNA was 
inserted. pGL3-MH100-TK luciferase reporters containing miR-1 upstream enhancers were 
generous gifts from Dr. D. Srivastava at University of California San Francisco (Zhao et al., 
2005). The enhancerless reporter was generated from the miR-1-2 enhancer reporter construct by 
deleting the enhancer at Kpn I sites. The 2.5 kb miR-1/133a intragenic enhancer, a generous gift 
from Dr. E. N. Olson at UT Southwestern Medical Center (Liu et al., 2007), was subcloned into 
pGL2-promoter (Promega). 
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IV.2.6. Lentivirus-mediated RNAi. shRNAs in the pLKO.1-puro vector for knocking down 
mTOR and HDAC4 were purchased from Sigma-Aldrich (MISSION® TRC). For viral 
packaging, pLKO-shRNA, pCMV-dR8.91 and pCMV-VSV-G were cotransfected into 293T cells 
using FuGENE 6 at 0.5µg:0.45µg:0.05µg (in 1 mL for a 6-well plate). Media containing viruses 
were collected 48 hrs after transfection. The Sigma clone ID for the shRNA constructs used in 
this study are:  mTOR#1, NM_020009.1-7569s1c1; mTOR#2, NM_020009.1-5493s1c1; 
HDAC4, NM_207225.1-1619s1c1. C2C12 cells were transduced with lentiviruses in growth 
medium containing 8 μg/ml polybrene, selected in 2 μg/ml puromycin for one day, followed by 
plating into 12-well plates for differentiation.  
IV.2.7. Real-time quantitative PCR for mRNA and microRNA. Total RNA was isolated from 
cultured cells or muscle tissues using the mirVana RNA isolation kit (Ambion). cDNA was 
synthesized from 2 µg of total RNA with SuperScript II Reverse Transcriptase (Invitrogen) using 
oligo (dT) primer (Invitrogen). Quantitative (q)PCR was performed on a Bio-Rad iCycler system 
(Bio-Rad Laboratories, Inc.) using a SYBR Green PCR kit (Applied Biosystems) in a MicroAmp 
96-well reaction plate (Bio-Rad Laboratories, Inc.) following the manufacturer's protocols. β -
actin was used as a reference to obtain the relative fold change for target samples using the 
comparative CT method. The primers used are as follows. Mouse follistatin forward: 5’-
AAAACCTACCGCAACGAATG; mouse follistatin reverse: 5’-
GGTCTGATCCACCACACAAG; mouse β-actin forward: 5’-TTGCTGACAGGATGCAGAA 
G; mouse β-actin reverse: 5’-ATCCACATCTGCTGGAAGGT. Primers for pri-miR-1-1 and pri-
miR-1-2 were as reported by others (Liu et al., 2007). miRNAs were quantified using qPCR-
based Taqman microRNA assay kits (Applied Biosystems), following the manufacturer’s 
recommendations, with snoRNA 202 as the internal control for normalization. 
IV.2.8. Northern blotting. Anti-sense DNA oligonucleotides for mature miR-1 and let-7a were 
end-labeled with [γ–32P]ATP. RNA Decade Maker (Applied Biosystems) was similarly 
radiolabeled as size markers. RNAs (20 µg per sample) were separated on 12% denaturing 
polyacrylamide gels, transferred to Nylon membranes (GE Healthcare) and UV cross-linked. Pre-
hybridization was carried out in ULTRAhyb Ultrasensitive Hybridization Buffer (Applied 
Biosystems) for 2 hrs at 42 0C, followed by hybridization with probe in the same buffer (1x106 
CPM/ml) overnight at 42 0C. The membranes were then washed with 2xSSC, 0.1% SDS at 42 0C, 
followed by exposure to X-ray films overnight at -80 0C. 
IV.2.9. Luciferase assays. Cells transfected with various enhancer reporters were treated as 
described, and then lysed in Passive Lysis Buffer (Promega). Luciferase assays were performed 
using the Luciferase Assay Systems kit (Promega) following the manufacturer’s protocol. 
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IV.2.10. Immunofluorescence microscopy and quantitative analysis of myocytes. C2C12 
cells differentiated in 12-well plates were fixed in 3.7% formaldehyde (in PBS), permeabilized in 
0.1% Triton X-100, and then incubated with MF-20 (anti-MHC) antibody in 3% BSA (in PBS) 
followed by fluorescein isothiocyanate conjugated anti-mouse IgG in 3% BSA (in PBS), with 4 
μg/ml 4,5-diamidino-2-phenylindole (DAPI). The stained cells were examined with a Leica DMI 
4000B fluorescence microscope, and the fluorescent images were captured using a RETIGA EXi 
camera. The images were then processed as 24-bit images using Adobe Photoshop CS2. MHC 
and DAPI signals were pseudo-colored green and blue, respectively. The fusion index was 
calculated as the ratio of nuclei number in myocytes with two or more nuclei versus the total 
number of nuclei. Each data point was generated from at least 200 randomly chosen MHC-
positive cells or myotubes. 
IV.2.11. ELISA for follistatin measurement. Relative follistatin protein levels in media 
collected from differentiating C2C12 cells were measured using the human follistatin ELISA kit 
(26% cross-reactivity with mouse follistatin) from R&D, following the manufacturer’s protocols. 
IV.2.12. Adenovirus production. Adenoviruses expressing human follistatin (AdexCA-FS288) 
or EGFP (AdexCA-GFP) under the CAG promoter were generous gifts from Dr. W. Vale at the 
Salk Institute (Leal et al., 2002). The viruses were amplified through infection of 293 cells, and 
purified by ultracentrifugation with a cesium chloride gradient (Luo et al., 2007), followed by 
dialysis against phosphate-buffered saline.  
IV.2.13. Muscle tissue cryosection and histological Analysis. TA muscles were isolated by 
dissection, frozen in liquid nitrogen-cooled 2-methylbutane, and embedded in TBS tissue freezing 
medium (Fisher Scientific). Sections of 10 µm thickness were made with a Microm HM550 
cryostat at -20 0C, placed on uncoated slides, and stained with hematoxylin and eosin (H&E). The 
stained slides were examined with a Leica DMI 4000B microscope, and the images were captured 
with a 20x dry objective (Leica Fluotar, numerical aperture 0.4) using a RETIGA EXi camera. 
The images were then processed as 24-bit colored images using Adobe Photoshop CS2. The 
cross-section area (CSA) of myofibers was measured using Q-capture Pro 6.0 software (Q 
Imaging). For each muscle section, all central-nucleated (regenerating) myofibers larger than 100 
µm2 within a 307,200 µm2 view in the center of injury were analyzed. 
IV.2.14. In situ hybridization. In situ hybridization of miR-1 was performed on cryosections of 
TA muscles prepared as above. miR-1 was detected by anti-sense locked nucleic acid (LNA) 
probes labeled with the Dig-3-end labeling kit (Roche), following reported protocols (Naguibneva 
et al., 2006b) with some modifications. Briefly, muscle cryosections were fixed in 
paraformaldehyde, de-proteinized with proteinase K, and acetylated with acetic anhydride and 
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triethanolamine, followed by incubation with labeled probes (20 nM) in hybridization buffer 
(65% Formamide, 5xSSC, 0.1% Tween-20, 50 mg/ml heparin, 500 mg/ml yeast tRNA, pH 6.0) at 
50 0C overnight. The slides were subsequently washed with 50% formamide/2xSSC at 50 0C, and 
then with PBST at room temperature, followed by blocking and incubation with anti-digoxigenin 
(Roche, 1:1000) at 4 0C overnight. The slides were washed, and developed in NBT-BCIP (Sigma) 
for 4 hrs, dehydrated and mounted. A probe with scrambled sequence was used as negative 
control. Anti-miR-1 LNA probe: 5’-atacataCTTCTTTAcattcca (upper case: LNA). Scrambled 
LNA probe: 5’-catgtcaTGTGTCACatctctt. An anti-miR-1 probe purchased from Exiqon was also 
used, and similar in situ hybridization signal patterns were observed. 
IV.2.15. Statistical analysis. All data are presented as mean ± standard deviation. Whenever 
necessary, statistical significance of the data was analyzed by performing one-sample t-tests, 
paired two-tailed t-tests, or one-way analysis of variance (ANOVA) with Bonferroni’s post-test, 
using GraphPad Prism 4.0. The specific types of tests and the P values, when applicable, are 
indicated in figure legends. 
 
IV.3. Results 
IV.3.1. mTORC1 regulates miR-1 levels in skeletal muscle. 
 To examine a potential link between microRNA and mTORC1 signaling in skeletal 
myogenesis, we carried out microRNA microarray analyses. We compared microRNA expression 
profiles of C2C12 cells at differentiation time 0 and 72 hrs, the latter with or without rapamycin 
treatment. Among the miRNAs up-regulated during differentiation (Fig. IV.11 and Table IV.1), 
miR-1 expression was drastically inhibited by rapamycin (Table IV.1). qRT-PCR results 
confirmed that miR-1 increased dramatically during C2C12 differentiation (Fig. IV.1A), 
consistent with a previous report (Chen et al., 2006), and the increase was almost completely 
blocked by rapamycin treatment. As expected, rapamycin abolished myotube formation (data not 
shown) and drastically inhibited the expression of myogenic markers including myogenin, MHC, 
MEF2A and MEF2C (Fig. IV.12). To directly confirm mTOR’s role in controlling miR-1 levels, 
I knocked down mTOR in C2C12 cells using lentivirus-delivered small hairpin RNA (shRNA) 
with two independent target sequences, which inhibited S6K1 phosphorylation and suppressed 
MHC expression (Fig. IV.1B). At the same time, the miR-1 level during differentiation was 
suppressed by mTOR knockdown (Fig. IV.1C). 
 To validate the dependence of miR-1 levels on mTORC1 in vivo, I examined miR-1 
expression in mouse regenerating skeletal muscle. Muscle regeneration was induced upon injury 
elicited by barium chloride (BaCl2) injection into the tibialis anterior (TA) muscle (Caldwell et 
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al., 1990; Ge et al., 2009). On various days after injury (AI), the TA muscle was isolated and 
miR-1 levels were measured by qRT-PCR. miR-1 was found to increase during regeneration, and 
the increase was blocked by daily rapamycin administration to the mice (Fig. IV.1D), 
accompanied by inhibition of regeneration as I had reported previously (Ge et al., 2009). It should 
be mentioned that others reported a decrease of miR-1 levels in injured muscles (Greco et al., 
2009; Yuasa et al., 2008), which was not observed by us at any time point from day 1 to day 21 
after injury (Fig. IV.1D). It has been proposed that the temporary decrease of miR-1 during 
muscle injury is associated with the loss of myofibers and induction of fibrosis upon injury, rather 
than muscle regeneration (Greco et al., 2009). Thus, it is possible that miR-1 levels do not decline 
in my experimental system owing to less extensive tissue damage induced by BaCl2 compared to 
the methods used by the others (Greco et al., 2009; Yuasa et al., 2008). MiR-1 expression in 
regenerating muscles was also confirmed by in situ hybridization, which showed accumulation of 
miR-1 signals adjacent to both centrally and peripherally localized nuclei (see enlarged image in 
Fig. IV.13) and dramatic decrease of signals upon rapamycin administration (Fig. IV.13). Taken 
together, my observations suggest that mTORC1 controls the levels of miR-1 in skeletal 
myocytes both in vitro and in vivo. 
 
IV.3.2. mTORC1 regulates transcription of mir-1 through an upstream enhancer. 
 MicroRNAs are transcribed as pri-miRNAs, cleaved by Drosha to form pre-miRNAs, 
followed by another cleavage by Dicer, which results in mature miRNAs. A blockage by 
rapamycin at any of those steps would result in a decrease of mature miR-1 levels. As revealed by 
Northern blotting (Fig. IV.2A), rapamycin treatment of differentiating C2C12 cells drastically 
decreased the level of mature miR-1 without inducing pre-miR-1 (73nt and 78nt), indicating that 
rapamycin is unlikely to block the processing of pre-miR-1 to miR-1. The lack of detectable pre-
miR-1 by Northern analysis is consistent with rapid processing by Dicer observed for most 
miRNAs. To test whether the decrease of mature miR-1 could be attributed to a blockage in the 
processing of pri-miR-1 to pre-miR-1, I measured pri-miR-1 levels by qRT-PCR. MiR-1 is 
encoded at two chromosomal loci, resulting in two distinct primary transcripts. As shown in Fig. 
IV.2B, rapamycin inhibited, rather than enhanced, the levels of both forms of pri-miR-1, which 
excludes the possibility that suppression of pri-miR-1 processing is responsible for the decreased 
mature miR-1 levels. It is noteworthy that the steady-state level of pri-miRNA does not directly 
reflect the actual transcription rate, due to potentially rapid processing of the transcripts. 
Nevertheless, the increase of both pri-miR-1 during differentiation and its sensitivity to 
rapamycin (Fig. IV.2B) are consistent with transcriptional regulation of the miR-1 genes. Taken 
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together, my observations suggest that rapamycin suppresses miR-1 levels by impacting the 
transcription, rather than maturation, of miR-1. 
 To further investigate the possibility that mTORC1 signaling might regulate the 
transcription of miR-1, I considered the upstream enhancers for the two miR-1 genes that had 
been found to regulate the expression of miR-1 in cardiac muscle (Zhao et al., 2005). I set out to 
examine luciferase reporters for these enhancers in C2C12 cells. As shown in Fig. IV.3A, the 
miR-1-2 enhancer reporter activity increased during C2C12 differentiation, indicating that the 
enhancer regulating miR-1 in cardiac muscle is also functional in skeletal muscle. Remarkably, 
rapamycin treatment abolished the increase of the enhancer activity (Fig. IV.3A, grey bars). A 
reporter for the miR-1-1 enhancer displayed similar up-regulation during differentiation and 
inhibition by rapamycin (data not shown).  To ask whether the effect of rapamycin on miR-1 
enhancer was direct or a consequence of rapamycin inhibition of differentiation, we examined the 
effect of inhibiting PI3K and p38 – two pathways required for C2C12 differentiation (Cuenda and 
Cohen, 1999; Kaliman et al., 1996). Strikingly, prolonged (3 days) treatment of C2C12 cells with 
either wortmannin or SB203580 – specific inhibitors of PI3K and p38-MAPK, respectively – had 
no impact on the miR-1 enhancer reporter activity (Fig. IV.3B), even though both drugs 
drastically inhibited the differentiation of C2C12 cells from which reporter assays were 
performed. These observations, together with the fact that not all miRNAs regulated during 
differentiation were sensitive to rapamycin (Fig. IV.11 and Table IV.1), suggest that mTORC1 
signaling may directly regulate miR-1 expression through the upstream enhancer.  
 
IV.3.3. mTORC1 regulates miR-1 through MyoD. 
 Next, I set out to probe the mechanism underlying mTORC1 regulation of miR-1 
transcription. MyoD is a transcription factor that is essential and specific for skeletal myogenesis. 
Furthermore, putative MyoD-binding sites have been found in both miR-1-1 and miR-1-2 
enhancers (Zhao et al., 2005). Indeed, expression of recombinant MyoD in C3H10T1/2 cells, 
which lack endogenous MyoD expression, drastically stimulated the expression of miR-1 (Fig. 
IV.4A). The expression of recombinant MyoD also markedly activated the miR-1 enhancer 
reporter in the same cells (Fig. IV.4B). A reporter with the putative MyoD binding site on the 
enhancer mutated was found to be almost completely insensitive to the expression of MyoD (Fig. 
IV.4B), suggesting that the effect of MyoD on the enhancer is most likely direct, rather than a 
consequence of MyoD induction of differentiation in C3H10T1/2 cells (Davis et al., 1987). 
 Consistent with a role of mTORC1 in regulating miR-1 transcription, rapamycin 
significantly diminished MyoD-induced miR-1 enhancer activity during 24 hrs of differentiation 
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in C3H10T1/2 cells (Fig. IV.4C). Furthermore, I observed that a short period (4 hrs) of rapamycin 
treatment was as effective as 24-hr treatment in suppressing MyoD-induced miR-1 enhancer 
activity (Fig. IV.4D), once again confirming that the regulation of miR-1 expression by mTORC1 
through MyoD is direct. The incomplete rapamycin inhibition of the reporter activity may suggest 
the existence of additional pathways in the regulation of MyoD activity, but an equally likely 
possibility is that overexpression of MyoD partially overrides regulation by mTORC1, rendering 
MyoD somewhat “constitutively active” and thus partially resistant to rapamycin.  
 To gain further insight into the mechanism by which mTOR may control MyoD activity, 
I examined the endogenous MyoD protein upon rapamycin treatment. As shown in Fig. IV.4E, 
rapamycin treatment induced reduction of MyoD protein levels in C2C12 cells. The rapid 
response to rapamycin exposure (4 hrs) is consistent with a direct effect of rapamycin on MyoD 
levels. In addition, the proteasome inhibitor MG-132 completely reversed the effect of rapamycin 
on MyoD, suggesting that the stability of MyoD is regulated in a proteasome-dependent manner. 
A similar effect of rapamycin was found on the level of recombinant MyoD in C3H10T1/2 cells 
(Fig. IV.4F), further confirming that the decrease of MyoD protein is post-translational. Indeed, 
rapamycin treatment has no effect on the mRNA levels of MyoD in C2C12 cells (Fig. IV.14A) or 
of recombinant MyoD in C3H10T1/2 cells (Fig. IV.14B). Taken together, my data suggest that 
mTORC1 controls MyoD by suppressing its proteasome-dependent degradation. 
 
IV.3.4. miR-1 regulates skeletal myogenesis through HDAC4 and follistatin. 
 To delineate the pathway downstream of mTOR and miR-1 in myogenesis, I first 
considered the targets of miR-1. Several potential targets of miR-1 in skeletal and cardiac 
muscles have been reported (Chen et al., 2006; Yang et al., 2007; Zhao et al., 2007; Zhao et al., 
2005). Specifically, miR-1 was shown to promote the differentiation of skeletal myoblast by 
suppressing the expression of HDAC4, a class II HDAC (Chen et al., 2006). It was also reported 
that HDAC inhibitors induced myocyte fusion, through the production of follistatin (Iezzi et al., 
2004), but the identity of the HDAC was not known. I hypothesized that miR-1 might promote 
skeletal myogenesis by suppressing HDAC4 and subsequently inducing follistatin expression. To 
examine this hypothesis, I first asked whether HDAC4 could be involved in follistatin production 
and myogenesis. To this end, I knocked down HDAC4 in C2C12 cells with a lentivirus-delivered 
shRNA (Fig. IV.5A). Depletion of HDAC4 led to an increase in follistatin mRNA levels (Fig. 
IV.5B) as well as the amount of secreted follistatin protein (Fig. IV.5C). Meanwhile, HDAC4 
knockdown enhanced myocyte differentiation (Fig. IV.5D), with an increase in fusion index, 
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defined as percentage of nuclei in multinucleated cells (Fig. IV.5E). These data suggest that 
HDAC4 suppresses follistatin production and is a negative regulator of myogenic fusion. 
 Next, I examined the requirement of miR-1 for follistatin expression. Inhibition of miR-1 
function was achieved by a locked nucleic acid (LNA)-containing anti-sense oligonucleotide 
approach that had been reported to be effective in blocking the actions of the targeted microRNAs 
(Naguibneva et al., 2006a). As shown in Fig. IV.6A, anti-miR-1 significantly suppressed the 
mRNA levels of follistatin, suggesting that miR-1 is required for the expression of follistatin. In 
addition, the inhibition of follistatin by anti-miR-1 was almost completely reversed when cells 
were treated with the HDAC inhibitor TSA (Fig. IV.6A). These data are consistent with a cascade 
in which miR-1 regulates follistatin expression through impairing an HDAC. At the same time, a 
negative effect of anti-miR-1 was found on C2C12 myogenic differentiation (Fig. IV.6B), 
reflected by suppressed expression of myogenin and MHC (Fig. IV.6C). The percentage of 
myotubes containing five or more nuclei was significantly reduced by anti-miR-1 (Fig. IV.6D), 
and the overall fusion index was also lower in anti-miR-1 expressing cells (Fig. IV.6E). More 
important, addition of recombinant follistatin to the cell medium fully rescued the myogenic 
protein expression (Fig. IV.6C), myotube size (Fig. IV.6D) and fusion index (Fig. IV.6E) in the 
presence of anti-miR-1. Inhibition of HDAC by TSA had a similar rescue effect (Fig. IV.6C-E).  
 I further probed the specific role of HDAC4 in mediating miR-1 regulation of follistatin. 
I found that anti-miR-1 indeed enhanced the expression of HDAC4 modestly but consistently 
(Fig. IV.7A). Furthermore, knockdown of HDAC4 completely overrode the negative effect of 
anti-miR-1 on follistatin expression (Fig. IV.7B) and, at the same time, restored myocyte fusion 
as indicated by both the fusion index and the percentage of large myotubes (Fig. IV.7C). Taken 
together, these observations strongly support the existence of a miR-1—HDAC4—follistatin 
cascade in the regulation of myogenesis. 
 
IV.3.5. mTORC1 regulates myocyte fusion through follistatin. 
 Now that I have established a regulatory pathway from miR-1 to follistatin via HDAC4, 
the immediate question is whether mTORC1 controls this pathway, in other words, whether 
inhibition of mTORC1 enhances HDAC4 expression and in turn suppresses follistatin expression. 
Indeed, I found that rapamycin treatment increased HDAC4 protein levels (Fig. IV.8A), and at 
the same time markedly suppressed the mRNA level of follistatin (Fig. IV.8B). Notably, 
rapamycin’s inhibitory effect on follistatin was only obvious at a later stage during differentiation 
(day 2 and 3), when myocyte fusion takes place, supporting the idea that follistatin is a myogenic 
factor that promotes fusion rather than the initiation of differentiation. The comparable kinetics of 
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miR-1 and follistatin expression (dramatic increase of both at 48 hrs and 72 hrs of differentiation; 
see Fig. IV.1A and Fig. IV.8B) is also consistent with miR-1 regulation of follistatin. 
 Previously we have demonstrated that mTORC1 regulates at least two distinct processes 
of myogenesis, and that its regulation of the second-stage myocyte fusion leading to myotube 
maturation or growth is through a yet-to-be-identified secreted factor (Park and Chen, 2005). In 
light of the discovery of a connection between mTORC1 and follistatin through miR-1 and 
HDAC4, I wondered whether follistatin might be the long-sought second-stage fusion factor 
under the control of mTOR. To this end, I tested whether follistatin could rescue myogenic 
differentiation from rapamycin inhibition. When C2C12 cells were induced to differentiate in the 
presence of rapamycin, follistatin alone failed to rescue differentiation (unpublished observation). 
This outcome was not unexpected, as rapamycin would block the production of both the fusion 
factor and IGF-II, the latter required for the initiation of differentiation (Erbay et al., 2003). To 
bypass the initiation of differentiation thus allowing examination of myocyte fusion specifically, I 
added recombinant IGF-II to the differentiation medium, which would fully support the initial 
differentiation and formation of nascent myotubes in the presence of rapamycin (Erbay et al., 
2003; Park and Chen, 2005). In the presence of both IGF-II and rapamycin, C2C12 cells 
differentiated into myotubes but arrested at a small myotube size with fewer myonuclei than 
mature myotubes (Fig. IV.9A&C). Strikingly, the addition of recombinant follistatin in this 
system led to a complete rescue of mature myotube size (Fig. IV.9A&C), suggesting that 
follistatin is a strong candidate for an mTORC1-regulated second-stage fusion factor. 
 Previously we had reported that C2C12 cells stably expressing a rapamycin-resistant and 
kinase-inactive (RR/KI) mTOR differentiated in the presence of rapamycin but arrested at the 
nascent myotube stage (Park and Chen, 2005). To confirm that follistatin was the missing factor 
in those cells, I added follistatin to the medium of the RR/KI-mTOR cells containing rapamycin. 
Remarkably, this resulted in a dramatic increase of myotube size as indicated by the higher 
percentage of myotubes containing five or more nuclei (Fig. IV.9B&D). The effectiveness of 
follistatin was comparable to that of conditioned medium from fully differentiated C2C12 cells. 
In addition, inhibiting HDAC by TSA had a similar effect (Fig. IV.9B&D). Collectively, these 
data strongly suggest that follistatin is a fusion factor regulated by mTORC1. 
 
IV.3.6. Follistatin is regulated by mTORC1 during muscle regeneration in vivo. 
 Regeneration of damaged adult skeletal muscles involves satellite cell activation and 
proliferation, followed by myoblast differentiation and fusion. Systemic administration of 
rapamycin impairs the regeneration of skeletal muscle induced by BaCl2 injection in mice, 
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suggesting that mTORC1 plays a key role in muscle regeneration (Ge et al., 2009). Significantly, 
follistatin mRNA levels increased by ~2-fold during regeneration, and this increase was abolished 
by rapamycin administration (Fig. IV.10A), consistent with mTORC1 regulation of follistatin in 
vivo. I further probed the involvement of follistatin in mTORC1-regulated myocyte fusion and 
myofiber growth in vivo. In order to study myofiber maturation, which relies on myocyte fusion, 
BaCl2 injected muscles were allowed to regenerate for 7 days, during which time new fibers were 
formed but not fully matured, before rapamycin was systemically administered. As shown in Fig. 
IV.10B&C, rapamycin administration significantly diminished the growth of regenerating 
myofibers, as indicated by the smaller average cross-section area of the fibers. Most important, 
intramuscular injection of adenovirus expressing recombinant follistatin alleviated the negative 
effect of rapamycin, resulting in normal growth of the regenerating myofibers in the presence of 
rapamycin (Fig. IV.10B&C), whereas adenovirus expressing GFP did not have any effect 
(unpublished observation). TSA has been shown to induce the expression of follistatin in skeletal 
muscles in vivo (Minetti et al., 2006). Indeed, similar to intramuscular expression of recombinant 
follistatin, systemic administration of TSA fully rescued the growth of regenerating myofibers 
from rapamycin inhibition (Fig. IV.10B&C). Taken together, these observations provide in vivo 
validation for follistatin as an mTORC1-regulated myogenic fusion factor.  
 
IV.4. DISCUSSION 
 My study has revealed the regulation of another miRNA by mTOR, a master regulator of 
cell growth and differentiation. I have also identified follistatin as the long-sought myogenic 
fusion factor under the regulation of mTORC1 signaling (Park and Chen, 2005). I propose a 
myogenic pathway (Fig. IV.10D) in which rapamycin-sensitive mTORC1 controls MyoD-
dependent transcription of miR-1, which in turn suppresses HDAC4 and subsequently 
upregulates the production of follistatin, stimulating skeletal myocyte fusion in vitro and in vivo. 
The linearity of this pathway presented here would be an over-simplification of the actual 
regulatory network, as most likely miR-1, as well as HDAC4, would have multiple targets in 
myogenesis, and mTOR certainly regulates other myogenic pathways independent of miR-1. 
Nevertheless, my study identifies a functional pathway important for myocyte fusion and muscle 
growth, providing a new target for therapeutic intervention in muscle repair and regeneration. 
IV.4.1. mTOR regulation of microRNA 
 Best known as a regulator of protein synthesis through its effectors S6K1 and 4E-BP1 
(Gingras et al., 2001; Hay and Sonenberg, 2004), the rapamycin-sensitive mTORC1 also 
regulates RNA polymerase I-dependent ribosomal DNA transcription through the initiation 
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factors TIF-IA, SL-1 and UBF (Mayer and Grummt, 2006). Regulation of mRNA expression has 
been implicated for mTORC1 as well, although the mechanisms remain to be deciphered. Our 
discovery that mTORC1 regulates biogenesis of microRNA further expands the repertoire of this 
master regulator for mammalian cellular and developmental processes.  
 There are two distinct chromosomal loci for the miR-1 gene – miR-1-1 and miR-1-2. An 
upstream enhancer has been found at each locus to mediate the regulation of miR-1 expression in 
cardiac muscle, and regulatory sites for serum response factor, MyoD and MEF2 have been 
identified in the enhancers (Zhao et al., 2005). My results have indicated that the miR-1 enhancer 
activity is indeed up-regulated during skeletal myocyte differentiation and inhibited by 
rapamycin, suggesting mTORC1 regulation of miR-1 expression through this enhancer. I have 
further shown that MyoD mediates mTOR regulation of the miR-1 enhancer activity, and that 
mTORC1 controls the protein stability of MyoD. mTOR regulation of MyoD and miR-1 is most 
likely direct, based on the following observations: (1) the effects of rapamycin on MyoD 
degradation and miR-1 enhancer activity were acute and not dependent on myogenic 
differentiation (Fig. IV.4D-F); (2) while rapamycin abolished miR-1 enhancer activity, other 
drugs that block differentiation did not have any effect (Fig. IV.3). In addition to the upstream 
enhancers of miR-1 genes, an intragenic enhancer has been reported to activate muscle-specific 
transcription of the bicistronic primary transcript encoding miR-1-2 and miR-133a-1 (Liu et al., 
2007). Interestingly, I found that a reporter of this intragenic enhancer was activated during 
C2C12 cells differentiation and inhibited by rapamycin (Fig. IV.15). Since MyoD also regulates 
this enhancer (Liu et al., 2007), it raises the possibility that the mTORC1-MyoD axis controls 
miR-1 transcription at multiple levels. 
 In contrast to mTOR regulation of ribosomal DNA transcription which requires S6K1 
(Mayer et al., 2004), mTOR regulation of miR-1 expression does not seem to involve S6K1, as 
knockdown of S6K1 has no effect on miR-1 expression during myogenesis (unpublished 
observations). It is conceivable that mTORC1 phosphorylates MyoD and, in turn, stabilizes 
MyoD. We have indeed observed that mTOR phosphorylates MyoD in vitro (unpublished 
observations). The reported MyoD phosphorylation sites – Ser5 and Ser200 – do not conform to 
this model, as their phosphorylation correlates with degradation of MyoD (Song et al., 1998; 
Tintignac et al., 2004). The exact mechanism by which mTORC1 regulates MyoD stability is 
currently under investigation.  
 MicroRNA profiling of differentiating C2C12 cells has been reported by other groups 
(Chen et al., 2006; Wong and Tellam, 2008). Although there is some degree of agreement within 
the results obtained by different groups including ours, our data have revealed more myogenically 
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regulated miRNAs than the other studies, possibly due to the difference in the miRNA chips used, 
robustness of cell differentiation, and/or methods of data analysis (e.g., we used statistical 
significance, rather than fold-change, to set the threshold for data selection). In any event, our 
array results have confirmed the up-regulation, during differentiation, of almost all reported 
regulators of myogenesis in addition to miR-1, including miR-24, miR-26a, miR-27b, miR-133, 
miR-206, miR-181, miR-214, and miR-499 (Crist et al., 2009; Juan et al., 2009; Naguibneva et 
al., 2006b; Sun et al., 2008; van Rooij et al., 2009; Williams et al., 2009; Wong and Tellam, 
2008) (Table IV.1). Many miRNAs not previously reported to be involved in myogenesis are 
found to be up- or down-regulated during differentiation (Table IV.1), potentially representing 
novel regulators of myogenic pathways that are worthy of future investigation. Intriguingly, 
among 50 or so miRNAs that were differentially expressed during myogenesis (out of ~500 
total), 24 miRNAs other than miR-1 displayed various degrees of rapamycin sensitivity (Fig. 
IV.11 and Table IV.1). Although some of these miRNAs may lie far downstream of mTORC1 in 
myogenesis, it is conceivable that other miRNAs in addition to miR-1 may be directly regulated 
by mTORC1. Further characterization of those candidate miRNAs will likely enhance our 
understanding of the myogenic regulatory network. 
IV.4.2. Follistatin as an mTOR-regulated fusion factor 
 Previously we reported the existence of a fusion factor under the control of mTORC1 
signaling in a mTOR kinase-dependent manner, which promoted maturation of myotubes arrested 
at the nascent myotube stage by the treatment of rapamycin (Park and Chen, 2005). My current 
study has revealed follistatin as this long-sought fusion factor, regulated by mTORC1 through a 
miR-1-mediated pathway. Several other secreted factors have been found in the conditioned 
medium of normally maturing myotubes but not of rapamycin-arrested nascent myotubes 
(unpublished observations), including the established second-stage fusion factor IL-4 (Horsley et 
al., 2003) and the NF-kB induced myogenic stimulator IL-6 (Baeza-Raja and Munoz-Canoves, 
2004). However, none of them is able to rescue rapamycin-inhibited myotube maturation 
(unpublished observations). The capacity of exogenous follistatin to fully rescue from rapamycin 
inhibition myotube maturation in vitro (Fig. IV.9) and muscle regeneration in vivo (Fig. 
IV.10B&C), together with the inhibitory effect of rapamycin on follistatin expression both in 
vitro and in vivo (Fig. IV.8B & Fig. IV.10A), makes follistatin the major, if not the only, fusion 
factor regulated by mTORC1. 
 Follistatin, an activin-binding protein essential for multiple aspects of mouse 
development (Matzuk et al., 1995), is thought to control skeletal muscle development through 
antagonizing the myogenic inhibitor myostatin (Amthor et al., 2004; Lee and McPherron, 2001). 
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The stimulatory effect of follistatin on adult muscle growth has been demonstrated in the mdx 
mice (Haidet et al., 2008; Minetti et al., 2006; Nakatani et al., 2008). In vitro, follistatin was 
shown to mediate TSA- or NO/cGMP-induced myoblast fusion (Iezzi et al., 2004; Pisconti et al., 
2006). It is likely that follistatin plays a role in both the initial myoblast fusion and the second-
stage fusion, as we have observed that differentiating C2C12 cells exposed to recombinant 
follistatin display increased fusion index in addition to increased size of myotubes (unpublished 
observations). This well corroborates our observation that inhibiting miR-1 results in decreased 
myotube size and fusion index (Fig. IV.6) supporting the notion that miR-1 and follistatin act on 
the same pathway to regulate two stages of myocyte fusion. The new regulatory pathway for 
follistatin (Fig. IV.10D) discovered in our study should expand the therapeutic potential of this 
important myogenic factor. 
 
IV.5. Contributions of Co-Worker  
 This chapter is the result of collaboration with Dr. Yuting Sun. Dr. Sun initiated this 
project and made significant contributions to the final results including Figs 4.1A-C, 4.4A-D, 
4.6A-B, 4.8, 4.9, 4.S1, 4.S3 (I prepared the slides and Dr. Sun conducted the in situ 
hybridizations) and Table IV.1.
  105 
 
IV.6. Figures And Tables 
 
 
 
 
 
Figure IV.1. mTOR controls miR-1 levels during myogenesis both in vitro and in vivo. (A) 
C2C12 cells were induced to differentiate in the absence or presence of 50 nM rapamycin (Rap). 
RNA was isolated at indicated time points of differentiation (Diff.), and miR-1 levels were 
measured by qRT-PCR. (B) C2C12 cells were transduced with lentiviruses expressing two 
independent mTOR shRNAs or scrambled shRNA, selected with puromycin, and then induced to 
differentiate. At 72hr differentiation, cells were lysed and subjected to Western analysis. S6K1 
(59 kDa) has an apparent molecular weight of 70 kDa on SDS-PAGE. (C) Cells treated as in (B) 
were harvested at the indicated times of differentiation, and miR-1 levels were measured by qRT-
PCR. In both (A) and (C), relative levels are shown as fold increase compared to the level at 0 hr. 
(D) TA muscles in mice hind limbs were injured by intramuscular injection of BaCl2, followed by 
daily intraperitoneal injection of rapamycin. On various days after injury, injected muscles were 
isolated and homogenized for RNA isolation, followed by qPCR to determine relative miR-1 
levels, shown as fold increase compared to uninjured muscles. Data are presented as mean ± 
standard deviation (n=3). 
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Figure IV.2. miR-1 maturation is not affected by rapamycin. C2C12 cells were induced to 
differentiate in the absence or presence of 50 nM rapamycin (Rap). RNA was isolated at indicated 
time points of differentiation (Diff.). (A) Northern blotting was performed to examine miR-1 
(22nt) and pre-miR-1 (73nt and 78nt). Let-7a was blotted as a loading control. (B) qRT-PCR was 
performed to measure the relative levels of pri-miR-1-1 and pri-miR-1-2. Data shown are the 
representative results of four independent experiments (A) and the mean ± standard deviation of 
three independent experiments (B). 
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Figure IV.3. Rapamycin inhibits miR-1 enhancer activity. (A) C2C12 cells were transfected 
with the miR-1-2 enhancer reporter or the corresponding enhancer-less reporter, induced to 
differentiate in the absence or presence of 50 nM rapamycin (Rap), and lysed for luciferase assays 
at the times indicated. (B) Cells were transfected as in (A) and induced to differentiate for 72 hrs 
in the presence of 50 nM rapamycin (Rap), 100 nM wortmannin (Wort), or 1 µM SB203580 
(SB), followed by cell lysis and luciferase assays. The enhancer-less reporter activity was 
subtracted from the enhancer reporter activity for each condition, and the data shown have been 
normalized with 0 hr activity as “1”. Data shown are the mean ± standard deviation of three 
independent experiments. 
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Figure IV.4. mTORC1 regulates miR-1 through MyoD. (A) C3H10T1/2 cells were transfected 
with MyoD for 24 hrs, followed by extraction of total RNA and qRT-PCR to measure relative 
miR-1 levels. (B) C3H10T1/2 cells were co-transfected with MyoD and the miR-1-2 enhancer 
reporter (miR-1-Luc) or the MyoD site-mutated reporter (miR-1*-Luc), induced to differentiate 
for 24 hrs, followed by luciferase assays. (C) C3H10T1/2 cells were co-transfected with the miR-
1-2 enhancer reporter and two different doses of MyoD, induced to differentiate in the absence or 
presence of 50 nM Rap for 24 hrs, followed by luciferase assays. (D) C3H10T1/2 cells were 
transfected as in (C) but with a single dose of MyoD, induced to differentiate for 1 day, and then 
treated with 50 nM Rap for 4 hrs, followed by luciferase assays. For the data in (A-D), relative 
values are shown, with the following samples as the references: (A) lower amount of MyoD 
transfected (100%); (B) miR-1-luc with MyoD (100%); (C) without MyoD and without Rap (1); 
(D) with MyoD without Rap (100%). (E) At the induction of differentiation (0 hr), confluent 
C2C12 cells were treated with 50 nM rapamycin, with or without 1 µM MG-132, for 4 hrs, 
followed by cell lysis and Western analysis for endogenous MyoD. (F) C3H10T1/2 cells were 
transfected with MyoD, grown to confluence, and treated with 50 nM rapamycin in 
differentiation medium for 4 hrs, followed by Western analysis of the cell lysates for recombinant 
MyoD. Tubulin is shown as a loading control in both E and F. 
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Figure IV.5. Knockdown of HDAC4 enhances follistatin expression and myocyte fusion. 
C2C12 cells were transduced with lentiviruses expressing shRNA for HDAC4 or a scrambled 
sequence as negative control (Scram). After puromycin selection, the cells were induced to 
differentiate for 72 hrs, followed by (A) Western analysis of cell lysates, (B) qRT-PCR assays to 
determine the relative levels of follistatin mRNA, (C) ELISA to measure relative levels of 
secreted follistatin protein, (D) immunostaining with anti-MHC (green) and DAPI (blue) (scale 
bar: 50 µm), and (E) measurement of fusion index. One-sample t tests were performed in (B) and 
(C). Paired two-tailed t test was performed in (E), respectively. *P ≤ 0.02. 
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Figure IV.6. miR-1 is required for myocyte fusion through HDAC and follistatin. C2C12 
cells were transfected with LNA anti-miR-1 or a scrambled LNA oligo as control, and then 
induced to differentiate. To inhibit HDAC activity, TSA (25 nM) was added to the growth 
medium when cell density was around 60%, and removed the next day upon switching to 
differentiation medium. Where indicated, recombinant follistatin (“FS”, 0.2 µg/ml) was added to 
the medium during the last two days of differentiation. (A) Relative follistatin mRNA levels after 
2 days of differentiation were determined by qRT-PCR. (B) C2C12 cells after 3 days of 
differentiation were immunostained with anti-MHC (green) and DAPI (blue). Scale bar: 100 µm. 
(C) Myogenic marker expression was examined by Western analysis in 3 day-differentiated 
C2C12 cells. The percentage of myotubes containing 5 or more nuclei (D), and the fusion index 
(E) were calculated. In (E), paired two-tailed t tests were performed to compare each data with 
the control. *P < 0.05. 
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Figure IV.7. HDAC4 functions downstream of miR-1. (A) C2C12 cells were transfected with 
LNA anti-miR-1 or a scrambled LNA oligo as control, and then induced to differentiate for 72 
hrs. HDAC4 protein levels in cell lysates were examined by Western blotting and quantified by 
densitometry using Image J. The ratio of HDAC4 to tubulin was normalized with LNA-Scram as 
1. One-sample t test was performed. *P < 0.05. (B, C) C2C12 cells were transduced with 
lentiviruses expressing shRNA for HDAC4 or a scrambled hairpin sequence, puromycin-selected, 
and then transfected with anti-miR-1 or LNA-scramble, followed by induction of differentiation 
for 72 hrs. The cells were subjected to (B) RNA isolation and qRT-PCR to measure follistatin 
mRNA, or (C) characterization of myotube fusion as described in Fig. IV.6 legend. All data 
shown are mean ± standard deviation (n=3). 
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Figure IV.8. Rapamycin leads to increased HDAC4 levels and decreased follistatin levels. 
(A) C2C12 cells were differentiated for 2 days in the presence or absence of 50 nM rapamycin 
(Rap), and the lysates were analyzed by Western blotting. Western blots were quantified using 
Image J, and the relative ratio of HDAC4 to tubulin is shown. One-sample t test was performed. 
*P < 0.01. (B) C2C12 cells were induced to differentiate in the absence or presence of 50 nM 
rapamycin, and total RNA was isolated at indicated time points of differentiation (Diff.). Relative 
follistatin mRNA levels were measured by qRT-PCR with the 24 hr sample without rapamycin as 
“1”. Data shown are mean ± standard deviation of three independent experiments. 
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Figure IV.9. mTORC1 regulates myocyte fusion through follistatin. (A) C2C12 cells were 
differentiated in the absence or presence of 300 ng/ml IGFII and 50 nM rapamycin (Rap) for 3 
days. Where indicated, 0.2 µg/ml follistatin (FS) was present during the last two days of 
differentiation. Differentiated cells were immunostained with anti-MHC (green) and DAPI (blue). 
(B) C2C12 cells stably expressing RR/KI-mTOR were induced to differentiate in the presence of 
rapamycin (50 nM) for 3 days. Follistatin  (0.2 µg/ml) was added to the medium for the last two 
days of differentiation. TSA (25 nM) was added when the cells where around 60% confluent, and 
removed the next day upon induction of differentiation. Conditioned medium (CM) was collected 
daily from parental C2C12 cells that had been induced to differentiate one day earlier than the 
RR/KI-mTOR cells, and fed to the latter with 50 nM rapamycin added. The cells were 
immunostained as in (A). Scale bars: 100 µm. (C, D) Percentage of myotubes containing ≥5 
nuclei was calculated from experiments in (A) and (B), respectively. All data shown are mean ± 
standard deviation of at least three independent experiments. 
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Figure IV.10. Follistatin is regulated by mTORC1 during muscle regeneration in vivo. (A) 
Mouse hind limb TA muscles were injected with BaCl2, followed by daily systemic 
administration of rapamycin starting Day 1 after injury. On various days indicated, the injected 
muscles were isolated and total RNA extracted, followed by qRT-PCR to measure levels of 
follistatin mRNA. Data shown are mean ± standard deviation (n=3). (B) TA muscles were 
injected with BaCl2, followed by daily systemic administration of rapamycin with or without TSA 
from day 7 to day 13 post-injury. For some animals, a single dose of adenovirus expressing 
follistatin was injected into the injured TA muscle on Day 7 post-injury. A schematic diagram is 
shown to summarize the various injections of animals. On Day 1, 7 or 14 post-injury, the animals 
were sacrificed and the injured muscles were dissected and cryosectioned, followed by H&E 
staining. Representative images are shown (n=7 mice for each time point). Scale bar: 50 µm. (C) 
Cross-section areas of regenerating myofibers shown in (B) were measured. Data shown are 
average ± standard deviation (n=7 mice for each data point). One-way ANOVA was performed to 
analyze the data. Significant difference comparing each data point to that of Day 14 without 
treatment: *P < 0.001. (D) A schematic representation of the myogenic pathway discovered in 
this study: mTORC1 controls MyoD-dependent expression of miR-1 that targets HDAC4 and 
subsequently up-regulates the production of follistatin, which in turn governs myocyte fusion in 
skeletal myogenesis. 
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Figure IV.11. Summary of microRNA profiling. microRNA profiling was performed to 
compare confluent undifferentiated cells and 3-day differentiated cells in the presence or absence 
of rapamycin. The numbers of miRNAs that underwent statistically significant up-regulation, 
down-regulation, or no change during differentiation are shown, and their responses to rapamycin 
treatment are indicated. An enlarged lower region of the graph (y-axis: 0-50) is shown at the 
right. The details of microarray experiments and statistical analysis are described in Materials and 
Methods.  
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Figure IV.12. Myogenic differentiation is inhibited by rapamycin. C2C12 cells were induced 
to differentiate in the absence or presence of 50 nM rapamycin (Rap). At various time points as 
indicated, the cell lysates were subjected to Western analysis. 
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Figure IV.13. In situ hybridization of miR-1 in regenerating muscles. TA muscles in mice 
hind limbs were injured by intramuscular injection of BaCl2, followed by daily intraperitoneal 
injection of rapamycin. On day 14 after injury, the TA muscles were isolated, cryosectioned, and 
then subjected to in situ hybridization for miR-1. A scrambled probe was used as a negative 
control. The enlarged image shows overlay of in situ hybridization (dark blue) and DAPI staining 
(pseudo-colored green). Four independent experiments were performed with similar outcome, and 
the representative results are shown. Scale bars: 50 µm. 
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Figure IV.14. MyoD mRNA levels are not affected by rapamycin. Confluent C2C12 cells (A) 
or MyoD-transfected C3H10T1/2 cells (B) were withdrawn from serum with or without 50 nM 
rapamycin for 4 hrs, followed by RNA extraction and qRT-PCR to determine the relative levels 
of MyoD mRNA. The results of three independent experiments are shown as mean ± SD. 
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Figure IV.15. Rapamycin inhibits the activity of an intragenic enhancer of miR-1/133a. 
C2C12 cells were transfected with a luciferase reporter for the intragenic enhancer or the 
enhancer-less reporter (pGL2-promoter), induced to differentiate in the absence or presence of 50 
nM rapamycin (Rap), and lysed for luciferase assays at the times indicated. The enhancer-less 
reporter activity was subtracted from the enhancer reporter activity for each condition, and the 
data shown have been normalized with 0 hr activity as “1”. The results of three independent 
experiments are shown as mean ± SD. 
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MicroRNA   Fold Change Rapamycin effect 
mmu-miR-1 11.811 - 
mmu-miR-133b 10.875 - 
mmu-miR-133a 10.418 - 
mmu-miR-206 7.6 - 
mmu-miR-146b 2.914 - 
mmu-miR-322 2.868 0 
mmu-miR-335-5p 2.838 - 
miRPlus_17653 2.719 - 
mmu-miR-378 2.604 - 
mmu-miR-143 2.255 0 
mmu-miR-199a-3p/199b 2.048 0 
mmu-miR-128a/128b 2.042 - 
mmu-miR-499 2.036 - 
mmu-miR-199b* 2.01 + 
mmu-miR-26a 1.996 0 
mmu-miR-181b 1.892 0 
mmu-miR-218 1.854 0 
mmu-miR-362-5p 1.843 - 
mmu-miR-199a-5p 1.818 + 
mmu-miR-503 1.779 - 
mmu-miR-152 1.717 0 
mmu-miR-26a_MM1 1.702 + 
mmu-miR-450a-5p 1.693 0 
mmu-miR-532-5p 1.667 - 
mmu-miR-145 1.649 0 
 
 
Table IV.1. Results of miRNA profiling in differentiating C2C12 cells.
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MicroRNA   Fold Change Rapamycin effect 
mmu-miR-500 1.628 - 
mmu-miR-24 1.599 0 
mmu-miR-30a 1.515 0 
mmu-miR-27b 1.506 0 
mmu-miR-214 1.497 + 
mmu-miR-378* 1.409 - 
mmu-miR-132 1.378 0 
mmu-miR-501-3p 1.28 - 
mmu-miR-351 1.248 - 
mmu-miR-29a -1.377 0 
mmu-miR-677 -1.413 0 
mmu-miR-125b-5p -1.44 + 
mmu-miR-15b -1.468 0 
mmu-miR-20b -1.553 0 
mmu-miR-18a -1.563 0 
miRPlus_27561 -1.592 + 
miRPlus_17890 -1.629 + 
mmu-miR-222 -1.676 0 
mmu-miR-150 -1.686 0 
mmu-miR-20a -1.786 0 
miRPlus_17833 -1.866 0 
mmu-miR-326 -1.897 0 
mmu-miR-805 -2.004 0 
mmu-miR-762 -2.216 + 
 
 
Table IV.1. Results of miRNA profiling in differentiating C2C12 cells. (con’t) microRNA 
profiling was performed to compare confluent undifferentiated cells and 3-day differentiated cells 
in the presence or absence of rapamycin. miRNAs that underwent statistically significant changes 
in their levels during differentiation are listed. Fold change of each miRNA in 3-day 
differentiated cells versus undifferentiated cells is shown. The effect of rapamycin is indicated as 
no effect (0), inhibiting (-) or activating (+). The details of microarray experiments and statistical 
analysis are described in Materials and Methods.
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CHAPTER V. RAPTOR AND RHEB NEGATIVELY REGULATE SKELETAL 
MYOGENESIS THROUGH SUPPRESSION OF IRS1 
 
V.1. Introduction 
During embryonic skeletal myogenesis, cells in somites commit to myogenic lineage and 
become myoblasts, which differentiate and fuse to form multinucleated myofibers (Buckingham, 
2001). This is a highly coordinated process where various environmental cues and signaling 
pathways integrate to regulate the formation of skeletal muscle (Lassar and Munsterberg, 1994; 
Naya and Olson, 1999). This process is largely recapitulated by the in vitro differentiation of 
myoblasts, such as the C2C12 mouse satellite cell line. Upon growth factor withdrawal, these 
cells produce insulin-like growth factor II (IGF-II), which in an autocrine fashion stimulates 
myogenic differentiation (Florini et al., 1991). One of the critical pathways downstream of 
myogenic IGF signaling is the PI3K-Akt pathway (Coolican et al., 1997; Kaliman et al., 1998), 
and insulin receptor substrate 1 (IRS1) is a well-established mediator of IGF receptor activation 
of downstream signaling (Taguchi and White, 2008). 
mTOR, the mammalian target of rapamycin, has long been recognized as a nutrient- and 
energy-sensing signaling hub regulating a wide spectrum of cellular processes including 
proliferation, growth, survival, differentiation, and metabolism (Zoncu et al., 2011). It nucleates 
two distinct biochemical complexes: the raptor-associated mTORC1 is acutely sensitive to 
rapamycin, and it targets S6K1 and 4E-BP1 to regulate translation initiation, among other 
functions; the rictor-associated mTORC2 is a kinase for the multifunctional kinase Akt and it also 
regulates cytoskeleton reorganization (Laplante and Sabatini, 2009). Although mTORC2 was 
initially characterized as the rapamycin-insensitive complex, prolonged rapamycin treatment 
inhibits mTORC2 in some cellular contexts (Sarbassov et al., 2005). 
Accumulative evidence has revealed mTOR’s role as a master regulator of skeletal 
myogenesis. mTOR regulates the initiation of myoblast differentiation in vitro and early stage of 
muscle regeneration in vivo by controlling the production of IGF-II at two levels – transcriptional 
regulation through a muscle-specific enhancer (Erbay et al., 2003; Ge et al., 2009) and post-
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transcriptional regulation through the microRNA miR-125 (Ge et al., 2011). Myocyte fusion is 
also regulated by mTOR via a MyoD/microRNA-1/HDAC4/Follistatin pathway (Sun et al., 
2010). Interestingly, mTOR utilizes distinct mechanisms in regulating different stages of 
myogenesis: the kinase activity of mTOR is entirely dispensable for the early stage of myogenesis 
and IGF-II production (Erbay and Chen, 2001; Erbay et al., 2003; Ge et al., 2009), whereas 
myotube and myofiber maturation – involving late-stage fusion – requires mTOR kinase activity 
(Park and Chen, 2005; Sun et al., 2010).  
While all the myogenic functions of mTOR mentioned above are sensitive to rapamycin, 
it is not clear whether mTORC1 mediates those functions. Efforts to directly examine mTOR’s 
role in vivo with skeletal muscle-specific gene knockout have been invaluable in determining the 
physiological functions of mTOR and its binding proteins. Consistent with their essential roles in 
muscle development, muscles depleted of either mTOR (Risson et al., 2009) or raptor (Bentzinger 
et al., 2008) display severe muscular dystrophy during postnatal development. Rictor, on the 
other hand, appears to be dispensable for muscle development as no defect is detectable in rictor-
depleted muscles (Bentzinger et al., 2008). However, it is important to note that all the 
aforementioned gene deletions are induced by Cre recombinase expression driven by the human 
skeletal actin (HSA) promoter, which is only active in differentiated myofibers and not in satellite 
cells (Nicole et al., 2003). Thus, any role of mTOR, raptor, or rictor in early stages of 
myogenesis, in particular initiation of differentiation, could conceivably have been missed in 
those investigations. Systemic s6k1 deletion leads to skeletal muscle atrophy, but the s6k1-/- 
myofibers, albeit smaller than wt myofibers in diameter, contain normal myonuclei numbers 
(Ohanna et al., 2005), suggesting a lack of myogenic defect. 
The depletion of raptor by RNAi in human skeletal myoblasts has been reported to have 
little effect on differentiation although it augments the inhibitory effect of myostatin 
(Trendelenburg et al., 2009). In C2C12 myoblasts, rictor and mTORC2, rather mTORC1, have 
been suggested to be the mediator of rapamycin inhibition of differentiation (Shu and Houghton, 
2009). To further probe into the role of mTORC1 in myogenic differentiation, I investigated the 
effects of manipulating protein levels of the canonical mTORC1 signaling components in C2C12 
cells. I have found that the rapamycin-sensitive mTOR function in myogenic differentiation is 
independent of the canonical mTORC1. Instead, raptor, along with the activator of mTORC1, 
Rheb, negatively regulates myoblast differentiation through suppression of IRS1 and inhibition of 
Akt activation. 
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V.2. Materials and Methods 
V.2.1. Antibodies and other reagents. Anti-MHC (MF20) and anti-myogenin (F5D) were 
obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the 
NICHD, National Institutes of Health and maintained by The University of Iowa, Department of 
Biological Sciences. Anti-tubulin was from Abcam. All other primary antibodies were from Cell 
Signaling Technology. All secondary antibodies were from Jackson ImmunoResearch 
Laboratories, Inc. Rapamycin was from LC labs. Gelatin was from Sigma. 
V.2.2. Plasmids. pRK5-HA-raptor was obtained from Addgene (Kim et al., 2002). pRK7-Flag-
Rheb was a generous gift from the Blenis laboratory (Tee et al., 2003). 
V.2.3. Cell culture and transfection. C2C12 myoblasts were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM) containing 1 g/L glucose with 10% fetal bovine serum at 37°C with 
7.5% CO2. Transfection of myoblasts was performed using TransIT-LT1 (Mirus) following the 
manufacturer’s recommendations. To induce differentiation, cells were plated on tissue culture 
plates coated with 0.2% gelatin and grown to 100% confluence before switching to differentiation 
medium (DMEM containing 2% horse serum). The cells were replenished with fresh 
differentiation medium daily for 3 days.  
V.2.4. Western blotting. Cells were lysed in 50 mM Tris-HCl, pH 7.2, 150 mM NaCl, 1% NP- 
40, and 1% protease inhibitor cocktail (Sigma). The lysates were cleared by micro-centrifugation 
at 14,000 rpm, and then mixed with 2xSDS sample buffer. Proteins were resolved by SDS-PAGE 
and transferred onto PVDF membranes (Millipore), which were then incubated with various 
antibodies following the manufacturer’s recommendations. Detection of horseradish peroxidase-
conjugated secondary antibodies was performed with Western LightningTM Chemiluminescence 
Reagent Plus (Perkin Elmer Life Sciences, Inc.), and images were developed on X-ray films. 
Quantification of Western band intensities was performed by densitometry using the software 
Image J. 
V.2.5. Immunofluorescence microscopy and quantitative analysis of myocytes. C2C12 cells 
differentiated in 12-well plates were fixed and stained for MHC and DAPI as previously 
described (Park and Chen, 2005). The stained cells were examined with a Leica DMI 4000B 
fluorescence microscope, and the fluorescent images were captured using a RETIGA EXi camera, 
and analyzed with Q-capture Pro51 software (Q-ImagingTM). The differentiation and fusion 
indexes were calculated as the percentage of nuclei in MHC-positive myocytes and in myotubes 
with ≥2 nuclei, respectively. Each data point was generated from at least 200 randomly chosen 
MHC-positive cells or myotubes. 
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V.2.6. Lentivirus-mediated RNAi. shRNAs in the pLKO.1-puro vector for knocking down were 
purchased from Sigma-Aldrich (MISSION® TRC). Lentivirus packaging and testing were 
performed as previously described (Yoon and Chen, 2008). The Sigma clone ID for the shRNA 
constructs used in this study are: mTOR #1, NM_020009.1-7569s1c1; mTOR #2, NM_020009.1-
5493s1c1; rictor #1, NM_030168.2-6240s1c1, rictor #2, NM_030168.2-5030s1c1; Rheb #1, 
NM_053075 .2-740s1c1, Rheb #2, NM_053075.2-339s1c1; IRS1 #1, NM_010570.4-2308s21c1, 
IRS1 #2, NM_010570.2-3585s1c1; S6K1 #1, NM_028259.1 -264s1c1; S6K1 #2, NM_028259.1-
616s1c1; raptor #1, NM_028898.1-3729s1c1. Raptor #2 shRNA was cloned by inserting the 
following sequence into pLKO.1puro: 5’CCGGGGCTAGTCTGTTTCGAAATTTCTTCCT 
GTCAAAATTTCGAAACAGACTAGCCTTTTTG3’. C2C12 cells were transduced with 
lentiviruses in growth medium with 8 µg/ml polybrene, selected in 3 µg/ml puro for 2 days, 
followed by plating into 12-well plates for differentiation. 
V.2.7. Statistical analysis. All data are presented as mean ± standard deviation (SD) of at least 3 
sets of independent experiments. Whenever necessary, statistical significance of the data was 
analyzed by performing one-sample or paired t-tests. The specific types of tests and the P values, 
when applicable, are indicated in figure legends. 
 
V.3. Results 
V.3.1. mTOR and raptor have opposite roles in regulating myoblast differentiation 
To directly examine the role of mTOR, raptor and rictor in myoblast differentiation, 
lentivirus-delivered shRNA-mediated knockdown of each of those proteins was carried out in 
C2C12 myoblasts, which were then induced to differentiate by serum withdrawal. Consistent with 
the inhibitory effect of rapamycin in myogenesis, mTOR knockdown drastically inhibited C2C12 
cell differentiation, as evidenced by both severely impaired myotube formation (Fig. V.1A&B) 
and blocked expression of the differentiation markers myogenin and myosin heavy chain (MHC) 
(Fig. V.1C) by Day 3 of differentiation induction. Since mTOR is known to regulate cell growth 
and proliferation, and the capacity of myoblast differentiation is correlated to cell density, I took 
care to equalize the cell numbers between mTOR knockdown samples and control samples 
expressing a scrambled hairpin sequence at the initiation of differentiation (Day 0). The cell 
numbers across samples remained similar on Day 3 of differentiation (see Fig. V.1A DAPI stain). 
Hence, the differentiation defect in mTOR knockdown cells is unlikely to be a consequence of 
growth defect. 
 130 
 Surprisingly, raptor knockdown led to enhanced differentiation (Fig. V.1D), with 
elevated differentiation and fusion indexes, as well as a larger average size of myotubes (Fig. 
V.1E). Myogenin and MHC expression were also increased by raptor knockdown (Fig. V.1F). A 
modest decrease of mTOR levels was observed in raptor knockdown cells (Fig. V.1F), consistent 
with the proposed inter-dependence of protein stability between mTOR and raptor (Kim et al., 
2002). The positive effect of raptor on differentiation was evident despite the partial loss of 
mTOR. These observations suggest that the rapamycin-sensitive function of mTOR in myogenic 
differentiation is independent of the raptor-defined mTORC1. Instead, raptor appears to have a 
negative role in myogenesis. 
Rictor knockdown, on the other hand, did not affect myoblast differentiation (Fig. V.1G-
I). The efficiency of rictor knockdown was high and comparable to that of raptor knockdown 
(Fig. V.1I), but I cannot formally rule out the possibility that the residual rictor protein is 
functionally sufficient. In all the knockdown experiments two independent shRNAs were used for 
each gene, yielding consistent results, thus ruling out off-target effects. 
 
V.3.2. Raptor and Rheb negatively regulate myoblast differentiation 
To probe into the potentially negative role of raptor, I considered the other components in 
the canonical mTORC1 pathway. To that end, I knocked down the activator of mTORC1, Rheb 
(Laplante and Sabatini, 2009), and examined its effect on myoblast differentiation. Rheb-depleted 
cells differentiated more robustly, with higher differentiation and fusion indexes, as well as 
increased average myotube size, compared to control cells (Fig. V.2A&B). The expression of 
myogenin and MHC was also elevated (Fig. V.2C). Rheb and raptor, therefore, might reside in 
the same pathway as negative regulators of myogenesis, in contrast to mTOR’s positive role.  
On the other hand, knockdown of S6K1, the immediate downstream effector of 
mTORC1, did not affect differentiation (Fig. V.2D-F). This is consistent with our previous 
conclusion that S6K1 is dispensable for myoblast differentiation (Erbay and Chen, 2001), and 
also with the observation that s6k1-/- mice form normal numbers of myofibers with wild-type 
myonuclei number (Ohanna et al., 2005). However, I did not observe smaller diameter of S6K1-
depleted myotubes (Fig. V.2D), in contrast to the observations that s6k1-/- myofibers are smaller 
during both development (Ohanna et al., 2005) and regeneration (Ge et al., 2009). While I cannot 
rule out the possibility that residual S6K1 in the knockdown cells is fully functional, given the 
high efficiency of knockdown (Fig. V.2F), it is more likely that the in vitro culture system does 
not have the resolution to reveal a modest myotube growth defect. 
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To further confirm the function of raptor and Rheb, recombinant HA-raptor or Flag-Rheb 
was overexpressed in C2C12 myoblasts. Consistent with their negative roles in myogenesis, both 
raptor and Rheb overexpression impaired myotube formation (Fig. V.3A), as quantified by 
different-tiation index, fusion index, and average size of myotubes (Fig. V.3B). Stable expression 
of the recombinant protein resulted in a total protein level that was at least 2-fold of that of 
endogenous protein, for both raptor and Rheb (Fig. V.3C). Furthermore, the expression of an 
array of myogenic markers was found to be decreased by raptor and Rheb expression (Fig. V.3D). 
At the same time, overexpression of S6K1, or 4E-BP1 (another target of mTORC1 in cell growth 
regulation), did not have any effect on myogenic differentiation (Fig. V.3E). These data are not 
only consistent with those two mTORC1 effectors being dispensable, but also help exclude non-
specific effects of protein overexpression on differentiation. Taken together, my results have 
revealed a negative regulation of myogenic differentiation by the canonical mTORC1 signaling 
components raptor and Rheb. 
 
V.3.3. mTOR/raptor negatively regulates Akt activation 
To decipher the mechanism under-lying the negative roles of raptor and Rheb in 
myogenic mTOR signaling, I considered the well-established feedback inhibition of PI3K/Akt 
signaling by mTORC1 activation in a variety of cellular contexts (Um et al., 2006). Indeed, raptor 
and Rheb knockdown each increased Akt phosphorylation on both Ser473 and Thr308, to 
statistically significant degrees (Fig. V.4A). Enhanced Akt phosphorylation was also seen in 
raptor-deleted mouse skeletal muscles in vivo (Bentzinger et al., 2008), which accompanied 
muscular dystrophy, contrary to the enhanced differentiation we observed here. As expected, 
S6K1 phosphorylation on Thr389 was dampened by the knockdown of either protein (Fig. V.4A). 
Interestingly, mTOR knockdown also led to increased Akt phosphorylation (Fig. V.4B), as was 
reported for in mTOR-depleted muscle in vivo (Risson et al., 2009). This is consistent with a 
negative feedback regulation of Akt by mTOR/raptor and at the same time suggests that mTOR 
might not be the main kinase for Akt in muscle cells. Indeed, mTORC2-independent 
phosphorylation of Akt has been reported in mouse skeletal muscles (Bentzinger et al., 2008). 
IGF-II is a well-established autocrine factor that promotes differentiation of C2C12 cells 
(Florini et al., 1991), and mTOR regulates its expression during initiation of differentiation 
(Erbay et al., 2003; Ge et al., 2009). Therefore, I wondered what the effect of raptor and Rheb 
knockdown might be in the presence of exogenous IGF-II. To minimize the complication from 
endogenous IGF-II, I chose a time point before IGF-II expression became significant (Erbay et 
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al., 2003) and supplemented the cell media with recombinant IGF-II during the first 12 hr of 
differentiation. In the presence of exogenous IGF-II, the effects of knocking down mTOR, raptor 
and Rheb on pThr389-S6K1, pSer473-Akt and pThr308-Akt (Fig. V.4C) were very similar to 
those without exogenous IGF-II (Fig. V.4A&B), although the degree of change varied somewhat. 
This observation is consistent with IGF-II (via IGF-I receptor) acting upstream of Akt and IRS1 – 
the point of raptor/Rheb action (see below). 
I also examined whether S6K1 mediated the regulation of Akt phosphorylation. As 
shown in Fig. V.4D, knockdown of S6K1 did not affect Akt phosphorylation on either Ser473 or 
Thr308. Therefore, enhanced Akt activation in raptor or Rheb depleted myocytes is likely a direct 
consequence of mTOR/raptor inactivation, rather than mediated by S6K1.  
 
V.3.4. mTOR/raptor negatively regulates IRS1 protein levels 
Since activation of mTORC1 is known to induce feedback inhibition of the insulin/IGF-
PI3K-Akt pathway by modulating IRS1 levels (Manning, 2004), I went on to examine IRS1 in 
C2C12 cells. Acute (30 min) rapamycin treatment in myoblasts led to increased IRS1 protein 
levels, and so did mTOR knockdown (Fig. V.5A), suggesting that mTORC1 activity may indeed 
negatively regulate the level of IRS1 protein. Raptor and Rheb knockdown also each increased 
IRS1 levels, whereas S6K1 knockdown had no effect (Fig. V.5B). Therefore, a Rheb-
mTOR/raptor pathway negatively regulates IRS1 levels in myoblasts independently of S6K1. It 
should be pointed out that, since mTOR is a regulator of multiple aspects of myogenesis, its 
inactivation by knockdown or rapamycin inhibits differentiation despite increased IRS1 levels. 
Interestingly, the IRS1 protein was naturally increased upon myogenic differentiation 
(Fig. V.5C, Scramble), consistent with a positive role this protein plays in myogenesis. 
Importantly, the elevation of IRS1 in myoblasts upon raptor/Rheb knockdown correlated well 
with enhanced myogenic marker expression in these cells during the early phase of differentiation 
(Fig. V.5C), suggesting that raptor/Rheb may regulate differentiation through controlling IRS1 
levels. Notably, while raptor and Rheb knockdown increased IRS1 levels in myoblasts, in 
differentiated myotubes the knockdown no longer had any effect on the naturally elevated IRS1 
protein level (Fig. V.5C). It is thus possible that endogenous raptor and/or Rheb activity is 
suppressed at the initiation of differentiation to allow IRS1 accumulation. The protein levels of 
raptor and Rheb were not changed during differentiation, nor was the interaction between raptor 
and mTOR (data not shown). 
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I noticed that in addition to IRS1 protein level change, rapamycin and mTOR knockdown 
down-shifted IRS1 mobility on SDS-PAGE (Fig. V.5A), as would be expected when the serine 
residues on IRS1 were drastically de-phosphorylated. However, raptor or Rheb knockdown 
increased IRS1 levels without detectable alteration of its mobility (Fig. V.5B). This could 
potentially be explained by the existence of mTOR-dependent (rapamycin-sensitive) inputs other 
than Rheb/raptor governing IRS1 phosphorylation, but the Rheb/raptor input was apparently 
sufficient to modulate IRS1 protein levels. I then asked whether Rheb/raptor regulated IRS1 
through the reported rapamycin-sensitive serine phosphorylation sites (Harrington et al., 2004; 
Shah and Hunter, 2006; Tzatsos and Kandror, 2006; Um et al., 2006). Because of the higher IRS1 
levels upon differentiation, assessment of IRS1 serine phosphorylation was done in myotubes, 
which was more reliable than in myoblasts, even though the relative degrees of IRS1 
phosphorylation were lower in myotubes. As expected, all three reported mTORC1 sites were 
sensitive to acute (30 min) rapamycin treatment (Fig. V.5D). However, only phosphorylation on 
Ser307 (equivalent to Ser312 of human IRS1) was clearly inhibited by raptor or Rheb knockdown 
(Fig. V.5E). It has been reported that phosphorylation of Ser312 on human IRS1 is responsible 
for IRS1 degradation (Greene et al., 2003). Hence, the raptor/mTOR activity, downstream of 
Rheb, may modulate IRS1 levels by targeting Ser307 (human Ser312) during myogenesis. Taken 
together, my results strongly suggest that the Rheb-mTOR/raptor pathway negatively regulates 
IRS1 and Akt signaling in myogenic differentiation. 
 
V.3.5. The function of raptor and Rheb in myogenesis is mediated by IRS1 
Next, I set out to validate the functional significance of Rheb/raptor regulation of IRS1 in 
myogenesis. Knockdown of IRS1 in C2C12 cells impaired differentiation as evidenced by 
suppressed myogenin and MHC expression (Fig. V.6A), consistent with an indispensable role of 
IRS1 in muscle differentiation. If the increased IRS1 levels were responsible for the enhanced 
myogenic differentiation upon Rheb or raptor knockdown, one would expect that simultaneous 
knockdown of IRS1 and raptor or Rheb would eliminate the positive effect of raptor/Rheb 
depletion. That was indeed what I observed: IRS1 depletion suppressed the differentiation 
enhancement elicited by raptor or Rheb depletion, as shown by decreased MHC and myogenin 
expression in double knockdown cells compared to raptor or Rheb knockdown cells (Fig. V.6B). 
These observations are in full agreement with IRS1 being a critical target in the negative 
regulation of myogenesis by the Rheb-raptor/mTOR pathway. 
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V.4. Discussion 
Although rapamycin had long been known to inhibit myoblast differentiation (Conejo et 
al., 2001; Coolican et al., 1997; Cuenda and Cohen, 1999; Erbay and Chen, 2001) and mTOR was 
established as a master regulator controlling different stages of skeletal myogenesis, the role of 
the rapamycin-sensitive mTORC1 (with raptor as a defining component) in myogenesis remained 
to be fully defined. In this study I find that raptor, together with mTOR, as well as the mTORC1 
activator Rheb, negatively regulates myoblast differentiation. This is in stark contrast to the 
reported positive role of raptor in skeletal muscle maintenance and metabolic functions 
(Bentzinger et al., 2008). Most likely, the use of the HSA promoter to drive Cre-dependent raptor 
deletion in that study led to normal myogenic differentiation prior to raptor depletion, thus, an 
early myogenic function of raptor would have been missed. The only function of Rheb in skeletal 
muscle reported so far is its role in stimulating muscle hypertrophy when overexpressed 
(Goodman et al., 2010), analogous to the canonical mTORC1 function in cell growth regulation. 
The negative regulation of myogenic differentiation by the Rheb-mTOR/raptor pathway suggests 
a homeostatic role of mTOR, and attests to the versatility of mTOR signaling in biological 
regulation.  
Curiously, two other studies did not find any significant effect of knocking down raptor 
on myoblast differentiation – one in human myoblasts (Trendelenburg et al., 2009) and one in 
C2C12 cells (Shu and Houghton, 2009). This apparent discrepancy with our observation could 
potentially be explained by differences in the degrees of differentiation in different experimental 
systems. When myoblasts are maximally differentiated in culture, it may be difficult to observe 
further increase of differentiation upon knockdown of a negative regulator. During the 
preparation of this manuscript, Jaafar et al. also reported a negative role of mTORC1 in 
vasopressin-induced differentiation of rat L6 myoblasts (Jaafar et al., 2011), in agreement with 
our findings in C2C12 cells. 
I have shown that the Rheb-mTOR/raptor pathway inhibits IRS1-PI3K-Akt signaling by 
suppressing IRS1 protein levels, and that the downregulation of IRS1 is likely responsible for the 
inhibitory function of Rheb and raptor in myogenesis (Fig. V.7). The negative feedback 
regulation of insulin/IGF signaling by mTORC1 through serine phosphorylation and/or stability 
of the adaptor protein IRS1 has been widely reported (Harrington et al., 2005; Manning, 2004; 
Shah and Hunter, 2005), but for the first time this feedback pathway is now found to impact 
myogenic differentiation. In my current experimental system, IRS1 is believed to mediate 
autocrine IGF-II signaling to PI3K-Akt (Coolican et al., 1997; Florini et al., 1991; Kaliman et al., 
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1998; Taguchi and White, 2008). The functional importance of IRS1 in myogenesis has been 
confirmed by the smaller myofiber size in IRS1-depleted skeletal muscle (Long et al., 2011), and 
by the effect of IRS1 RNAi on inhibiting myoblast differentiation ((Lee et al., 2010) and my 
current study). mTOR/raptor suppresses the protein level of IRS1 in myoblasts, possibly through 
phosphorylation of IRS1 at Ser307 (Ser312 in human IRS1). This suppression is removed upon 
myogenic differentiation to allow accumulation of IRS1 and facilitation of PI3K-Akt signaling. 
The mechanism by which the de-repression of IRS1 occurs is not clear, but it is conceivable that 
down-regulation of mTORC1 activity toward IRS1 may be responsible. The phosphorylation of 
Ser307 (human Ser312) has been shown to be at least partially dependent on S6K1 in some cell 
types as well as fat tissues (Shah and Hunter, 2006; Um et al., 2004), but a direct role of S6K1 on 
this site has not been reported for muscles or myoblasts. Our data suggest that mTORC1 itself, 
rather than S6K1, may be the kinase for Ser307 in muscle cells, perhaps similar to Ser632/635 
(human Ser636/639) (Tzatsos and Kandror, 2006). The exclusion of S6K1 as the mediator of 
mTORC1 negative regulation of IRS1 by my data corroborates well with the fact that S6K1 
activity increases upon myogenic differentiation (Conejo et al., 2001; Coolican et al., 1997; 
Cuenda and Cohen, 1999; Erbay and Chen, 2001).  
It is intriguing that the negative function of raptor in myogenesis involves both mTOR 
and Rheb – the canonical mTORC1 well accepted as a positive regulator of cell growth and other 
cellular functions. The lack of positive contribution from raptor and Rheb to myogenic 
differentiation also implicates the existence of novel mTOR complexes and/or mechanisms 
responsible for rapamycin-sensitive functions of mTOR in myogenesis. One possible mechanism 
was proposed by Shu and Houghton to be through mTORC2 and Akt (Shu and Houghton, 2009). 
There are likely other yet-to-be-identified mechanisms. At least two distinct mechanisms underlie 
known mTOR myogenic signaling – one is dependent on the kinase activity of mTOR and 
regulates myocyte fusion through a MyoD/microRNA-1/HDAC4 /follistatin pathway (Park and 
Chen, 2005; Sun et al., 2010), and the other controls IGF-II production in a kinase-independent 
manner (Erbay et al., 2003; Ge et al., 2009) (Fig. V.7). Identification of the putative myogenic 
mTOR complexes and dissection of signaling mechanisms at or upstream of mTOR are of great 
interest in our future investigations. 
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V.5. Figures 
 
 
 
 
 
 
Figure V.1. mTOR and raptor have opposite roles in myoblast differentiation. C2C12 
myoblasts were transduced overnight with lentiviruses expressing shRNAs for mTOR (A-C), 
raptor (D-F), or rictor (G-I) (“Scramble” or “Scr” as a non-targeting control), and subjected to 
puromycin selection for 2 days followed by differentiation for 3 days. (A, D, G) Differentiated 
myocytes were stained for MHC (green) and DAPI (red). (B, E, H) Myocytes were quantified for 
differentiation index, fusion index and average myotube size (myonuclei number per myotube). 
(C, F, I) Cells were lysed for Western analyses, and band intensities were quantified by 
densitometry and normalized to tubulin control. All data shown are mean ± SD (n = 3 for each 
condition). For B, E, H, paired t test was performed to compare each data to Scramble control. 
For C, F, I, one-sample t test was performed to compare each data to Scramble control. *P <0.05, 
**P <0.01. 
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Figure V.2. Rheb, but not S6K1, negatively regulates myoblast differentiation. C2C12 
myoblasts were transduced overnight with lentiviruses expressing shRNAs for Rheb (A-C) or 
S6K1 (D-F) (“Scramble” or “Scr” as a non-targeting control), and subjected to puromycin 
selection for 2 days followed by differentiation for 3 days. (A, D) Differentiated myocytes were 
stained for MHC (green) and DAPI (red). (B, E) Myocytes were quantified for differentiation 
index, fusion index and average myotube size (myonuclei number per myotube). (C, F) Cells 
were lysed for Western analyses, and band intensities were quantified by densitometry and 
normalized to tubulin control. All data shown are mean ± SD (n = 3 for each condition). For B & 
E paired t test was performed to compare each data to Scramble control. For C & F one-sample t 
test was performed to compare each data to Scramble control. *P <0.05, **P <0.01. 
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Figure V.3. Raptor and Rheb negatively regulate myoblast differentiation. (A) C2C12 
myoblasts were transfected with HA-raptor or Flag-Rheb together with pCDNA3 (vector), 
selected with G418 for 2 days, and then induced to differentiate for 3 days. Cells were fixed and 
stained for MHC (green) and DAPI (red). (B) Myocytes in (A) were quantified for differentiation 
index, fusion index and average myotube size (myonuclei number per myotube). (C) Cells were 
transfected as in (A), selected with G418 for 10 days to establish stably transfected pools. 
Expression of recombinant raptor and Rheb was assessed by Western blotting. (D) The stably 
transfected cells were induced to differentiate for 3 days, and lysed for Western blotting at the 
indicated time points. (E) Myoblasts were transfected with Myc-S6K1 or Flag-4E-BP1, selected 
with G418 for 2 days, and then induced to differentiate for 3 days. Differentiated myocytes were 
lysed for Western blotting. Tubulin served as a loading control. Each experiment was repeated at 
least 3 times with representative blots shown or mean ± SD. For data in (B), paired t test was 
performed to compare each data to vector control. **P <0.01. 
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Figure V.4. mTOR/raptor negatively regulates Akt activation. C2C12 myoblasts were 
transduced overnight with lentiviruses expressing shRNAs for raptor or Rheb (A), mTOR (B), or 
S6K1 (D) (“Scr” as a non-targeting control), and subjected to puromycin selection for 2 days 
followed by differentiation for 3 days and lysis for Western blotting. (C) Cells were transduced 
with lentiviruses expressing shRNAs for raptor, Rheb or mTOR, and drug-selected as described 
above, followed by incubation in differentiation medium for 12 hr in the presence of 300 ng/mL 
IGF-II, and then lysis for Western blotting. The “scr/no IGF-II” lane was from the same Western 
blot as the “+IGF-II” lanes for each protein blotted (the separation of lanes in this figure is due to 
removal of other lanes irrelevant to the experiment), therefore, the band intensities could be 
directly compared. Band intensities were quantified and normalized to tubulin control. Black 
bars: pT389-S6K1; grey bars: pS473-Akt; white bars: pT308-Akt. All data shown are mean ± SD 
(n = 3 for each condition). For (A), (B) and (D), one-sample t test was performed to compare each 
data to Scr control. For (C), the “+IGF-II” scramble samples were compared to “–IGF-II” 
scramble control by one-sample t test; the other “+IGF-II” samples were compared to their 
corresponding “+IGF-II” scramble samples by paired t test.  *P <0.05, **P <0.01. 
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Figure V.5. mTOR/raptor negatively regulates IRS1 protein levels. (A) C2C12 myoblasts 
were treated with 50 nM rapamycin for 30 min (left panels), or infected overnight with mTOR 
lentivirus followed by 2-day puromycin selection (right panels), before cell lysis and Western 
analyses. (B) Myoblasts were transduced overnight with lentiviruses expressing shRNA for raptor 
or Rheb (left panels), or S6K1 (right panels), followed by 2-day puromycin selection before cell 
lysis and Western analyses. (C) Myoblasts were infected overnight with lentiviruses expressing 
shRNA for raptor or Rheb followed by 2-day puromycin selection; myoblasts (MB) or time-
course differentiating myocytes (diff. day 0-3) were lyzed for Western analyses. (D) 3-day 
differentiated myocyte were treated with 50 nM rapamycin for 30 min and lyzed for Western 
analyses. (E) 3-day differentiated myocyte depleted with raptor or Rheb as described in (C) were 
lyzed for Western blot. Scramble (“Scr”) was a non-targeting shRNA control. Tubulin served as a 
loading control. Results were repeated at least 3 times with representative blots shown. 
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Figure V.6. The function of raptor and Rheb in myogenesis is mediated by IRS1.  (A) C2C12 
myoblasts were transduced overnight with lentiviruses expressing shRNA for IRS1, and subjected 
to 2-day puromycin selection followed by 3-day differentiation. Differentiated myocytes were 
lysed for Western analyses. (B) Myoblasts were co-infected overnight with lentiviruses 
expressing shRNAs for IRS1 and raptor or Rheb, and treated as in (A). Scramble (“Scr”) was a 
non-targeting shRNA control. Tubulin served as a loading control. Western bands were quantified 
and normalized to tubulin control. All data shown are mean ± SD (n = 3 for each condition). One-
sample t test was performed to compare each data to Scramble control. *P <0.05, **P <0.01. 
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Figure V.7. mTOR regulates skeletal myogenesis through multiple pathways. See text for 
details. 
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CHAPTER VI. CONCLUSIONS AND PERSPECTIVES 
 
The initial observation that rapamycin blocked myoblast differentiation pointed toward 
its cellular target, mTOR, being a master regulator of skeletal myogenesis. For over a decade, 
mTOR’s function in skeletal muscle development and homeostasis had been widely investigated, 
and its essential role was unequivocally established, among a plethora of other cellular and 
developmental functions. However, the underlying molecular mechanisms in muscle 
development remained largely unknown. Best known as a serine/threonine kinase regulating 
protein translation, mTOR was recently revealed to regulate muscle metabolic homeostasis 
through the pathways well characterized in cell growth regulation. The regulatory pathways 
involving rapamycin-sensitive mTOR in skeletal myogenesis, however, required further 
investigation. A surprising function of mTOR was the control of IGF-II transcription, in a kinase-
independent manner. Interestingly, mTOR was also found to regulate myocyte maturation 
through a secreted fusion factor(s) in a kinase-dependent fashion. 
The first question I encountered during my thesis work was, do these mechanisms of 
mTOR discovered in vitro hold true in vivo? Taking advantage of a mouse model for muscle 
regeneration, I have confirmed mTOR’s essential role in myogenesis in vivo. Using two 
transgenic mouse lines with muscle-specific expression of mTOR-mutants (RR and RR/KI), I 
have demonstrated kinase-independent regulation of IGF-II production and kinase-dependent 
regulation of maturation during muscle regeneration. These mouse models not only confirm our 
previous in vitro observations, but will also be useful for future investigation of mTOR myogenic 
functions in vivo.  
In search for additional mTOR targets in myogenesis, a newly emerged group of 
myogenic regulators, microRNAs, caught our attention. I have identified miR-125b as a novel 
negative regulator of myogenesis, which regulates IGF-II post-transcriptionally under the control 
of kinase-independent mTOR signaling. This adds another layer to mTOR regulation of IGF-II, 
and once again confirms the kinase-independent function of mTOR. At the same time, we have 
found that miR-1, a known myogenic microRNA, regulates the expression of follistatin through 
HDAC4 during myocyte maturation. Interestingly, miR-1 biogenesis is regulated by mTOR  in a 
kinase-dependent manner through the myogenic transcription factor MyoD. With this pathway 
identified, the long-sought mTOR regulated myocyte maturation factor is finally revealed to be 
follistatin, and another connection between mTOR and myogenic miRNAs is established.  
With these diverse downstream pathways identified for mTOR’s myogenic function, a 
pressing question was what the immediate mediators of mTOR might be. The obvious candidates 
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were the established components of mTORC1 in cell growth regulation. However, to our surprise, 
I have found that Rheb and raptor, both mTORC1 components, negatively regulate myogenesis. I 
have shown that this regulation is through the suppression of IRS1, most likely via mTORC1 
phosphorylation, whereas S6K1, a direct target of mTORC1, does not seem to be involved in 
myogenesis. Hence, the myogenesis-promoting function of mTOR is not mediated by mTORC1; 
rather, mTORC1 acts as a negative regulator. mTORC2, on the other hand, may mediate some of 
the mTOR functions in myogenesis, as rictor depletion has been reported to impair myoblast 
differentiation, and prolonged rapamycin treatment is known to disrupt mTORC2 function. But it 
is unlikely that mTORC2 alone is the answer to myogenic regulation by mTOR, considering the 
kinase-independent function of mTOR. My findings reveal more complexity of mTOR myogenic 
signaling, and certainly raise additional questions regarding the mechanisms of mTOR regulation 
in myogenesis.  
Finally, toward a better understanding of myogenesis, I set out to look for novel 
myogenic regulators by performing an RNAi screen of secreted factors (Appendix B). A few 
interesting groups of candidates are found to either suppress or enhance myogenic differentiation, 
or specifically affect different steps of myoblast fusion. These secreted factors may prove to be 
novel regulators of skeletal myogenesis. Further characterization of their function and regulation 
will likely be highly rewarding. 
Taken together, the myogenic mechanisms identified in our studies reveal the versatility 
and complexity of mTOR signaling (Fig. VI.1), while they raise new questions. How mTOR does 
exert these diverse functions, especially through the kinase-independent mechanism? Although 
regulation of transcription by mTOR has been suggested in other cellular contexts, the kinase 
activity seems to be required in those instances. Therefore the regulation of IGF-II or miR-125b 
transcription is most likely governed by a novel mechanism. Since the canonical mTORC1 and 
mTORC2 are not involved in or suffice for the myogenic functions of mTOR, it is conceivable 
that novel mTOR binding proteins, subcellular localization, or post-tranlational modifications are 
yet to be identified in myogenic regulation. What are the upstream signals that activate myogenic 
mTOR? Does mTOR sense nutrient availability or cellular energy levels to exert a checkpoint 
control of myogenic differentiation? Does mTOR regulate other myogenic microRNAs? How 
wide spread is the MyoD-mediated mTOR regulation of miRNAs? How does mTOR regulate 
myoD? Is mTOR itself or are mTOR signaling components subject to post-transcriptional 
regulation by miRNAs during myogenesis? Finally, do those candidate myogenic factors 
assemble novel pathways, or hijack existing ones? Do they cross talk to mTOR signaling? 
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Answers to these questions will further our understanding of myogenic regulation, and potentially 
uncover novel therapeutic targets for muscular dystrophies and other muscle diseases. 
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VI. 1. Figures 
 
 
 
 
 
Figure VI.1. Versatility of mTOR signaling in skeletal myogenic regulation.  See text for 
details. 
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APPENDIX A. REGULATION OF MYOBLAST FUSION (A LITERATURE SURVEY) 
 
Skeletal muscle is composed of post-mitotic multinucleated myofibers, formed by the 
fusion of mononucleated progenitor myoblasts with one another in a series of ordered steps. 
Initially, myoblasts differentiate into elongated cells that migrate towards one other and undergo 
recognition and adhesion. Several differentiated myoblasts then fuse to one another to form a 
small nascent myotube with a few myonuclei. Additional differentiated myoblasts fuse with the 
nascent myotubes during subsequent rounds of fusion to generate a mature myotube that contains 
many myonuclei (Jansen and Pavlath, 2008). Note that biochemical differentiation (launch of 
myogenic transcriptional program) comes before those physical fusion steps, thus very often, 
fusion changes are observed with myogenic differentiation markers unaltered. The molecular 
pathways and myogenic fusion factors involved in each steps of mammalian myoblast fusion 
process are summarized in Table A.1 and discussed as following. 
 
A.1. Elongation.  
As myoblasts undergo differentiation, they elongate and align with neighboring 
differentiated myoblasts. This process likely involves cooperation of multiple groups of 
molecules including integrins and matrix remodeling enzymes whose deficiency results in 
cytoskeletal network malfunction and myoblast elongation defect (Jansen and Pavlath, 2008). 
Myoblast depleted with Kindlin-2, an integrin associated adaptor protein, is unable to elongate 
and fuse, displaying decreased adhesion and increased motility, with decreased β1 integrin level 
(Dowling et al., 2008). Meanwhile, the early myogenic marker myogenin is not affected but later 
marker sarcomere myosin heavy chain (MHC) is decreased, suggesting its role in differentiation 
in addition to fusion (Dowling et al., 2008). Kindlin-2 is the homolog of C. elegans UNC-112 
that is required for worm muscle development. Knockdown of MT1-MMP, an extra-cellular 
matrix (ECM) protease that is known to cleave fibronectin and laminin, inhibits myoblast 
elongation and fusion in vitro and results in smaller myofibers formation and dystrophy in vivo 
(Oh et al., 2004; Ohtake et al., 2006). No changes in differentiation markers are detected, 
suggesting a fusion-specific role for MT1-MMP (Oh et al., 2004; Ohtake et al., 2006). Similar 
fusion defect is also observed in myoblasts depleted with EB3, a microtubule binding protein, 
whose differentiation accompanies with disorganized microtubules and failure in stabilizing 
polarized membrane protrusions (Straube and Merdes, 2007); or those depleted of non-muscle 
myosin 2A, an actin filament binding protein, resulting in blockage of elongation and fusion, as 
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well as decreased adhesion (Duan and Gallagher, 2009; Swailes et al., 2006). Differentiation 
marker expressions were not examined in the last two examples.  
 
A.2. Migration.  
Migration is necessary to achieve cell-cell contact during myogenesis, which is required 
both to trigger differentiation and to allow differentiated myoblasts to fuse with one another and 
with nascent myotubes. Some regulatory factors that influence myoblast migration modulate the 
velocity or direction of cell migration, whereas others regulate the clearance of the extracellular 
matrix at the leading edge of migrating cells, thus facilitating cell motility (Jansen and Pavlath, 
2008). Both positive and negative regulators of migration can be beneficial to myoblast fusion 
and a fine balance between these two groups is required. Pro-migrative ones (e.g., CD164 (Cxcr4-
associated sialomucin) (Bae et al., 2008), Interleukin-4 (IL-4) (Horsley et al., 2003), Mannose 
receptor (MR, an endocytic C-type lectin) (Jansen and Pavlath, 2006), Mouse odorant receptor 
23 (MOR23) (Griffin et al., 2009)) can promote cell migrating towards each other, whereas anti-
migrative ones (e.g., Prostacylin (Prostaglandin I2) (Bondesen et al., 2007)) can set a brake 
whenever cells meet and start contact and adhesion. Other molecules that might affect fusion 
through migration include: the Ca2+ channel TRPC, whose depletion results in decreased Ca2+, 
impaired fusion and migration (Louis et al., 2008); meanwhile, m-calpain (calpain-2, a cysteine 
protease activated by myoD and required for fusion (Dedieu et al., 2003; Honda et al., 2008)) is 
down-regulated, and the calpain substrate MARCKS (myristoylated alanine-rich C-kinase 
substrate, an actin binding protein, required to be down-regulated for fusion to occur (Dulong et 
al., 2004; Kim et al., 2002)) is up-regulated. They might be partially responsible for the fusion 
defect observed from TRPC knockdown. 
 
A.3. Adhesion.  
In order for fusion to occur, myoblasts must recognize and adhere to one another, which 
likely involves multiple adhesion molecules and results in activation of specific intracellular 
signaling pathways (Jansen and Pavlath, 2008).  
M-cadherin is a Ca2+ dependent transmembrane glycoprotein required for adhesion prior 
to fusion (Kaufmann et al., 1999; Zeschnigk et al., 1995). Downstream of M-cad, it activates Trio 
(Rho GEF), which then activates Rac1 (Charrasse et al., 2007) - both are small G proteins 
required for fusion (to be discussed later). Regulators of M-cadherin that also participate in fusion 
include the following. RhoA and ROCK induce M-cadherin degradation (Charrasse et al., 2006). 
Their knockdown increases fusion without changing differentiation marker expression 
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(Nishiyama et al., 2004), and RhoA overexpression decreases fusion but potentiates 
differentiation marker expression (Meriane et al., 2000). Beside degradation of M-cadherin 
(Charrasse et al., 2006), RhoA/ROCK’s negative effects are also possibly mediated by direct 
phosphorylation of FoxO1a resulting its exportation from nucleus (Nishiyama et al., 2004), 
induction of MRTF-A/Smad dependent transcription of Id3 (Iwasaki et al., 2008), induction of 
SRF (Wei et al., 1998), as well as inhibitory phosphorylation of IRS1/2 (Lim et al., 2007). 
Myoblasts depleted with RhoE, inhibitor of RhoA/ROCK, fail to elongate and fuse with 
differentiation markers unchanged (Fortier et al., 2008). At the same time, M-cad expression is 
decreased and its accumulation at cell-cell contact disrupted (Fortier et al., 2008). calpain-3 
depletion results in disorganized sarcomere, increased myonuclei number but dis-organized 
myotubes, and meanwhile, M-cadherin and β-catenin  (major constituent of cadherin-based 
adheren junctions) levels are increased (Kramerova et al., 2006); calpeptin (a calpain inhibitor) 
inhibits fusion and differentiation (Kook et al., 2008); the function of caveolin-3, structural 
component of caveolae, is controversial - it has been observed that overexpression results in 
impairs fusion and depletion in increased fusion, where M-cadherin levels are inversely 
correlated (Volonte et al., 2003); it has also been reported that knockdown of caveolin-3 
decreased fusion without changing differentiation, where its expression requires p38 MAPK 
(Galbiati et al., 1999).  
Interestingly, M-cadherin null mice do not have defects in skeletal muscle formation or 
regeneration (Hollnagel et al., 2002), suggesting potential compensation by other cell adhesion 
molecules such as N-cadherin in vivo. Indeed, depletion of N-cadherin results in both decreased 
fusion and decreased myogenic markers (Goichberg and Geiger, 1998; Knudsen et al., 1990b). 
Interestingly, N-cadherin increases RhoA and β-catenin levels, and decreases Rac1, Cdc42, and 
JNK activity (Charrasse et al., 2002). It’s been shown that induction of p27Kip1 is a critical step 
of the N-cadherin-dependent signaling involved in myogenesis (Messina et al., 2005). CDO and 
BOC, two promyogenic Ig superfamily members that bind to each other in a cis fashion, form 
complexes with N- and M-cadherin (Kang et al., 2008; Kang et al., 2003; Kang et al., 2002; Leem 
et al., 2011). Three more Ig superfamily adhesion molecules, NCAM (Charlton et al., 2000; 
Dickson et al., 1990; Knudsen et al., 1990a; Mege et al., 1992; Suzuki et al., 2003), VCAM 
(Rosen et al., 1992), and MCAM (Cerletti et al., 2006) are cell adhesion molecules widely 
reported in myoblast adhesion and fusion, although both positive and negative functions have 
been proposed.  
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A.4. Actin Cytoskeleton.  
There are extensive cytoskeletal reorganizations occurring before and after fusion. 
Processes dependent on the actin cytoskeleton play fundamental roles in myoblast fusion as 
latrunculin B, an inhibitor of actin polymerization, inhibits fusion of mouse myoblasts in vitro 
(Kim et al., 2007; Nowak et al., 2009; O'Connor et al., 2008). Following adhesion, the structure 
of the actin cytoskeleton at the contact site of fusing myoblasts is highly regulated by a complex 
signaling cascade. Various GTPases and guanine nucleotide exchange factors (GEFs) are 
activated, which in turn regulate Wiskott-Aldrich syndrome protein (WASP) and Wasp family 
verprolin-homologous protein (WAVE), whose activation is critical for actin polymerization 
initiated by Arp2/3 complex (Jansen and Pavlath, 2008).  
Disruption of Arf6, the GTPase for Rac1, caused paxillin and β1-integrin dissociation 
and disruption of paxillin transport to sites of focal adhesion (Pajcini et al., 2008); the M-
cadherin/Rac1/Trio complex also fails to form (Bach et al., 2010). ARF6 is proposed to regulate 
myoblast fusion through activation of phospholipase D (PLD) and actin cytoskeletal 
reorganization (Bach et al., 2010). Brag2 (ARF-GEP100) is the mammalian homologue of 
drosophila Loner, and GEF for Arf6/Rac1. Its knockdown caused decreased fusion and 
differentiation marker expression (Pajcini et al., 2008). Pronouncedly, it results in stubby 
“bragballs” whose elongation failed and nuclei are centrally clustered (Pajcini et al., 2008). 
Dock180 (Dock1) is the mammalian homologue of drosophila myoblast city, GEF for Rac1. Its 
knockdown also decreased fusion and differentiation marker expression (Pajcini et al., 2008). In 
the knockdown cells, elongation does occur but results in atrophic myotubes (Pajcini et al., 2008). 
Interestingly, Dock180 deficiency also prevented fusion of macrophages and the formation of 
multinucleated giant cells (Pajcini et al., 2008), suggesting that fusion machinery is conserved 
among distinct cell types.  Trio is the GEF for Rac1, RhoA, RhoG, and its depletion decreased 
fusion whereas overexpression increased differentiation and regeneration (Bryan et al., 2005; 
Charrasse et al., 2007). Cdc42, GTPase for N-WASP, and Rac1, GTPase for Arp2/3, are essential 
for myoblast fusion, as knockdown of either decreases fusion and causes a deficit in the 
recruitment of actin fibers and vinculin to myoblast contact sites (Vasyutina et al., 2009). They 
are proposed to regulate myoblast fusion through p38 MAPK (Kang et al., 2008; Meriane et al., 
2000). Nap1 is the GEF for WAVE, and its mediated actin remodeling is essential for myoblast 
fusion (Nowak et al., 2009). Knockdown of Filamin C, an actin cross-linking protein, decrease 
fusion, with multinucleated “myoballs” formation in C2C12 cells and round myofibers formation 
in knockout mice (Dalkilic et al., 2006), similar as Trio depletion phenotype. Knockdown of Hic-
5, a LIM domain protein, member of the paxillin superfamily of focal adhesion proteins, results in 
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decreased fusion with unaffected differentiation marker expression, defects in cell spreading, 
disrupted dynamics of laminin expression (Gao et al., 2007). Another LIM domain protein, 
FHL2, interacts with β-catenin and its overexpression promotes fusion (Martin et al., 2002). 
cAMP-PKA modulates actin cytoskeleton and lamellipodium formation and is required for 
myoblast fusion (Mukai and Hashimoto, 2008; Mukai et al., 2009). 
 
A.5. Integrin Signaling.  
Integrins are heterodimeric transmembrane receptors comprised of an α and a β chain that 
bind to extracellular matrix, cell-surface ligands, and various intracellular proteins to regulate 
numerous downstream signaling pathways (Hynes, 2002). Skeletal muscle expresses many 
integrin subunits that are regulated during myogenesis (Gullberg, 2003). Integrins could function 
in myoblasts through controlling the levels or formation of protein complexes necessary for 
fusion or by sending signals for actin cytoskeleton remodeling (Jansen and Pavlath, 2008). 
Myoblasts lack of β1 integrin adhere but plasma membrane fails to breakdown, and CD9 is lost 
on membrane with sarcomere assembly defect (Menko and Boettiger, 1987; Schwander et al., 
2003). Other integrin subunits, e.g. integrin α3 (Brzoska et al., 2006), have also been suggested 
to be involved in myoblast fusion. CD9/CD81 form complex with β1 integrin, knockdown of 
either impairs fusion without changing myogenic differentiation markers (Tachibana and Hemler, 
1999). Other intracellular molecules connected to integrins include: FAK, whose knockdown 
decreases fusion without changing differentiation markers expression, and at the same time 
caveolin 3 and β1 integrin are decreased (Quach et al., 2009); integrin associated protein Talin1, 
2, double knockout of the two exhibits decreased fusion and sarcomere assembly defect, although 
β1 integrin expression remains unchanged (Conti et al., 2009); SLIM1 (skeletal muscle LIM 
protein 1) seems to be important for integrin mediated myoblast adhesion and migration 
(Robinson et al., 2003).  
 
A.6. Maturation.  
Differentiated myoblasts fuse with one another to form small, nascent myotubes with few 
nuclei and subsequently, additional myoblasts fuse with the nascent myotube, leading to the 
mature multinucleated cell characterized by increased myonuclear number and cell size. The 
requirement for distinct molecules at different stages of myoblast fusion was first suggested by 
experiments in C2C12 cells, where treatment with wheat germ agglutinin (WGA) resulted in 
normal formation of nascent myotubes, but an inhibition of mature myotube formation (Muroya 
et al., 1994), suggesting specific cell surface molecules were required in later steps of fusion. 
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A typical phenotype from depletion of a maturation factor is unaffected differentiation 
and fusion but decreased myocyte size. Until now, second-stage fusion factors identified include 
the above-mentioned IL-4 (Horsley et al., 2003), MR (Jansen and Pavlath, 2006), as well as 
PGF2α (Horsley and Pavlath, 2003), growth hormone (Sotiropoulos et al., 2006), myoferlin 
(phospholipid binding protein) (Demonbreun et al., 2009; Doherty et al., 2005) and its associated 
protein EHD2 (endocytic recycling protein) (Doherty et al., 2008), SHP-2 (protein tyrosine 
phosphatase that’s activated by c-src downstream of integrin) (Fornaro et al., 2006), Nephrin (Ig 
superfamily, the Drosophila sticks and stones (sns) homolog) (Lee Sohn et al., 2009), and 
Neogenin (the receptor for netrin and co-receptor as CDO) (Bae et al., 2009). A regulatory hub of 
maturation is NFATc2, a transcription factor regulated by calcium (Horsley et al., 2001). 
NFATc2 can be activated by PGF2α and possibly by c-src through SHP-2; in turn it regulates 
production of IL-4, which regulates maturation partially through MR expression (Horsley et al., 
2001). 
Why myoblast-myotube fusion should require unique molecules compared to myoblast-
myoblast fusion is unclear. It may be related to specific challenges inherent with myoblast fusion 
to a multinucleated cell, and these molecules may direct myoblast fusion to specific sites along 
the myotube or with specific myotubes (Jansen and Pavlath, 2008). Or, these molecules could 
represent a fine-tuning mechanism for controlling the ultimate number of nuclei within a 
myotube/myofiber, or limiting the number of myotube/myofiber formed so that growth can occur 
as demanded (Jansen and Pavlath, 2008).  
 
A.7. Other Fusion Factors.  
There are still a lot of factors as following known to be involved in myoblast fusion but 
not clearly categorized into a specific fusion step. In some cases, differentiation is equally 
affected, possibly contributing to the crippled downstream fusion events. The provided list of 
myogenic fusion factors will not include some well-established myogenic pathways (e.g., mTOR, 
p38 MAPK, Erk MAPK, etc) that exhibit clear effects on biochemical differentiation upstream of 
fusion; instead, this list focuses on the molecules/pathways specifically examined in terms of 
myoblast fusion phenotype. 
 
A.7.1. Cell surface and membrane proteins.  
Deficiency the ECM protease ADAM12 (meltrin α), aborted fusion with differentiation 
marker unchanged, whereas overexpression of ADAM12 results in isotrophic and less tubular 
structures (Yagami-Hiromasa et al., 1995). Interestingly, a close homolog of ADAM12, fertilin, is 
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known to regulate sperm-egg fusion (Yagami-Hiromasa et al., 1995), again suggesting a 
conserved mechanism between different mammalian fusion processes. Knockdown of galectin (a 
member of lectin family) decreased fusion and regeneration (Georgiadis et al., 2007). Defect in 
dystroglycan that connects dystrophin to ECM results in myofiber maintenance failure (Brown et 
al., 1999; Durbeej et al., 1998; Henry and Campbell, 1999; Jacobson et al., 2001). Knockdown of 
the gap junction protein connexin43 decreased fusion and myogenin, myoD expression, whereas 
fusion is advanced by it overexpression; it is however rapidly down-regulated after initiation of 
myoblast fusion (Araya et al., 2005; Gorbe et al., 2007). Knockdown of another gap junction 
protein connexin39 increased fusion and regeneration, and at the same time increased 
connexin43 (von Maltzahn et al., 2011). Inhibition of potassium channel Kir2.1 decreased fusion 
as well as myogenin, MEF2 expression, and it is proposed to act through calcineurin regulation 
(Fischer-Lougheed et al., 2001; Konig et al., 2006; Konig et al., 2004). Blockage of the T-type 
α1H calcium channel CaV3 also decreased fusion, and its expression is down-regulated by TGFβ 
and BMP-2 in myoblasts (Avila et al., 2006; Bijlenga et al., 2000). Knockdown of plasmin, a 
fibrinolytic enzyme that is cleaved by plasminogen activators urokinase-type plasminogen 
activator (uPA, required for skeletal muscle regeneration (Lluis et al., 2001)) and tissue-type 
plasminogen activator (tPA), caused decreased fusion and regeneration (Suelves et al., 2002). On 
the other hand, deletion of Syndecan-3, a transmembrane proteoglycan, increases fusion 
(Fuentealba et al., 1999). 
 
A.7.2. Secreted factors.  
Down-regulation of Neuregulin, an ErbB3 ligand, decreases fusion and MHC expression 
without affecting myogenin or cell cycle (Kim et al., 1999). It is recently demonstrated in vivo 
that neural crest cells secret neuregulin to signal myoblast progenitor cells through ErbB3 for 
sustained myogenesis during development (Ho et al., 2011). Interleukin-6 (IL-6) is an essential 
regulator of satellite cell-mediated skeletal muscle hypertrophy, and its deficiency results in both 
muscle growth defect and less myonuclei addition (fusion) (Serrano et al., 2008); its family 
member Cardiotrophin (CT-1) however, has been suggested as a negative myogenic factor as its 
depletion results in increased myogenesis (Miyake et al., 2009). TGFβ  is proposed as positive 
myogenic factor as its depletion results in decreased fusion and differentiation (Allegra et al., 
2004; Zhu et al., 2004), whereas the pro-inflammatory cytokines TNFα  and IL-1β  block 
myogenesis through NF-κB (Guttridge et al., 1999; Langen et al., 2001). 
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A.7.3. Intracellular proteins.  
GRP94 is an ER resided chaperone glycoprotein. Its deletion causes decreased fusion 
without affecting myoD upstream events but decreased MHC and aborted IGF-II production; the 
defect can be rescued by IGF-II (Gorza and Vitadello, 2000; Ostrovsky et al., 2010; Wanderling 
et al., 2007). STAT3 inhibits fusion and differentiation through suppressing myoD (Kataoka et 
al., 2003). The MAPK ERK5 positively regulates fusion through Klf transcription factors 
(Sunadome et al., 2011). Mirk/dyrk1B is an arginine-directed serine/threonine kinase induced by 
Rho, whose down-regulation results in decreased fusion and differentiation (Deng et al., 2003). 
Two UNC-45 like isoforms (C elegans UNC-45 homolog) are found in mammals: decreasing the 
general cell isoform reduces myoblast proliferation and fusion, while decreasing the striated 
muscle isoform affects fusion and sarcomere organization (Price et al., 2002). Two 
deubiquitinating enzymes, UBP69 and UBP45 exhibit opposing effects: in cultured myoblasts, 
UBP69 mRNA markedly but transiently increased before membrane fusion, whereas UBP45 
mRNA increased as the cells fused to form myotubes; Both myoblast fusion and accumulation of 
MHC were dramatically stimulated by the stable expression of UBP69 but completely blocked by 
that of UBP45 (Park et al., 2002). Most Ras proteins are known to inhibit C2C12 differentiation, 
but overexpression of an active form of R-Ras promotes their migration, survival and fusion 
(Suzuki et al., 2000). Thrombin, key protease involved in blood coagulation, has been found to 
inhibit myoblast differentiation and fusion (Chinni et al., 1999; de Niese et al., 2002; Guttridge et 
al., 1997). 
 
A.7.4. Nuclear factors.  
FoxO1a (forkhead box group O 1a, also called FoxO1 or FHKR) is expressed in skeletal 
muscle and translocates to the nucleus at the onset of differentiation. Ectopic expression of a 
mutant form of FOXO1a lacking the transactivation domain severely inhibits fusion of primary 
mouse muscle cells, whereas expression of a non-phosphorylatable FOXO1a enhances the rate 
and extent of fusion (Bois and Grosveld, 2003). As mentioned previously, ROCK can 
phosphorylate FOXO1a in vitro, and the addition of a ROCK inhibitor to differentiating C2C12 
myoblasts leads to nuclear accumulation of FOXO1a and accelerated myoblast fusion (Nishiyama 
et al., 2004). Interestingly, FOXO1a regulates transcription of cyclic GMP-dependent kinase 1, 
which in turn phosphorylates FOXO1a, abolishing its DNA binding activity (Bois et al., 2005). 
This negative feedback loop involving FOXO1a and cyclic GMP-dependent kinase 1 may help 
control the rate of myoblast fusion. However, FoxO1 has also been suggested with a negative role 
in myogenesis (Hribal et al., 2003; Wu et al., 2008) and it is well known to activate atrophic 
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genes in skeletal muscle (Leger et al., 2006; Stitt et al., 2004). FoxO3 is another forkhead 
transcription factor found to positively regulate fusion and regeneration with pax3/7 through 
activating myoD (Hu et al., 2008). Smn (survival motor neuron protein) is a spliceosome 
component that regulates myoblast fusion and its depletion results in “bumpy” myotubes 
phenotype (Shafey et al., 2005). MNF, a forkhead/winged helix transcription factor, is required 
for fusion as its depletion results in decreased fusion, differentiation and regeneration (Garry et 
al., 2000). Barx2, a homeobox protein, is required for myotube formation under the regulation of 
myogenic regulatory factors (Meech et al., 2003). P204 is a nuclear factor activated by myoD, 
and its knockdown decreased fusion and differentiation; it is proposed to act through binding and 
inhibiting Id protein (Liu et al., 2002; Liu et al., 2000).  
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A.8. Tables 
 
 
Table A.1 Myoblast fusion factors. 
 
Molecule Locali-zation Biochemical character Process involved References 
Kindlin-2 C Integrin associated adaptor protein  Elongation (Jansen and Pavlath, 2008) 
MT1-MMP M ECM protease Elongation 
(Oh et al., 
2004; Ohtake 
et al., 2006) 
EB3 C Microtubule binding protein Elongation (Straube and Merdes, 2007) 
Non-muscle 
myosin 2A C 
Structural, actin filament binding 
protein Elongation 
(Duan and 
Gallagher, 
2009; Swailes 
et al., 2006) 
CD164 M Cxcr4-associated sialomucin Migration (Bae et al., 2008) 
Interleukin-4 E Cytokine Migration and maturation 
(Horsley et al., 
2003) 
Mannose 
receptor M Type I transmembrane protein 
Migration and 
maturation 
(Jansen and 
Pavlath, 2006) 
MOR23 M Mouse odorant receptor 23, GPCR Migration  (Griffin et al., 2009) 
Prostacylin E PGI2, bind to IP and elicit Ca2+/cAMP Migration 
(Bondesen et 
al., 2007) 
TRPC M Ca2+ channel Migration (Louis et al., 2008) 
m-calpain C Cysteine protease Others 
(Dedieu et al., 
2003; Honda 
et al., 2008) 
MARCKS C myristoylated alanine-rich C-kinase substrate Others 
(Dulong et al., 
2004; Kim et 
al., 2002) 
M-cadherin M Ca
2+ dependent transmembrane 
glycoprotein Adhesion 
(Charrasse et 
al., 2007; 
Kaufmann et 
al., 1999; 
Zeschnigk et 
al., 1995) 
RhoA/ROCK C Small G proteins Others 
(Charrasse et 
al., 2006; 
Iwasaki et al., 
2008; Lim et 
al., 2007; 
Meriane et al., 
2000; 
Nishiyama et 
al., 2004; Wei 
et al., 1998) 
RhoE C RhoA and ROCK inhibitor Elongation and adhesion 
(Fortier et al., 
2008) 
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Table A.1 Myoblast fusion factors. (con’t) 
Molecule Locali-zation Biochemical character Process involved References 
Calpain 3 C Cysteine protease Adhesion 
(Kramerova et 
al., 2006) 
 
Calpeptin C Inhibit calpain Others (Kook et al., 2008) 
Caveolin-3 M Structural component of caveolae Adhesion and others 
(Galbiati et al., 
1999; Volonte 
et al., 2003) 
N-cadherin M Ca
2+ dependent transmembrane 
glycoprotein Adhesion 
(Charrasse et 
al., 2002; 
Goichberg and 
Geiger, 1998; 
Knudsen et al., 
1990b; 
Messina et al., 
2005) 
β-catenin C 
constituent of cadherin-based 
adherens junctions Adhesion 
(Goichberg et 
al., 2001) 
CDO and 
BOC M 
Ig superfamily, form complex with 
M- and N-cad Adhesion 
(Kang et al., 
2008; Kang et 
al., 2003; 
Kang et al., 
2002; Leem et 
al., 2011) 
NCAM M Ig superfamily, neuronal cell adhesion molecule Adhesion 
(Charlton et 
al., 2000; 
Dickson et al., 
1990; Knudsen 
et al., 1990a; 
Mege et al., 
1992; Suzuki 
et al., 2003) 
VCAM M Ig superfamily, vascular cell adhesion molecule Adhesion 
(Rosen et al., 
1992) 
MCAM M Ig superfamily, melanoma cell adhesion molecule Adhesion 
(Cerletti et al., 
2006) 
Arf6 C GTPase for Rac1 Actin cytoskeleton 
(Bach et al., 
2010; Pajcini 
et al., 2008) 
Brag2/ARF-
GEP100 
C GEF for Arf6/Rac1 Actin cytoskeleton 
(Pajcini et al., 
2008) 
Dock1/Dock1
80 C GEF for Rac1  
Actin 
cytoskeleton 
(Pajcini et al., 
2008) 
Trio C GEF for Rac1, RhoA, RhoG Actin cytoskeleton 
(Bryan et al., 
2005; 
Charrasse et 
al., 2007) 
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Table A.1 Myoblast fusion factors. (con’t) 
 
Molecule Locali-zation Biochemical character Process involved References 
Cdc42 C GTPase for N-WASP Actin cytoskeleton 
(Kang et al., 
2008; Meriane 
et al., 2000; 
Vasyutina et 
al., 2009) 
Rac1 C GTPase for Arp2/3 Actin cytoskeleton 
(Kang et al., 
2008; Meriane 
et al., 2000; 
Vasyutina et 
al., 2009) 
Nap1 C GEF for WAVE complex formation Actin cytoskeleton 
(Nowak et al., 
2009) 
Filamin C C Actin cross-linking protein Actin cytoskeleton 
(Dalkilic et al., 
2006) 
Hic-5 C 
LIM-only member of the paxillin 
superfamily of focal adhesion 
proteins 
Actin 
cytoskeleton 
(Gao et al., 
2007) 
FHL2 C LIM-domain protein Others (Martin et al., 2002) 
cAMP-PKA C Lamellipodium formation Actin cytoskeleton 
(Du et al., 
2008; Mukai 
and 
Hashimoto, 
2008; Mukai et 
al., 2009) 
PLD C Phospholipase D 
Actin 
cytoskeleton and 
others 
(Bach et al., 
2010; Yoon 
and Chen, 
2008) 
β1 integrin M Integrin subunit Integrin signaling 
(Menko and 
Boettiger, 
1987; 
Schwander et 
al., 2003) 
Integrin α3  Integrin subunit Integrin signaling 
(Brzoska et al., 
2006) 
CD9/CD81 M Transmembrane 4 superfamily Integrin signaling 
(Tachibana 
and Hemler, 
1999) 
FAK C Tyrosin kinase Integrin signaling (Quach et al., 2009) 
Talin1, 2 C Integrin associated adaptor protein Integrin signaling (Conti et al., 2009) 
SLIM1 N, C skeletal muscle LIM protein 1 Integrin signaling (Robinson et al., 2003) 
Prostaglandin 
F2α 
E PGF2α, bind to FP activating NFATc2 by Ca2+ Maturation 
(Horsley and 
Pavlath, 2003) 
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Table A.1 Myoblast fusion factors. (con’t) 
Molecule Locali-zation Biochemical character Process involved References 
Neuregulin E ErbB3 ligand Others 
(Ho et al., 
2011; Kim et 
al., 1999) 
Interleukin-6 E Cytokine Others (Serrano et al., 2008) 
Cardiotrophin E Member of the IL-6 family of cytokines Others 
(Miyake et al., 
2009) 
TGFβ E TGFβ/Smad signaling Others 
(Allegra et al., 
2004; Zhu et 
al., 2004) 
TNFα and 
IL-1β 
E Cytokines that signal through NF-κB Others 
(Guttridge et 
al., 1999; 
Langen et al., 
2001) 
GRP94 C ER resided chaperone glycoprotein Others 
(Gorza and 
Vitadello, 
2000; 
Ostrovsky et 
al., 2010; 
Wanderling et 
al., 2007) 
STAT3 C JAK/STAT signaling, repress myoD Others (Kataoka et al., 2003) 
ERK5 C MAPK, through Klf Others (Sunadome et al., 2011) 
Mirk/dyrk1B C arginine-directed serine/threonine kinase Others 
(Deng et al., 
2003) 
UNC-45-like C Mammalian homolog of C elegans UNC-45 Others 
(Price et al., 
2002) 
UBP45, 
UBP69 C deubiquitinating enzymes Others 
(Park et al., 
2002) 
R-Ras C Ras family member Others (Suzuki et al., 2000) 
thrombin C key protease involved in blood coagulation Others 
(Chinni et al., 
1999; de Niese 
et al., 2002; 
Guttridge et 
al., 1997) 
FOXO1a N Transcription factor Others 
(Bois et al., 
2005; Bois and 
Grosveld, 
2003; Hribal et 
al., 2003; 
Nishiyama et 
al., 2004; Wu 
et al., 2008) 
FoxO3 N Transcription factor Others (Hu et al., 2008) 
Smn N Spliceosome component Others (Shafey et al., 2005) 
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Table A.1 Myoblast fusion factors. (con’t) See text for details (C: cytoplasm, M: membrane, E: 
extracellular, N: nucleus). 
Molecule Locali-zation Biochemical character Process involved References 
MNF N forkhead/winged helix transcription factor Others 
(Garry et al., 
2000) 
Barx2 N homeobox protein Others (Meech et al., 2003) 
P204 N Activated by myoD Others 
(Liu et al., 
2002; Liu et 
al., 2000) 
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APPENDIX B. SCREENING AND CHARACTERIZATION OF SECRETED  
MYOBLAST FUSION FACTORS 
 
B.1. Materials and Methods 
B.1.1. Antibodies and other reagents. Anti-MHC (MF20) and anti-myogenin (F5D) were 
obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the 
NICHD, National Institutes of Health and maintained by The University of Iowa, Department of 
Biological Sciences. Anti-tubulin was from Abcam. All other primary antibodies were from Cell 
Signaling Technology. All secondary antibodies were from Jackson ImmunoResearch 
Laboratories, Inc. Gelatin was from Sigma-Aldrich. 
B.1.2. Cell culture. C2C12 myoblasts were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) containing 1 g/L glucose with 10% fetal bovine serum at 37°C with 7.5% CO2. To 
induce differentiation, cells were plated on tissue culture plates coated with 0.2% gelatin and 
grown to 100% confluence before switching to differentiation medium (DMEM containing 2% 
horse serum). The cells were replenished with fresh differentiation medium daily for 3 days.  
B.1.3. Immunofluorescence microscopy and quantitative analysis of myocytes. C2C12 cells 
differentiated in 12-well plates were fixed and stained for MHC and DAPI as previously 
described (Park and Chen, 2005). The stained cells were examined with a Leica DMI 4000B 
fluorescence microscope, and the fluorescent images were captured using a RETIGA EXi camera, 
and analyzed with Q-capture Pro51 software (Q-ImagingTM). The differentiation and fusion 
indexes were calculated as the percentage of nuclei in MHC-positive myocytes and in myotubes 
with ≥2 nuclei, respectively. Each data point was generated from at least 200 randomly chosen 
MHC-positive cells or myotubes. 
B.1.4. Lentivirus-mediated RNAi and screening. shRNAs in the pLKO.1-puro vector for 
knocking down were purchased from Sigma-Aldrich (MISSION® TRC). Lentivirus packaging 
and testing were performed as previously described (Yoon and Chen, 2008). A panel of 134 
cytokine and chemokine genes was selected and for each gene, 2~3 shRNA constructs were used. 
Primary screening was done in a 96-well format: C2C12 myoblasts seeded in 96-well plates were 
transduced with individual lentivirus and selected in puromycin for 2 days followed by 3-day 
differentiation. Myocytes at the end of differentiation were stained for myogenic differentiation 
marker MHC as well as DAPI, and myotube formation quantified using differentiation and fusion 
index. Each knockdown was repeated as least 3 times, and a positive hit is considered only when 
it is repe4. 
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B.1.5. Quantitative and semi-quantitative PCR. C2C12 cells were lysed directly in Trizol 
(Invitrogen). RNA was isolated following the manufacturer’s protocol. cDNA was synthesized 
from 1µg RNA using qScript cDNA synthesis kit (Quanta Biosciences) following the 
manufacturer’s protocol. Quantitative (q)PCR was performed on a StepOne Plus machine 
(Applied Biosystems) using a SYBR Green PCR mix in a MicroAmp Fast 96-well reaction plate 
(Applied Biosystems) following the manufacturer's protocols. β-actin was used as a reference to 
obtain the relative fold change for target samples using the comparative CT method. For semi-
qPCR, cDNA was similarly obtained, followed by PCR reactions in a conventional thermocycler. 
PCR produces were resolved on a 2% agarous gel. The primers used are listed in Table B. 4. 
 
B.2. Results and Discussion 
B.2.1. RNAi screening identifies potential myogenic factors.   
To seek for myogenic factors, I applied shRNA knockdown in mouse C2C12 myoblasts 
using lentiviral delivery. I screened 134 mouse cytokine and chemokine genes, each with 2~3 
individual shRNA constructs (Table B.3). Only the ones with multiple (>=2) knockdown shRNAs 
showing consistent phenotypes are considered as candidates, so as to rule out off-target effects. 
Among the 134 genes, 26 (19.4%, Table B.1) of them were found to exhibit consistent 
changes in myoblast differentiation when knockdown with different shRNAs. Therefore, these 
genes are considered potential regulators of myogenic differentiation. Note that among those 
candidates, a few genes had the third shRNA showing a different phenotype than the other two, 
rendering this outlier more likely to be an off-target effect (Table B.1, grey shaded). 
I also found 30 genes (22.4%, Table B.2) with only 1 shRNA showing a phenotype, or 
with 2 shRNAs showing opposite phenotypes. Since the possibility of off-target effects for those 
knockdowns couldn’t be confidently assessed at this time, they are not considered as candidates. 
These genes can be revisited using more individual shRNA constructs, and it is possible to reveal 
more functional candidates from them according to the multiple hits rule. In fact, cardiotrophin-1 
(Ctf1), which had only 1 shRNA showing increased differentiation when knockdown (Table B.2), 
was also found by another group to be important for antagonizing differentiation (Miyake et al., 
2009) during the time of my study. 
 
B.2.2. Distinct groups of regulators are found from RNAi screening.  
There are a few distinct phenotypes associated with those 26 candidates (Table B.1). The 
first (2 out of 26, 7.7%) and second group (13 out of 26, 50%) showed either suppressed (Figure 
B.1, Flt3L) or enhanced (Figure B.1, Cxcl10) differentiation in knockdown cells compared to 
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Scramble control, suggesting them as positive or negative regulators, respectively. It is likely that 
these general enhancement or inhibition would similarly result in change of the differentiation 
markers expression, which would indicate that differentiation itself was altered, indirectly 
resulting in subsequent fusion change.  
The third group (8 out of 26, 30.8%) showed enhanced differentiation and fusion while 
myotube size remained similar as Scramble control (Figure B.1, IL1f9). Interestingly, in some of 
the knockdown myocytes, the morphology of myotubes is quite different from normal mature 
myotubes. For example, IL1f9 depleted cells exhibited elongated but very thin myotubes (Figure 
B.1). These candidates might be important for fine-tuning the number of myotubes within a 
differentiating myotube population, and possibly orientate the new myoblast where to fuse along 
the myotubes. 
The last group (3 out of 26, 11.5%) showed unchanged differentiation accompanied with 
decreased fusion and myotube size (Figure B.1, Gdf15). This group also included a previously 
reported fusion factor, Cxcl12 (Figure B.1, Cxcl12). Cxcl12, along with its cognate receptor 
Cxcr4, has been widely implicated in myogenic regulation although the observations do not 
always agree (Bae et al., 2008; Chong et al., 2007; Griffin et al., 2011; Odemis et al., 2007; 
Odemis et al., 2005; Vasyutina et al., 2005; Yusuf et al., 2006). My knockdown of Cxcl12 agrees 
with the observation that knockdown of Cxcr4 in primary myoblast differentiation results in 
impaired myocyte fusion (Griffin et al., 2011), suggesting that Cxcl12 is essential for myoblast 
fusion. For those candidates that specifically affected fusion when knockdown, it will be 
interesting to find out whether the markers expression remained the same as Scramble control, as 
would be expected from unaltered differentiation index, confirming a specific function in fusion 
process. A detailed analysis of different steps of fusion (elongation, migration, adhesion, 
maturation) can be followed in those knockdown cells to pinpoint the exact process that the 
candidate fusion factor regulates.  
In fact, these severely blunted myotubes are reminiscent of the knockdown phenotype 
from a known fusion factor, interleukin-4, which regulates myoblast migration and myocyte 
maturation (Horsley et al., 2003). Indeed, I observed immature myotube formation when 
knockdown IL-4 during C2C12 differentiation (Figure B.1, IL-4). However, as a maturation 
factor, IL-4 knockdown in primary myoblasts did not change fusion (Horsley et al., 2003), which 
is true according to what I observed in C2C12 cells (Figure B.1, IL-4). Therefore, IL-4 belongs to 
a separate sub-group of fusion factors, which specifically regulates the myotubes size, a.k.a., 
myocyte maturation. It will be interesting to find out whether any of the rest candidates (Table 
B.2) would fall into this category. 
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Also, some of the immature or blunted myotubes observed in my knockdown 
experiments (Figure B.1, IL1f9, Gdf15, Cxcl12) are reminiscent of previously reported 
phenotypes (e.g., knockdown of Brag2, Dock1, Filamin C, Smn, etc) where atrophic or rounded 
myotubes are documented. In these studies, the differentiation and fusion of myotubes depleted 
with those genes were also impaired. Therefore, it is conceivable that some of identified 
candidate genes might be tightly correlated to those established cellular pathways where small G 
protein Rac1 or it downstream actin cytoskeleton organization was altered. 
 
B.2.3. Further characterization of myogenic candidates 
In order to further assess the efficiencies of knockdown from those shRNAs, I designed 
PCR primers to examine a subset of candidate gene expression in Scramble control or shRNA 
treated cells, using either quantitative or semi-quantitative PCR. For some genes, the knockdown 
efficiency well correlated to the cellular phenotypes, whereas other showed no knockdown effects 
although having caused a phenotype, which indicated off-target effect of that particular shRNA 
(Table B.1, B.2). Note that the examination here is done at the transcripts levels, and it is possible 
that at protein levels, knockdown could be more or less pronounced. Some of the PCR primers 
fail to detect robust gene expression thus we couldn’t reliably assess the knockdown efficiency 
(N.D.: not determined, Table B.1, B.2). Nevertheless, these genes could still be functional albeit 
expressed at a very low level. 
Cytokines are known to signal through cytokine receptors. For example, IL-18R1 is the 
cognate receptor for IL-18, IL-1RL1 for IL-1f9, and Flt3 for Flt3L (Tato and Cua, 2008a; Tato 
and Cua, 2008b; Tato and Cua, 2008c; Tato and Cua, 2008d). Some of the chemokines have well 
characterized receptors as well, for example, Cxcr3 for Cxcl10, Cxcr4 for Cxcl12, Ccr1/Ccr3 for 
Ccl9 (Zlotnik et al., 2006). Although these ligand-receptor relationships have been validated in 
other cell systems especially immune responses, their function in myoblast differentiation is 
mostly not known. In order to delineate the pathways downstream of those cytokines and 
chemokines, it is important to examine these candidate receptors for these candidates. It is 
expected that the depletion of a bona fide receptor should mimic that of its cognate ligand. For 
example, my preliminary results indicate that Cxcr3 knockdown also enhanced differentiation as 
Cxcl10 depletion (data not shown), suggesting a functional significance of Cxcl10-Cxcr3 ligand-
receptor pair in myogenic differentiation. 
It will be interesting to further connect the cytokine/chemokine signaling to major 
myogenic pathways. For example, treatment of major myogenic inhibitors, rapamycin (inhibitor 
of mTOR), LY294002 (inhibitor of PI3K/Akt), or SB203580 (inhibitor of p38 MAPK) might 
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reverse the enhanced myotube formation caused by depletion of negative myogenic factors, 
which would suggest the inhibited pathway being the mediator of myogenic effect from those 
secreted factors. Also, the immature myotube formation by candidate fusion factor depletion can 
be subjected to known fusion factor treatment, e.g., IGF-II or follistatin, where a rescue effect 
would indicate a linear pathway between these candidates and known fusion factors.  
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B.3. Figures and Tables 
 
 
Scramble Flt3L #1 Flt3L #2
Scramble Cxcl10 #1 Cxcl10 #2
Scramble IL1f9 #1 IL1f9 #2
Scramble Gdf15 #1 Gdf15 #2
Scramble IL-4
Scramble Cxcl12 #1 Cxcl12 #2
Phenotype:
-/-/-
+/+/+
diff / fusion / size
+/+/0
0/-/-
0/-/-
0/0/-
 
 
 
Figure B.1. Phenotypes associated with individual gene knockdown. C2C12 myoblasts were 
transduced overnight with lentiviruses expressing shRNAs for Flt3L. Cxcl10, IL1f9, Gdf15, IL4 
or Cxcl12 (“Scramble” or “Scr” as a non-targeting control), and subjected to puromycin selection 
for 2 days followed by differentiation for 3 days. Differentiated myocytes were stained for MHC 
(green) and DAPI (red). The resulting phenotypes (differentiation index, fusion index, and 
myotube size) are indicated with decreased “-”, increased “+” or unchanged “0” signs. 
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Symbol Clone name 
Knockdown phnotype 
Knockdown efficiency diff 
index 
fusion 
index 
myotube 
size 
Ccl1 
NM_011329.1-206s1c1 - - - 
N.D. NM_011329.1-114s1c1 + + + 
NM_011329.1-167s1c1 + + + 
Ccl9 
NM_011338.1-915s1c1 + + 0 91% ± 4% 
NM_011338.1-327s1c1 0 0 0 56% ± 13% 
NM_011338.1-457s1c1 + + 0 92% ± 3% 
Ccl17 
NM_011332.2-166s1c1 + + 0 34% ± 20% 
NM_011332.2-279s1c1 + + 0 38% ± 20% 
NM_011332.2-123s1c1 0 - - 27% ± 20% 
Cmtm2a 
NM_027022.4-474s21c1 + + 0 
N.D. NM_027022.4-803s21c1 0 0 0 
NM_027022.4-578s21c1 + + 0 
Cmtm5 
NM_026066.1-707s1c1 + + + 19% ± 8% 
NM_026066.1-579s1c1 + + + 0% 
NM_026066.1-608s1c1 + + + 10% ± 5% 
Cmtm8 
NM_027294.1-783s1c1 + + + 
N.D. NM_027294.1-503s1c1 + + + 
NM_027294.1-691s1c1 + + + 
Ctf2 
NM_198858.1-657s1c1 0 0 0 
N.D. NM_198858.1-371s1c1 + + + 
NM_198858.1-628s1c1 + + + 
Cxcl2 
NM_009140.1-172s1c1 + + 0 
N.D. NM_009140.1-252s1c1 + + + 
NM_009140.1-325s1c1 + + + 
Cxcl9 
NM_008599.1-1075s1c1 - - - 
N.D. NM_008599.1-284s1c1 - - - 
NM_008599.1-450s1c1 - - - 
Cxcl10 
NM_021274.1-895s1c1 + + + 0% 
NM_021274.1-124s1c1 + + + 42% ± 12% 
NM_021274.1-268s1c1 + + + 41% ± 19% 
Cxcl12 
NM_013655.2-315s1c1 0 - - 0% 
NM_013655.2-205s1c1 0 - - 80% ± 1% 
NM_013655.2-132s1c1 0 - - ? 
Cxcl14 
NM_019568.1-628s1c1 + + + 
N.D. NM_019568.1-526s1c1 + + + 
NM_019568.1-610s1c1 + + + 
Ebi3 
NM_015766.2-1028s1c1 + + 0 
N.D. NM_015766.2-846s1c1 + + 0 
NM_015766.2-413s1c1 0 0 0 
 
 
Table B.1.  Candidate myogenic fusion factors with multiple hits. 
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Fasl 
NM_010177.2-1604s1c1 + + + 
N.D. NM_010177.2-557s1c1 + + + 
NM_010177.2-771s1c1 0 - - 
Flt3l 
NM_013520.2-411s1c1 - - - 36% ± 14% 
NM_013520.2-558s1c1 + + + 0% 
NM_013520.2-427s1c1 - - - 15% ± 8% 
Gdf3 
NM_008108.1-1019s1c1 + + + 0% 
NM_008108.1-325s1c1 + + + 0% 
NM_008108.1-703s1c1 + + + 0% 
Gdf15 
NM_011819.1-1127s1c1 0 0 0 78% ± 6% 
NM_011819.1-603s1c1 0 - - 74% ± 4% 
NM_011819.1-536s1c1 0 - - 92% ± 18% 
IL5 
NM_010558.1-679s1c1 + + + 
N.D. NM_010558.1-324s1c1 + + + 
NM_010558.1-223s1c1 0 0 0 
IL17b 
NM_019508.1-284s1c1 0 0 0 
N.A. NM_019508.1-227s1c1 + + + 
NM_019508.1-214s1c1 + + + 
IL17c 
NM_145834.1-95s1c1 + + + 
N.A. NM_145834.1-321s1c1 + + + 
NM_145834.1-28s1c1 0 0 0 
IL18 
NM_008360.1-455s1c1 + + 0 26% ± 18% 
NM_008360.1-660s1c1 + + 0 60% ± 16% 
NM_008360.1-191s1c1 + - - 69% ± 13% 
IL1f9 
NM_153511.1-188s1c1 + + 0 30% ± 18% 
NM_153511.1-475s1c1 0 0 0 0% 
NM_153511.1-332s1c1 + + 0 49% ± 14% 
IL21 
NM_021782.1-676s1c1 0 0 0 
N.D. NM_021782.1-296s1c1 + + 0 
NM_021782.1-287s1c1 + + 0 
Iltifb 
NM_054079.1-488s1c1 + + 0 
N.D. NM_054079.1-202s1c1 + + 0 
NM_054079.1-298s1c1 + + 0 
Scg2 
NM_009129.1-328s1c1 + + + 
N.A. NM_009129.2-2244s1c1 + + + 
NM_009129.2-1670s1c1 + + + 
Scgb3a1 NM_170727.1-305s1c1 0 - - N.D NM_170727.1-364s1c1 0 - - 
 
Table B.1.  Candidate myogenic fusion factors with multiple hits. (con’t) C2C12 myoblasts 
were transduced overnight with lentiviruses expressing shRNAs as indicated and analyzed as Fig. 
6.1. Every knockdown was repeated at least 3 times. Only statistical significant results (p<0.05) 
are shown as increased or decreased. PCR results are shown as knockdown% ± s.d.% when 
statistically significant (p<0.05). Keys: grey shaded: possibly off-target hit; +: increased; -: 
decreased; 0: no change; blue: qPCR determined; pink: semi-qPCR determined; N.D.: not 
detected; N.A.: not available (not tested). 
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Symbol Clone name 
Knockdown phnotype Knockdown 
efficiency diff index 
fusion 
index 
myotube 
size 
Ccl2 
NM_011333.1-433s1c1 - - - 
N.A. NM_011333.1-190s1c1 0 0 0 
NM_011333.1-329s1c1 0 0 0 
Ccl4 
NM_013652.1-408s1c1 + + + 
N.D. NM_013652.1-261s1c1 0 0 0 
NM_013652.1-203s1c1 0 0 0 
Ccl8 NM_021443.1-322s1c1 - - - 0% NM_021443.1-207s1c1 + + + 26% ± 6% 
Ccl11 
NM_011330.1-206s1c1 0 0 0 
N.A. NM_011330.1-176s1c1 - - - 
NM_011330.1-297s1c1 0 0 0 
Ccl22 
NM_009137.1-1041s1c1 + + + 26% ± 6% 
NM_009137.1-380s1c1 0 - - 0% 
NM_009137.1-257s1c1 - - - 0% 
CKLF 
NM_029295.1-308s1c1 0 0 0 
N.A. NM_029295.1-462s1c1 + + + 
NM_029295.1-152s1c1 0 0 0 
CLCF1 
NM_019952.1-173s1c1 - - - 
N.A. NM_019952.1-628s1c1 0 0 0 
NM_019952.1-468s1c1 0 0 0 
Cmtm3 NM_024217.2-1402s1c1 - - - N.A. NM_024217.2-564s1c1 + + + 
Cmtm4 
NM_153582.3-908s1c1 0 0 0 19% ± 12% 
NM_153582.3-506s1c1 - - - 0% 
NM_153582.3-401s1c1 0 0 0 0% 
Cmtm6 
NM_026036.1-963s1c1 0 0 0 0% 
NM_026036.1-426s1c1 - - - 77% ± 4% 
NM_026036.1-526s1c1 0 - - 76% ± 16% 
Cmtm7 
NM_133978.1-345s1c1 0 0 0 15% ± 7% 
NM_133978.1-383s1c1 0 0 0 16% ± 5% 
NM_133978.1-494s1c1 - - - 0% 
Csf1 
NM_007778.1-1940s1c1 0 0 0 
N.A. NM_007778.1-1692s1c1 + + + 
NM_007778.1-344s1c1 0 0 0 
Csf2 
NM_009969.2-385s1c1 0 0 0 
N.A. NM_009969.2-200s1c1 - - - 
NM_009969.2-314s1c1 0 0 0 
Csf3 NM_009971.1-441s1c1 + + + N.A. NM_009971.1-494s1c1 - - - 
 
Table B.2. Candidate myogenic fusion factors with single hit.  
 
 183 
 
Ctf1 NM_007795.1-140s1c1 0 0 0 N.A. NM_007795.1-49s1c1 + + + 
Cx3cl1 
NM_009142.2-120s1c1 0 0 0 30% ± 13% 
NM_009142.2-579s1c1 - - - 0% 
NM_009142.2-827s1c1 0 - - 0% 
Cxcl5 NM_009141.1-254s1c1 - - - 0% NM_009141.1-312s1c1 0 0 - 0% 
Gdf9 
NM_008110.1-1557s1c1 0 0 0 
N.A. NM_008110.1-473s1c1 + + + 
NM_008110.1-979s1c1 0 0 0 
Gdf10 
NM_145741.2-1636s1c1 0 - - 
N.D. NM_145741.2-1083s1c1 - - - 
NM_145741.2-633s1c1 + + + 
Grem1 
NM_011824.3-771s1c1 0 - - 96% ± 2% 
NM_011824.3-413s1c1 - - - 78% ± 3% 
NM_011824.3-685s1c1 + + + 37% ± 14% 
Lif NM_008501.1-347s1c1 + + + N.A. NM_008501.1-429s1c1 - - - 
IL11 
NM_008350.1-818s1c1 + + + 
N.D. NM_008350.1-217s1c1 0 0 0 
NM_008350.1-459s1c1 0 0 0 
IL12b 
NM_008352.1-1508s1c1 0 0 0 45% ± 21% 
NM_008352.1-948s1c1 - - - 53% ± 9% 
NM_008352.1-796s1c1 + + + 39% ± 13% 
IL16 
NM_010551.2-4756s1c1 0 0 0 
N.A. NM_010551.2-1430s1c1 + + + 
NM_010551.2-891s1c1 0 - - 
IL17f 
NM_145856.1-142s1c1 0 - - 
N.A. NM_145856.1-306s1c1 0 0 0 
NM_145856.1-170s1c1 0 0 0 
IL22 
NM_016971.1-525s1c1 0 0 0 
N.D. NM_016971.1-560s1c1 - - - 
NM_016971.1-464s1c1 + + + 
IL27 
NM_145636.1-239s1c1 + + + 
N.A. NM_145636.1-459s1c1 - - - 
NM_145636.1-56s1c1 0 0 0 
Osm 
XM_137493.3-465s1c1 - - - 
N.D. XM_137493.3-580s1c1 0 0 0 
XM_137493.3-234s1c1 0 0 0 
Pglyrp1 NM_009402.1-435s1c1 0 0 0 44% ± 14% NM_009402.1-355s1c1 0 - - 0% 
Spp1 NM_009263.1-678s1c1 0 - - 0% NM_009263.1-416s1c1 - - - 74% ± 3% 
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TRCN0000080503 CCGGCCAGGCTCATTATATTCTAAACTCGAGTTTAGAATATAATGAGCCTGGTTTTTG NM_175628.2-1511s1c1 A2m 
TRCN0000080504 CCGGCGGGTTACCAAAGACAATTAACTCGAGTTAATTGTCTTTGGTAACCCGTTTTTG NM_175628.2-3091s1c1 A2m 
TRCN0000080505 CCGGCCTCCTGTTCAACCACCTAAACTCGAGTTTAGGTGGTTGAACAGGAGGTTTTTG NM_175628.2-230s1c1 A2m 
TRCN0000089050 CCGGCGAATGCAGATACATCGAGAACTCGAGTTCTCGATGTATCTGCATTCGTTTTTG NM_009704.2-649s1c1 Areg 
TRCN0000089051 CCGGCCACAAATATCCGGCTATATTCTCGAGAATATAGCCGGATATTTGTGGTTTTTG NM_009704.2-449s1c1 Areg 
TRCN0000077013 CCGGGTTTATCCAGTGTTACAGAAACTCGAGTTTCTGTAACACTGGATAAACTTTTTG NM_011329.1-206s1c1 Ccl1 
TRCN0000077016 CCGGGCCGTGTGGATACAGGATGTTCTCGAGAACATCCTGTATCCACACGGCTTTTTG NM_011329.1-114s1c1 Ccl1 
TRCN0000077017 CCGGCTGCTGCTTGAACACCTTGAACTCGAGTTCAAGGTGTTCAAGCAGCAGTTTTTG NM_011329.1-167s1c1 Ccl1 
TRCN0000067458 CCGGCAACAACAGATGCACCCTGAACTCGAGTTCAGGGTGCATCTGTTGTTGTTTTTG NM_011330.1-206s1c1 Ccl11 
TRCN0000067460 CCGGCACACTACTGAAGAGCTACAACTCGAGTTGTAGCTCTTCAGTAGTGTGTTTTTG NM_011330.1-176s1c1 Ccl11 
TRCN0000067461 CCGGGCCACAAAGCACCTGGACCAACTCGAGTTGGTCCAGGTGCTTTGTGGCTTTTTG NM_011330.1-297s1c1 Ccl11 
TRCN0000067653 CCGGGCTGTGATCTTCAGGACCATACTCGAGTATGGTCCTGAAGATCACAGCTTTTTG NM_011331.1-206s1c1 Ccl12 
TRCN0000067654 CCGGCGTGCTGTTATAATGTTGTTACTCGAGTAACAACATTATAACAGCACGTTTTTG NM_011331.1-117s1c1 Ccl12 
TRCN0000067655 CCGGCCACCATCAGTCCTCAGGTATCTCGAGATACCTGAGGACTGATGGTGGTTTTTG NM_011331.1-63s1c1 Ccl12 
TRCN0000067558 CCGGAGGAAGTTGGTGAGCTGGTATCTCGAGATACCAGCTCACCAACTTCCTTTTTTG NM_011332.2-166s1c1 Ccl17 
TRCN0000067559 CCGGGAAGGCCATCAGATTGGTGAACTCGAGTTCACCAATCTGATGGCCTTCTTTTTG NM_011332.2-279s1c1 Ccl17 
TRCN0000067560 CCGGCCGAGAGTGCTGCCTGGATTACTCGAGTAATCCAGGCAGCACTCTCGGTTTTTG NM_011332.2-123s1c1 Ccl17 
TRCN0000067608 CCGGCTGTTGTGTTCACCACACTAACTCGAGTTAGTGTGGTGAACACAACAGTTTTTG NM_011888.2-376s1c1 Ccl19 
TRCN0000067609 CCGGGAAGTCTTCTGCCAAGAACAACTCGAGTTGTTCTTGGCAGAAGACTTCTTTTTG NM_011888.2-461s1c1 Ccl19 
TRCN0000067610 CCGGCGCTACCTTCTTAATGAAGATCTCGAGATCTTCATTAAGAAGGTAGCGTTTTTG NM_011888.2-339s1c1 Ccl19 
TRCN0000034471 CCGGGAATGTGAAGTTGACCCGTAACTCGAGTTACGGGTCAACTTCACATTCTTTTTG NM_011333.1-433s1c1 Ccl2 
TRCN0000034472 CCGGCTGCTACTCATTCACCAGCAACTCGAGTTGCTGGTGAATGAGTAGCAGTTTTTG NM_011333.1-190s1c1 Ccl2 
TRCN0000034473 CCGGGAATGGGTCCAGACATACATTCTCGAGAATGTATGTCTGGACCCATTCTTTTTG NM_011333.1-329s1c1 Ccl2 
TRCN0000067704 CCGGCCTAAGAGTCAAGAAGATGTACTCGAGTACATCTTCTTGACTCTTAGGTTTTTG NM_016960.1-315s1c1 Ccl20 
TRCN0000067706 CCGGCCAAAGCAGAACTGGGTGAAACTCGAGTTTCACCCAGTTCTGCTTTGGTTTTTG NM_016960.1-274s1c1 Ccl20 
TRCN0000067788 CCGGCTAAGTCTGGAAAGAAAGGAACTCGAGTTCCTTTCTTTCCAGACTTAGTTTTTG NM_011124.3-401s1c1 Ccl21a 
TRCN0000067789 CCGGAGGAAGCAAGAACCAAGTTTACTCGAGTAAACTTGGTTCTTGCTTCCTTTTTTG NM_011124.3-217s1c1 Ccl21a 
TRCN0000067790 CCGGCTACAGTATTGTCCGAGGCTACTCGAGTAGCCTCGGACAATACTGTAGTTTTTG NM_011124.3-195s1c1 Ccl21a 
TRCN0000089509 CCGGCTGAACAGACACAGCCCTCAACTCGAGTTGAGGGCTGTGTCTGTTCAGTTTTTG NM_011335.1-419s1c1 Ccl21b 
TRCN0000089511 CCGGCTGGAAAGAAAGGAAAGGGCTCTCGAGAGCCCTTTCCTTTCTTTCCAGTTTTTG NM_011335.1-380s1c1 Ccl21b 
TRCN0000089512 CCGGACAGGACTGCTGCCTTAAGTACTCGAGTACTTAAGGCAGCAGTCCTGTTTTTTG NM_011335.1-129s1c1 Ccl21b 
TRCN0000067748 CCGGCGAGGCTATAGGAAGCAAGAACTCGAGTTCTTGCTTCCTATAGCCTCGTTTTTG NM_023052.1-172s1c1 Ccl21c 
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TRCN0000067749 CCGGCCTTAAGTACAGCCAGAAGAACTCGAGTTCTTCTGGCTGTACTTAAGGTTTTTG NM_023052.1-132s1c1 Ccl21c 
TRCN0000067750 CCGGCTATGTGCAAACCCTGAGGAACTCGAGTTCCTCAGGGTTTGCACATAGTTTTTG NM_023052.1-256s1c1 Ccl21c 
TRCN0000067833 CCGGGCTCAGAATCAGATTTCTTAACTCGAGTTAAGAAATCTGATTCTGAGCTTTTTG NM_009137.1-1041s1c1 Ccl22 
TRCN0000067834 CCGGGCTACTCCATAAACTGTCCTACTCGAGTAGGACAGTTTATGGAGTAGCTTTTTG NM_009137.1-380s1c1 Ccl22 
TRCN0000067835 CCGGGCCATCACGTTTAGTGAAGGACTCGAGTCCTTCACTAAACGTGATGGCTTTTTG NM_009137.1-257s1c1 Ccl22 
TRCN0000067878 CCGGCATCACCAAGAAGGGCCATAACTCGAGTTATGGCCCTTCTTGGTGATGTTTTTG NM_019577.2-248s1c1 Ccl24 
TRCN0000067879 CCGGACGTCCTTTATTTCCAAGAAACTCGAGTTTCTTGGAAATAAAGGACGTTTTTTG NM_019577.2-156s1c1 Ccl24 
TRCN0000067880 CCGGCGTGGCAATAGCACCGAGGTTCTCGAGAACCTCGGTGCTATTGCCACGTTTTTG NM_019577.2-390s1c1 Ccl24 
TRCN0000067915 CCGGCCAGAAAGTAGTGTGTGGGAACTCGAGTTCCCACACACTACTTTCTGGTTTTTG NM_009138.1-295s1c1 Ccl25 
TRCN0000067917 CCGGAGATTCTACTTCCGCCAGAAACTCGAGTTTCTGGCGGAAGTAGAATCTTTTTTG NM_009138.1-281s1c1 Ccl25 
TRCN0000065743 CCGGGCTGTCATCCTTCATGTTAAACTCGAGTTTAACATGAAGGATGACAGCTTTTTG NM_020279.2-241s1c1 Ccl28 
TRCN0000065744 CCGGCCCGCACAATCGTACTTTGAACTCGAGTTCAAAGTACGATTGTGCGGGTTTTTG NM_020279.2-282s1c1 Ccl28 
TRCN0000065745 CCGGCTGAGGTGTCTCATCATGTTTCTCGAGAAACATGATGAGACACCTCAGTTTTTG NM_020279.2-152s1c1 Ccl28 
TRCN0000068003 CCGGCGCCAATTCATCGTTGACTATCTCGAGATAGTCAACGATGAATTGGCGTTTTTG NM_011337.1-210s1c1 Ccl3 
TRCN0000068004 CCGGGCCGGAAGATTCCACGCCAATCTCGAGATTGGCGTGGAATCTTCCGGCTTTTTG NM_011337.1-196s1c1 Ccl3 
TRCN0000068005 CCGGGACTAAGAGAAACCGGCAGATCTCGAGATCTGCCGGTTTCTCTTAGTCTTTTTG NM_011337.1-275s1c1 Ccl3 
TRCN0000068048 CCGGCCTGATGCTTCTCACTGAGAACTCGAGTTCTCAGTGAGAAGCATCAGGTTTTTG NM_013652.1-408s1c1 Ccl4 
TRCN0000068049 CCGGGCTGTGGTATTCCTGACCAAACTCGAGTTTGGTCAGGAATACCACAGCTTTTTG NM_013652.1-261s1c1 Ccl4 
TRCN0000068050 CCGGGCTTCACAGAAGCTTTGTGATCTCGAGATCACAAAGCTTCTGTGAAGCTTTTTG NM_013652.1-203s1c1 Ccl4 
TRCN0000068098 CCGGTCTTGATTCTGACCCTGTATACTCGAGTATACAGGGTCAGAATCAAGATTTTTG NM_013653.1-327s1c1 Ccl5 
TRCN0000068099 CCGGCCAGAGAAGAAGTGGGTTCAACTCGAGTTGAACCCACTTCTTCTCTGGTTTTTG NM_013653.1-265s1c1 Ccl5 
TRCN0000068100 CCGGCGTGTTTGTCACTCGAAGGAACTCGAGTTCCTTCGAGTGACAAACACGTTTTTG NM_013653.1-225s1c1 Ccl5 
TRCN0000089328 CCGGCGGGTAATATCTAGCTGAGATCTCGAGATCTCAGCTAGATATTACCCGTTTTTG NM_009139.1-701s1c1 Ccl6 
TRCN0000089329 CCGGCGTCGCTATAACCCTCCAATACTCGAGTATTGGAGGGTTATAGCGACGTTTTTG NM_009139.1-143s1c1 Ccl6 
TRCN0000089330 CCGGGCCTCATACAAGAAATGGAAACTCGAGTTTCCATTTCTTGTATGAGGCTTTTTG NM_009139.1-114s1c1 Ccl6 
TRCN0000068135 CCGGCGAGGAGGCTATAGCATACTTCTCGAGAAGTATGCTATAGCCTCCTCGTTTTTG NM_013654.2-313s1c1 Ccl7 
TRCN0000068136 CCGGGCCGCTGCTTTCAGCATCCAACTCGAGTTGGATGCTGAAAGCAGCGGCTTTTTG NM_013654.2-110s1c1 Ccl7 
TRCN0000068173 CCGGCTTGACCAGAAGTCTCAAATTCTCGAGAATTTGAGACTTCTGGTCAAGTTTTTG NM_021443.1-322s1c1 Ccl8 
TRCN0000068176 CCGGCGAGAGAATCAACAATATCCACTCGAGTGGATATTGTTGATTCTCTCGTTTTTG NM_021443.1-207s1c1 Ccl8 
TRCN0000077008 CCGGGCCCTTTAGTTAGTAGTATTTCTCGAGAAATACTACTAACTAAAGGGCTTTTTG NM_011338.1-915s1c1 Ccl9 
TRCN0000077009 CCGGCCTGTCCTATAACTCACGGATCTCGAGATCCGTGAGTTATAGGACAGGTTTTTG NM_011338.1-327s1c1 Ccl9 
TRCN0000077010 CCGGCGGAGAGTTCAGAGATGCATTCTCGAGAATGCATCTCTGAACTCTCCGTTTTTG NM_011338.1-457s1c1 Ccl9 
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TRCN0000066583 CCGGCCTGTGTTGAACTGCCTATTTCTCGAGAAATAGGCAGTTCAACACAGGTTTTTG NM_011616.2-871s1c1 Cd40lg 
TRCN0000066584 CCGGGAAGACCTTGTCAAGGATATACTCGAGTATATCCTTGACAAGGTCTTCTTTTTG NM_011616.2-286s1c1 Cd40lg 
TRCN0000066585 CCGGGTGGGCCAAGAAAGGATATTACTCGAGTAATATCCTTTCTTGGCCCACTTTTTG NM_011616.2-426s1c1 Cd40lg 
TRCN0000098175 CCGGCCCTCTCTCTTCTCTCTATTTCTCGAGAAATAGAGAGAAGAGAGAGGGTTTTTG NM_009887.1-1017s1c1 Cer1 
TRCN0000098176 CCGGGCATCGGTTCATGTTCAGAAACTCGAGTTTCTGAACATGAACCGATGCTTTTTG NM_009887.1-484s1c1 Cer1 
TRCN0000098177 CCGGCTTTGGCAAATGCAGTTCCATCTCGAGATGGAACTGCATTTGCCAAAGTTTTTG NM_009887.1-640s1c1 Cer1 
TRCN0000089298 CCGGCGTGTGGACTTGACAAGATAACTCGAGTTATCTTGTCAAGTCCACACGTTTTTG NM_029295.1-308s1c1 Cklf 
TRCN0000089299 CCGGCCTGACAGTAACATGTACTATCTCGAGATAGTACATGTTACTGTCAGGTTTTTG NM_029295.1-462s1c1 Cklf 
TRCN0000089300 CCGGCCTTCTGCTGTACTCTGAAATCTCGAGATTTCAGAGTACAGCAGAAGGTTTTTG NM_029295.1-152s1c1 Cklf 
TRCN0000088928 CCGGGCTCTTAATCGCACAGGAGATCTCGAGATCTCCTGTGCGATTAAGAGCTTTTTG NM_019952.1-173s1c1 Clcf1 
TRCN0000088930 CCGGCCTCCAGAAGATGGATGACTTCTCGAGAAGTCATCCATCTTCTGGAGGTTTTTG NM_019952.1-628s1c1 Clcf1 
TRCN0000088931 CCGGCCACAGCTGAACTCCGACGTACTCGAGTACGTCGGAGTTCAGCTGTGGTTTTTG NM_019952.1-468s1c1 Clcf1 
TRCN0000241352 CCGGTTCCTTGGAGGTGGCATATACCTCGAGGTATATGCCACCTCCAAGGAATTTTTG NM_027022.4-474s21c1 Cmtm2a 
TRCN0000241353 CCGGCAACCTTAAACCTTAACTAACCTCGAGGTTAGTTAAGGTTTAAGGTTGTTTTTG NM_027022.4-803s21c1 Cmtm2a 
TRCN0000241354 CCGGCATCGACATGTTACTTCAATTCTCGAGAATTGAAGTAACATGTCGATGTTTTTG NM_027022.4-578s21c1 Cmtm2a 
TRCN0000246548 CCGGGTAATCCTGCTGCTTACTATGCTCGAGCATAGTAAGCAGCAGGATTACTTTTTG NM_028524.2-317s21c1 Cmtm2b 
TRCN0000246549 CCGGTCGAAAGTTTATTCTACTTACCTCGAGGTAAGTAGAATAAACTTTCGATTTTTG NM_028524.2-601s21c1 Cmtm2b 
TRCN0000246550 CCGGTTCCTCATAGGTGGTATATTCCTCGAGGAATATACCACCTATGAGGAATTTTTG NM_028524.2-452s21c1 Cmtm2b 
TRCN0000090318 CCGGGCGGTTACTGTGTGTGTCTTTCTCGAGAAAGACACACACAGTAACCGCTTTTTG NM_024217.2-1402s1c1 Cmtm3 
TRCN0000090319 CCGGGCCACAATTGTGTTCGCAATTCTCGAGAATTGCGAACACAATTGTGGCTTTTTG NM_024217.2-564s1c1 Cmtm3 
TRCN0000126359 CCGGCCGACTTTAATGACTGCTCTACTCGAGTAGAGCAGTCATTAAAGTCGGTTTTTG NM_153582.3-908s1c1 Cmtm4 
TRCN0000126360 CCGGCGGAAATTGCTGCCGTGATATCTCGAGATATCACGGCAGCAATTTCCGTTTTTG NM_153582.3-506s1c1 Cmtm4 
TRCN0000126361 CCGGCCCAGATCAACTGGAATCTAACTCGAGTTAGATTCCAGTTGATCTGGGTTTTTG NM_153582.3-401s1c1 Cmtm4 
TRCN0000090798 CCGGCCCATCTTTGTCATCTTTGAACTCGAGTTCAAAGATGACAAAGATGGGTTTTTG NM_026066.1-707s1c1 Cmtm5 
TRCN0000090799 CCGGGTCTCCGTCTTTGCCTATGATCTCGAGATCATAGGCAAAGACGGAGACTTTTTG NM_026066.1-579s1c1 Cmtm5 
TRCN0000090800 CCGGGATCTACCGAACTGAGCTGATCTCGAGATCAGCTCAGTTCGGTAGATCTTTTTG NM_026066.1-608s1c1 Cmtm5 
TRCN0000121352 CCGGCCGGAGATTTAATGAGTGTTTCTCGAGAAACACTCATTAAATCTCCGGTTTTTG NM_026036.1-963s1c1 Cmtm6 
TRCN0000121354 CCGGCCTCAGCTGAAATTGCTGCAACTCGAGTTGCAGCAATTTCAGCTGAGGTTTTTG NM_026036.1-426s1c1 Cmtm6 
TRCN0000121355 CCGGGCTGAGAAAGCCCGAGAACAACTCGAGTTGTTCTCGGGCTTTCTCAGCTTTTTG NM_026036.1-526s1c1 Cmtm6 
TRCN0000127226 CCGGGCACTATTTAATCGGCACGCTCTCGAGAGCGTGCCGATTAAATAGTGCTTTTTG NM_133978.1-345s1c1 Cmtm7 
TRCN0000127227 CCGGCCATAGTGATAGCCTCCAAGACTCGAGTCTTGGAGGCTATCACTATGGTTTTTG NM_133978.1-383s1c1 Cmtm7 
TRCN0000127228 CCGGTCACCTGTATAACCCAGTCTTCTCGAGAAGACTGGGTTATACAGGTGATTTTTG NM_133978.1-494s1c1 Cmtm7 
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TRCN0000104920 CCGGCCAGAACGAATCCCACTGTTACTCGAGTAACAGTGGGATTCGTTCTGGTTTTTG NM_027294.1-783s1c1 Cmtm8 
TRCN0000104921 CCGGACCCTGACTTACACCAGGATTCTCGAGAATCCTGGTGTAAGTCAGGGTTTTTTG NM_027294.1-503s1c1 Cmtm8 
TRCN0000104922 CCGGCTATGCTGGAAACACGTACTTCTCGAGAAGTACGTGTTTCCAGCATAGTTTTTG NM_027294.1-691s1c1 Cmtm8 
TRCN0000065813 CCGGCCTACCAGCTAGAGGAGTTAACTCGAGTTAACTCCTCTAGCTGGTAGGTTTTTG NM_170786.1-597s1c1 Cntf 
TRCN0000065814 CCGGGCTCTTATGGAATCTTATGTACTCGAGTACATAAGATTCCATAAGAGCTTTTTG NM_170786.1-335s1c1 Cntf 
TRCN0000065908 CCGGGCCTACCAAGACTGGATGAAACTCGAGTTTCATCCAGTCTTGGTAGGCTTTTTG NM_007778.1-1940s1c1 Csf1 
TRCN0000065911 CCGGCCTCCTGTTCTACAAGTGGAACTCGAGTTCCACTTGTAGAACAGGAGGTTTTTG NM_007778.1-1692s1c1 Csf1 
TRCN0000065912 CCGGCATGCCAGATTGCCTTTGAATCTCGAGATTCAAAGGCAATCTGGCATGTTTTTG NM_007778.1-344s1c1 Csf1 
TRCN0000054618 CCGGCGGATTTCATAGACAGCCTTACTCGAGTAAGGCTGTCTATGAAATCCGTTTTTG NM_009969.2-385s1c1 Csf2 
TRCN0000054619 CCGGCGTCTCTAACGAGTTCTCCTTCTCGAGAAGGAGAACTCGTTAGAGACGTTTTTG NM_009969.2-200s1c1 Csf2 
TRCN0000054620 CCGGAGCCAGCTACTACCAGACATACTCGAGTATGTCTGGTAGTAGCTGGCTTTTTTG NM_009969.2-314s1c1 Csf2 
TRCN0000066008 CCGGTGCAGGCTCTATCGGGTATTTCTCGAGAAATACCCGATAGAGCCTGCATTTTTG NM_009971.1-441s1c1 Csf3 
TRCN0000066009 CCGGCAGCTGGATGTTGCCAACTTTCTCGAGAAAGTTGGCAACATCCAGCTGTTTTTG NM_009971.1-494s1c1 Csf3 
TRCN0000066058 CCGGCTCCTGACCAAATATGCAGAACTCGAGTTCTGCATATTTGGTCAGGAGTTTTTG NM_007795.1-125s1c1 Ctf1 
TRCN0000066060 CCGGCGCCACCCTCTTCACGGCCAACTCGAGTTGGCCGTGAAGAGGGTGGCGTTTTTG NM_007795.1-490s1c1 Ctf1 
TRCN0000189772 CCGGGCCTTCTATCAGAAGTCCCAACTCGAGTTGGGACTTCTGATAGAAGGCTTTTTTG NM_198858.1-657s1c1 Ctf2 
TRCN0000190485 CCGGGACGACCAGAGTTATCTGAATCTCGAGATTCAGATAACTCTGGTCGTCTTTTTTG NM_198858.1-371s1c1 Ctf2 
TRCN0000190887 CCGGCAAGGCTAAGTACTCAGCATACTCGAGTATGCTGAGTACTTAGCCTTGTTTTTTG NM_198858.1-628s1c1 Ctf2 
TRCN0000065505 CCGGCGGCATGACGAAATGCGAAATCTCGAGATTTCGCATTTCGTCATGCCGTTTTTG NM_009142.2-120s1c1 Cx3cl1 
TRCN0000065506 CCGGGCCTCAGAGCATTGGAAGTTTCTCGAGAAACTTCCAATGCTCTGAGGCTTTTTG NM_009142.2-579s1c1 Cx3cl1 
TRCN0000065507 CCGGAGGAGATAAACCCAGTTCATACTCGAGTATGAACTGGGTTTATCTCCTTTTTTG NM_009142.2-827s1c1 Cx3cl1 
TRCN0000067209 CCGGCCTCAAGAACATCCAGAGCTTCTCGAGAAGCTCTGGATGTTCTTGAGGTTTTTG NM_008176.1-130s1c1 Cxcl1 
TRCN0000067210 CCGGCTGCAGACCATGGCTGGGATTCTCGAGAATCCCAGCCATGGTCTGCAGTTTTTG NM_008176.1-107s1c1 Cxcl1 
TRCN0000067212 CCGGGAAGCTCCCTTGGTTCAGAAACTCGAGTTTCTGAACCAAGGGAGCTTCTTTTTG NM_008176.1-236s1c1 Cxcl1 
TRCN0000068208 CCGGGCATTGTATATGGAAGAACTTCTCGAGAAGTTCTTCCATATACAATGCTTTTTG NM_021274.1-895s1c1 Cxcl10 
TRCN0000068209 CCGGCCGCTGCAACTGCATCCATATCTCGAGATATGGATGCAGTTGCAGCGGTTTTTG NM_021274.1-124s1c1 Cxcl10 
TRCN0000068212 CCGGTCCGGAATCTAAGACCATCAACTCGAGTTGATGGTCTTAGATTCCGGATTTTTG NM_021274.1-268s1c1 Cxcl10 
TRCN0000068243 CCGGCGCCTCATAATGCAGGCAATACTCGAGTATTGCCTGCATTATGAGGCGTTTTTG NM_019494.1-310s1c1 Cxcl11 
TRCN0000068244 CCGGCTTCTGTAATTTACCCGAGTACTCGAGTACTCGGGTAAATTACAGAAGTTTTTG NM_019494.1-206s1c1 Cxcl11 
TRCN0000068245 CCGGGTTACTATGAAGGCTCATAAACTCGAGTTTATGAGCCTTCATAGTAACTTTTTG NM_019494.1-253s1c1 Cxcl11 
TRCN0000184347 CCGGGATCCAAGAGTACCTGGAGAACTCGAGTTCTCCAGGTACTCTTGGATCTTTTTTG NM_013655.2-315s1c1 Cxcl12 
TRCN0000196073 CCGGGCCAACGTCAAGCATCTGAAACTCGAGTTTCAGATGCTTGACGTTGGCTTTTTTG NM_013655.2-205s1c1 Cxcl12 
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TRCN0000195944 CCGGCATCAGTGACGGTAAACCAGTCTCGAGACTGGTTTACCGTCACTGATGTTTTTTG NM_013655.2-132s1c1 Cxcl12 
TRCN0000068278 CCGGGCCAAATGGTTACAAAGATTACTCGAGTAATCTTTGTAACCATTTGGCTTTTTG NM_018866.1-270s1c1 Cxcl13 
TRCN0000068279 CCGGCTAAACATCATAGATCGGATTCTCGAGAATCCGATCTATGATGTTTAGTTTTTG NM_018866.1-162s1c1 Cxcl13 
TRCN0000068280 CCGGGAAGCCCATTACACAAACTTACTCGAGTAAGTTTGTGTAATGGGCTTCTTTTTG NM_018866.1-102s1c1 Cxcl13 
TRCN0000065368 CCGGCAAGTGGTACAATGCCTGGAACTCGAGTTCCAGGCATTGTACCACTTGTTTTTG NM_019568.1-628s1c1 Cxcl14 
TRCN0000065369 CCGGCTGCGAGGAGAAGATGGTTATCTCGAGATAACCATCTTCTCCTCGCAGTTTTTG NM_019568.1-526s1c1 Cxcl14 
TRCN0000065370 CCGGGAGCACCAAACGCTTCATCAACTCGAGTTGATGAAGCGTTTGGTGCTCTTTTTG NM_019568.1-610s1c1 Cxcl14 
TRCN0000112211 CCGGCCAATTACTAACAGGTTCCTACTCGAGTAGGAACCTGTTAGTAATTGGTTTTTG NM_011339.1-259s1c1 Cxcl15 
TRCN0000112212 CCGGCCCAATTACTAACAGGTTCCTCTCGAGAGGAACCTGTTAGTAATTGGGTTTTTG NM_011339.1-258s1c1 Cxcl15 
TRCN0000112213 CCGGGACCATTTACTGCAACAGAAACTCGAGTTTCTGTTGCAGTAAATGGTCTTTTTG NM_011339.1-159s1c1 Cxcl15 
TRCN0000065695 CCGGGCTGGAAGTTGTTCTTGTGATCTCGAGATCACAAGAACAACTTCCAGCTTTTTG NM_023158.3-180s1c1 Cxcl16 
TRCN0000065696 CCGGGAGGCAAATGAGAAACAGCAACTCGAGTTGCTGTTTCTCATTTGCCTCTTTTTG NM_023158.3-618s1c1 Cxcl16 
TRCN0000067258 CCGGGCCAAGGGTTGACTTCAAGAACTCGAGTTCTTGAAGTCAACCCTTGGCTTTTTG NM_009140.1-172s1c1 Cxcl2 
TRCN0000067259 CCGGCCACTCTCAAGGGCGGTCAAACTCGAGTTTGACCGCCCTTGAGAGTGGTTTTTG NM_009140.1-252s1c1 Cxcl2 
TRCN0000067260 CCGGACTGAACAAAGGCAAGGCTAACTCGAGTTAGCCTTGCCTTTGTTCAGTTTTTTG NM_009140.1-325s1c1 Cxcl2 
TRCN0000054598 CCGGTCCCAAATTGATCGCTAATTTCTCGAGAAATTAGCGATCAATTTGGGATTTTTG NM_009141.1-254s1c1 Cxcl5 
TRCN0000054601 CCGGGAAGTCATAGCTAAACTGAAACTCGAGTTTCAGTTTAGCTATGACTTCTTTTTG NM_009141.1-312s1c1 Cxcl5 
TRCN0000067293 CCGGCCATCTTCAGAGCTTATTCTACTCGAGTAGAATAAGCTCTGAAGATGGTTTTTG NM_008599.1-1075s1c1 Cxcl9 
TRCN0000067294 CCGGGCTACACTGAAGAACGGAGATCTCGAGATCTCCGTTCTTCAGTGTAGCTTTTTG NM_008599.1-284s1c1 Cxcl9 
TRCN0000067295 CCGGGTCGTCGTTCAAGGAAGACTACTCGAGTAGTCTTCCTTGAACGACGACTTTTTG NM_008599.1-450s1c1 Cxcl9 
TRCN0000089278 CCGGGCTCCGAAGCACTGGATAATTCTCGAGAATTATCCAGTGCTTCGGAGCTTTTTG NM_015766.2-1028s1c1 Ebi3 
TRCN0000089279 CCGGGCTCAGGACCTCACAGATTATCTCGAGATAATCTGTGAGGTCCTGAGCTTTTTG NM_015766.2-846s1c1 Ebi3 
TRCN0000089280 CCGGCACGTCCTTCATTGCCACTTACTCGAGTAAGTGGCAATGAAGGACGTGTTTTTG NM_015766.2-413s1c1 Ebi3 
TRCN0000066638 CCGGGCACAAATCATTCTCTACATACTCGAGTATGTAGAGAATGATTTGTGCTTTTTG NM_010177.2-1604s1c1 Fasl 
TRCN0000066639 CCGGCCAACCAAAGCCTTAAAGTATCTCGAGATACTTTAAGGCTTTGGTTGGTTTTTG NM_010177.2-557s1c1 Fasl 
TRCN0000066640 CCGGCTTCGTGTATTCCAAAGTATACTCGAGTATACTTTGGAATACACGAAGTTTTTG NM_010177.2-771s1c1 Fasl 
TRCN0000025060 CCGGCCTGCTTAAAGATTACCCAGTCTCGAGACTGGGTAATCTTTAAGCAGGTTTTT NM_013520.2-411s1c1 Flt3l 
TRCN0000025061 CCGGCGTCAACACCGAGATACATTTCTCGAGAAATGTATCTCGGTGTTGACGTTTTT NM_013520.2-558s1c1 Flt3l 
TRCN0000025059 CCGGCCAGTCACTGTGGCCGTCAATCTCGAGATTGACGGCCACAGTGACTGGTTTTT NM_013520.2-427s1c1 Flt3l 
TRCN0000077058 CCGGGTCGTCTTTGACCTGTCGAATCTCGAGATTCGACAGGTCAAAGACGACTTTTTG NM_008107.2-823s1c1 Gdf1 
TRCN0000077059 CCGGTCCGTGCTCTTCTTCGACAATCTCGAGATTGTCGAAGAAGAGCACGGATTTTTG NM_008107.2-1459s1c1 Gdf1 
TRCN0000077060 CCGGCCTGCGACACTACGAAGACATCTCGAGATGTCTTCGTAGTGTCGCAGGTTTTTG NM_008107.2-1494s1c1 Gdf1 
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TRCN0000067928 CCGGCCAGACAAGATGAACTCCCTTCTCGAGAAGGGAGTTCATCTTGTCTGGTTTTTG NM_145741.2-1636s1c1 Gdf10 
TRCN0000067929 CCGGGCTACAGAGATACGACCCATTCTCGAGAATGGGTCGTATCTCTGTAGCTTTTTG NM_145741.2-1083s1c1 Gdf10 
TRCN0000067930 CCGGGCCTGTGTATTTCTTCAACTTCTCGAGAAGTTGAAGAAATACACAGGCTTTTTG NM_145741.2-633s1c1 Gdf10 
TRCN0000067978 CCGGGCAAAGGAACAGAGAGGCAAACTCGAGTTTGCCTCTCTGTTCCTTTGCTTTTTG XM_125935.4-1439s1c1 Gdf11 
TRCN0000067979 CCGGCGAGTCCTAGAGAACACGAAACTCGAGTTTCGTGTTCTCTAGGACTCGTTTTTG XM_125935.4-757s1c1 Gdf11 
TRCN0000067980 CCGGCCTGCAGATCTTACGACTGAACTCGAGTTCAGTCGTAAGATCTGCAGGTTTTTG XM_125935.4-477s1c1 Gdf11 
TRCN0000055183 CCGGGCAGGCAACTCTTGAAGACTTCTCGAGAAGTCTTCAAGAGTTGCCTGCTTTTTG NM_011819.1-1127s1c1 Gdf15 
TRCN0000055184 CCGGGCCCTGGCAATGCCTGAACAACTCGAGTTGTTCAGGCATTGCCAGGGCTTTTTG NM_011819.1-603s1c1 Gdf15 
TRCN0000055185 CCGGTCAACTGAGGTTCCTGCTGTTCTCGAGAACAGCAGGAACCTCAGTTGATTTTTG NM_011819.1-536s1c1 Gdf15 
TRCN0000068023 CCGGCGTGTATTGATGGAGTCACTACTCGAGTAGTGACTCCATCAATACACGTTTTTG NM_019506.2-1977s1c1 Gdf2 
TRCN0000068024 CCGGCCCAAGGAATATGACGCCTATCTCGAGATAGGCGTCATATTCCTTGGGTTTTTG NM_019506.2-1151s1c1 Gdf2 
TRCN0000068025 CCGGCCAGTACATGATCGACTTGTACTCGAGTACAAGTCGATCATGTACTGGTTTTTG NM_019506.2-367s1c1 Gdf2 
TRCN0000068073 CCGGCCCTTCTCAATGACCACGTATCTCGAGATACGTGGTCATTGAGAAGGGTTTTTG NM_008108.1-1019s1c1 Gdf3 
TRCN0000068074 CCGGGCAGGACTTATGCTACGTGAACTCGAGTTCACGTAGCATAAGTCCTGCTTTTTG NM_008108.1-325s1c1 Gdf3 
TRCN0000068075 CCGGCCGACTGAAGAATTTGGACTTCTCGAGAAGTCCAAATTCTTCAGTCGGTTTTTG NM_008108.1-703s1c1 Gdf3 
TRCN0000068118 CCGGGCTCAGGAAAGGTGTTCTTAACTCGAGTTAAGAACACCTTTCCTGAGCTTTTTG NM_008109.1-2028s1c1 Gdf5 
TRCN0000068119 CCGGGCCAACAACGTGGTGTATAAACTCGAGTTTATACACCACGTTGTTGGCTTTTTG NM_008109.1-1747s1c1 Gdf5 
TRCN0000068120 CCGGCGTGTTTGACATCAGTGCCTTCTCGAGAAGGCACTGATGTCAAACACGTTTTTG NM_008109.1-969s1c1 Gdf5 
TRCN0000088998 CCGGGCCAGGAGAAATAACTTAAATCTCGAGATTTAAGTTATTTCTCCTGGCTTTTTG NM_013526.1-3103s1c1 Gdf6 
TRCN0000088999 CCGGGCTGTCAATCTACAAGACTTACTCGAGTAAGTCTTGTAGATTGACAGCTTTTTG NM_013526.1-409s1c1 Gdf6 
TRCN0000089000 CCGGCGGAGACAGAAGTATTTGTTTCTCGAGAAACAAATACTTCTGTCTCCGTTTTTG NM_013526.1-545s1c1 Gdf6 
TRCN0000068153 CCGGGCCATTAGACTACGAGGCATACTCGAGTATGCCTCGTAGTCTAATGGCTTTTTG NM_013527.1-1137s1c1 Gdf7 
TRCN0000068154 CCGGCCACTTCATGATGTCGCTTTACTCGAGTAAAGCGACATCATGAAGTGGTTTTTG NM_013527.1-276s1c1 Gdf7 
TRCN0000068155 CCGGCGCAAAGGAAAGAGAGTCTGTCTCGAGACAGACTCTCTTTCCTTTGCGTTTTTG NM_013527.1-806s1c1 Gdf7 
TRCN0000068223 CCGGCCAAGTGAAATGTAACTCATTCTCGAGAATGAGTTACATTTCACTTGGTTTTTG NM_008110.1-1557s1c1 Gdf9 
TRCN0000068224 CCGGGCCATGGAACACTTGCTCAAACTCGAGTTTGAGCAAGTGTTCCATGGCTTTTTG NM_008110.1-473s1c1 Gdf9 
TRCN0000068225 CCGGGCCACTTCTTACAGCATCCTTCTCGAGAAGGATGCTGTAAGAAGTGGCTTTTTG NM_008110.1-979s1c1 Gdf9 
TRCN0000111855 CCGGCCGTGTCCCTTCTCACCATATCTCGAGATATGGTGAGAAGGGACACGGTTTTTG NM_008155.1-1759s1c1 Gpi1 
TRCN0000111856 CCGGCCTGAGACTTCCCTCTTTATACTCGAGTATAAAGAGGGAAGTCTCAGGTTTTTG NM_008155.1-653s1c1 Gpi1 
TRCN0000098300 CCGGCCCGATTCCTACTTGGCTTAACTCGAGTTAAGCCAAGTAGGAATCGGGTTTTTG NM_011824.3-771s1c1 Grem1 
TRCN0000098301 CCGGCGCAAGTATCTGAAGCGAGATCTCGAGATCTCGCTTCAGATACTTGCGTTTTTG NM_011824.3-413s1c1 Grem1 
TRCN0000098302 CCGGCCGTTGCATATCCATCGACTTCTCGAGAAGTCGATGGATATGCAACGGTTTTTG NM_011824.3-685s1c1 Grem1 
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TRCN0000248548 CCGGCCTTCCAATCCTGCGCTTTCTCTCGAGAGAAAGCGCAGGATTGGAAGGTTTTTG NM_011825.1-595s21c1 Grem2 
TRCN0000248549 CCGGGCTGGTAAAGGTAGCTGAAACCTCGAGGTTTCAGCTACCTTTACCAGCTTTTTG NM_011825.1-290s21c1 Grem2 
TRCN0000248550 CCGGGCCAATATAGAGGGTAGTAATCTCGAGATTACTACCCTCTATATTGGCTTTTTG NM_011825.1-2026s21c1 Grem2 
TRCN0000089155 CCGGCCTAGAATAACGAGCCATCATCTCGAGATGATGGCTCGTTATTCTAGGTTTTTG NM_008175.2-190s1c1 Grn 
TRCN0000089153 CCGGACTCATCCTGAGTCACCCTATCTCGAGATAGGGTGACTCAGGATGAGTTTTTTG NM_008175.2-1920s1c1 Grn 
TRCN0000066355 CCGGCAGGCATTGTGGATGAGTGTTCTCGAGAACACTCATCCACAATGCCTGTTTTTG NM_010512.2-215s1c1 Igf1 
TRCN0000066357 CCGGTGATCTGAGGAGACTGGAGATCTCGAGATCTCCAGTCTCCTCAGATCATTTTTG NM_010512.2-249s1c1 Igf1 
TRCN0000066428 CCGGCCCTTTGCTATGGTGTCCTTTCTCGAGAAAGGACACCATAGCAAAGGGTTTTTG NM_010548.1-989s1c1 Il10 
TRCN0000066429 CCGGCCCAGAAATCAAGGAGCATTTCTCGAGAAATGCTCCTTGATTTCTGGGTTTTTG NM_010548.1-381s1c1 Il10 
TRCN0000066430 CCGGCGACTCCTTAATGCAGGACTTCTCGAGAAGTCCTGCATTAAGGAGTCGTTTTTG NM_010548.1-276s1c1 Il10 
TRCN0000066458 CCGGCCTGTGGCTTATTTATACTTACTCGAGTAAGTATAAATAAGCCACAGGTTTTTG NM_008350.1-818s1c1 Il11 
TRCN0000066459 CCGGGCTGCACAGATGAGAGACAAACTCGAGTTTGTCTCTCATCTGTGCAGCTTTTTG NM_008350.1-217s1c1 Il11 
TRCN0000066460 CCGGCCGCCGTTTACAGCTCTTGATCTCGAGATCAAGAGCTGTAAACGGCGGTTTTTG NM_008350.1-459s1c1 Il11 
TRCN0000066513 CCGGGCAGACCCTTACAGAGTGAAACTCGAGTTTCACTCTGTAAGGGTCTGCTTTTTG NM_008351.1-702s1c1 Il12a 
TRCN0000066514 CCGGCCTCCTAAACCACCTCAGTTTCTCGAGAAACTGAGGTGGTTTAGGAGGTTTTTG NM_008351.1-200s1c1 Il12a 
TRCN0000066515 CCGGGCACTTCAGAATCACAACCATCTCGAGATGGTTGTGATTCTGAAGTGCTTTTTG NM_008351.1-576s1c1 Il12a 
TRCN0000066568 CCGGCCAGGCCCTATTATGCAAATTCTCGAGAATTTGCATAATAGGGCCTGGTTTTTG NM_008352.1-1508s1c1 Il12b 
TRCN0000066569 CCGGCCATTCCTACTTCTCCCTCAACTCGAGTTGAGGGAGAAGTAGGAATGGTTTTTG NM_008352.1-948s1c1 Il12b 
TRCN0000066570 CCGGGCACGGCAGCAGAATAAATATCTCGAGATATTTATTCTGCTGCCGTGCTTTTTG NM_008352.1-796s1c1 Il12b 
TRCN0000066623 CCGGCCCTGACCAACATCTCCAATTCTCGAGAATTGGAGATGTTGGTCAGGGTTTTTG NM_008355.1-284s1c1 Il13 
TRCN0000066624 CCGGCTGACCCTTAAGGAGCTTATTCTCGAGAATAAGCTCCTTAAGGGTCAGTTTTTG NM_008355.1-160s1c1 Il13 
TRCN0000066625 CCGGCTGCTCAGCTACACAAAGCAACTCGAGTTGCTTTGTGTAGCTGAGCAGTTTTTG NM_008355.1-421s1c1 Il13 
TRCN0000066668 CCGGGCTTCCTAACAAGGAGATAATCTCGAGATTATCTCCTTGTTAGGAAGCTTTTTG NM_008357.1-1056s1c1 Il15 
TRCN0000066669 CCGGGCTGGCATTCATGTCTTCATTCTCGAGAATGAAGACATGAATGCCAGCTTTTTG NM_008357.1-550s1c1 Il15 
TRCN0000066670 CCGGCCAACTGGATAGATGTAAGATCTCGAGATCTTACATCTATCCAGTTGGTTTTTG NM_008357.1-608s1c1 Il15 
TRCN0000066498 CCGGGCCTTTGAAGACTCATAACATCTCGAGATGTTATGAGTCTTCAAAGGCTTTTTG NM_010551.2-4756s1c1 Il16 
TRCN0000066499 CCGGCCTGACTCTCAATGAAGTCTACTCGAGTAGACTTCATTGAGAGTCAGGTTTTTG NM_010551.2-1430s1c1 Il16 
TRCN0000066500 CCGGGACAGCATTTACGGCCCTATTCTCGAGAATAGGGCCGTAAATGCTGTCTTTTTG NM_010551.2-891s1c1 Il16 
TRCN0000066719 CCGGCCTCCAGAATGTGAAGGTCAACTCGAGTTGACCTTCACATTCTGGAGGTTTTTG NM_010552.2-187s1c1 Il17a 
TRCN0000066720 CCGGCTTCACTTTCAGGGTCGAGAACTCGAGTTCTCGACCCTGAAAGTGAAGTTTTTG NM_010552.2-457s1c1 Il17a 
TRCN0000066721 CCGGACCGCAATGAAGACCCTGATACTCGAGTATCAGGGTCTTCATTGCGGTTTTTTG NM_010552.2-297s1c1 Il17a 
TRCN0000066758 CCGGCCAGCCAAGAAGAAATGTGAACTCGAGTTCACATTTCTTCTTGGCTGGTTTTTG NM_019508.1-284s1c1 Il17b 
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TRCN0000066760 CCGGGAAGAGTATGAGCGGAACCTTCTCGAGAAGGTTCCGCTCATACTCTTCTTTTTG NM_019508.1-227s1c1 Il17b 
TRCN0000066761 CCGGCTACGCTCGAATGGAAGAGTACTCGAGTACTCTTCCATTCGAGCGTAGTTTTTG NM_019508.1-214s1c1 Il17b 
TRCN0000066808 CCGGGCTACTCTGCTGAGGAATTATCTCGAGATAATTCCTCAGCAGAGTAGCTTTTTG NM_145834.1-95s1c1 Il17c 
TRCN0000066809 CCGGTCGCATCGACACAGATGAGAACTCGAGTTCTCATCTGTGTCGATGCGATTTTTG NM_145834.1-321s1c1 Il17c 
TRCN0000066810 CCGGCCTACTGGGATGACCCACCAACTCGAGTTGGTGGGTCATCCCAGTAGGTTTTTG NM_145834.1-28s1c1 Il17c 
TRCN0000067414 CCGGGACATTCGAATCTTCAACCAACTCGAGTTGGTTGAAGATTCGAATGTCTTTTTG NM_145856.1-142s1c1 Il17f 
TRCN0000067415 CCGGTCAGGAAGACAGCACCATGAACTCGAGTTCATGGTGCTGTCTTCCTGATTTTTG NM_145856.1-306s1c1 Il17f 
TRCN0000067413 CCGGGCATTTCTGTCCCACGTGAATCTCGAGATTCACGTGGGACAGAAATGCTTTTTG NM_145856.1-170s1c1 Il17f 
TRCN0000054990 CCGGCCTCTCTGTGAAGGATAGTAACTCGAGTTACTATCCTTCACAGAGAGGTTTTTG NM_008360.1-455s1c1 Il18 
TRCN0000054991 CCGGGCTTTCAAACTCATTCTGAAACTCGAGTTTCAGAATGAGTTTGAAAGCTTTTTG NM_008360.1-660s1c1 Il18 
TRCN0000054992 CCGGCGTCAACTTCAAGGAAATGATCTCGAGATCATTTCCTTGAAGTTGACGTTTTTG NM_008360.1-191s1c1 Il18 
TRCN0000066953 CCGGGCTGTGGTATTTATAGCAATACTCGAGTATTGCTATAAATACCACAGCTTTTTG XM_283649.2-962s1c1 Il19 
TRCN0000066954 CCGGGCCTGGATTGACAGGAATCATCTCGAGATGATTCCTGTCAATCCAGGCTTTTTG XM_283649.2-616s1c1 Il19 
TRCN0000066955 CCGGGCAAACTAAGGACACCTTTAACTCGAGTTAAAGGTGTCCTTAGTTTGCTTTTTG XM_283649.2-270s1c1 Il19 
TRCN0000067048 CCGGCCAACCATCTAAAGATGGAAACTCGAGTTTCCATCTTTAGATGGTTGGTTTTTG NM_010554.3-1782s1c1 Il1a 
TRCN0000067049 CCGGCCAGAGTGATTTGAGATACAACTCGAGTTGTATCTCAAATCACTCTGGTTTTTG NM_010554.3-420s1c1 Il1a 
TRCN0000067050 CCGGGCTGCTTATCCAGAGCTGTTTCTCGAGAAACAGCTCTGGATAAGCAGCTTTTTG NM_010554.3-778s1c1 Il1a 
TRCN0000067103 CCGGGCAACCACTTACCTATTTATTCTCGAGAATAAATAGGTAAGTGGTTGCTTTTTG NM_008361.2-1069s1c1 Il1b 
TRCN0000067104 CCGGCCTCAAAGGAAAGAATCTATACTCGAGTATAGATTCTTTCCTTTGAGGTTTTTG NM_008361.2-602s1c1 Il1b 
TRCN0000067105 CCGGCCACCTCAATGGACAGAATATCTCGAGATATTCTGTCCATTGAGGTGGTTTTTG NM_008361.2-506s1c1 Il1b 
TRCN0000067163 CCGGGACCTATACAAGGGAGGTGAACTCGAGTTCACCTCCCTTGTATAGGTCTTTTTG NM_153077.1-290s1c1 Il1f10 
TRCN0000067164 CCGGGAGACCCTGATTCAGACAATTCTCGAGAATTGTCTGAATCAGGGTCTCTTTTTG NM_153077.1-117s1c1 Il1f10 
TRCN0000067165 CCGGCCAGAGAAGGTCTGTATCCTTCTCGAGAAGGATACAGACCTTCTCTGGTTTTTG NM_153077.1-143s1c1 Il1f10 
TRCN0000067213 CCGGGCACGCAGAGAAGGTCATTAACTCGAGTTAATGACCTTCTCTGCGTGCTTTTTG NM_019451.1-205s1c1 Il1f5 
TRCN0000067214 CCGGCCCATCACAGACTTCTACTTTCTCGAGAAAGTAGAAGTCTGTGATGGGTTTTTG NM_019451.1-545s1c1 Il1f5 
TRCN0000067215 CCGGCCTATCTTGTGGGACAGAGAACTCGAGTTCTCTGTCCCACAAGATAGGTTTTTG NM_019451.1-313s1c1 Il1f5 
TRCN0000067263 CCGGCCACTCATTCTGACCCAAGAACTCGAGTTCTTGGGTCAGAATGAGTGGTTTTTG NM_019450.2-576s1c1 Il1f6 
TRCN0000067264 CCGGCGAGATGATTGTGGTACATTACTCGAGTAATGTACCACAATCATCTCGTTTTTG NM_019450.2-623s1c1 Il1f6 
TRCN0000067265 CCGGGCAAACAGTTCCAGTCACTATCTCGAGATAGTGACTGGAACTGTTTGCTTTTTG NM_019450.2-278s1c1 Il1f6 
TRCN0000067298 CCGGCCTGTCATTCTTAGCTTGATACTCGAGTATCAAGCTAAGAATGACAGGTTTTTG XM_130058.1-272s1c1 Il1f8 
TRCN0000067299 CCGGGCTGGTTTATAGCCACCTCTTCTCGAGAAGAGGTGGCTATAAACCAGCTTTTTG XM_130058.1-525s1c1 Il1f8 
TRCN0000067300 CCGGCCTGGGAATCAAGAACAGAAACTCGAGTTTCTGTTCTTGATTCCCAGGTTTTTG XM_130058.1-343s1c1 Il1f8 
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TRCN0000067353 CCGGGCAGGTGTGGATCTTTCGTAACTCGAGTTACGAAAGATCCACACCTGCTTTTTG NM_153511.1-188s1c1 Il1f9 
TRCN0000067354 CCGGCCACCTTTGAATCAGTGGCTTCTCGAGAAGCCACTGATTCAAAGGTGGTTTTTG NM_153511.1-475s1c1 Il1f9 
TRCN0000067355 CCGGGAATCCAGATAAATGCCTGTTCTCGAGAACAGGCATTTATCTGGATTCTTTTTG NM_153511.1-332s1c1 Il1f9 
TRCN0000067198 CCGGGCTGAGAATTTCATCAGCAATCTCGAGATTGCTGATGAAATTCTCAGCTTTTTG NM_008366.2-396s1c1 Il2 
TRCN0000067199 CCGGCATCTCAACAAGCCCTCAATACTCGAGTATTGAGGGCTTGTTGAGATGTTTTTG NM_008366.2-536s1c1 Il2 
TRCN0000067200 CCGGCCTGAGCAGGATGGAGAATTACTCGAGTAATTCTCCATCCTGCTCAGGTTTTTG NM_008366.2-221s1c1 Il2 
TRCN0000067338 CCGGAGAACACTCCTGTCCAAGAATCTCGAGATTCTTGGACAGGAGTGTTCTTTTTTG NM_021380.1-623s1c1 Il20 
TRCN0000067339 CCGGCGTCATCTAGTGAGATTCTATCTCGAGATAGAATCTCACTAGATGACGTTTTTG NM_021380.1-320s1c1 Il20 
TRCN0000067340 CCGGGCAAACCTACAGGCAATACAACTCGAGTTGTATTGCCTGTAGGTTTGCTTTTTG NM_021380.1-179s1c1 Il20 
TRCN0000067398 CCGGCCCATTAACTAAGCAGACATTCTCGAGAATGTCTGCTTAGTTAATGGGTTTTTG NM_021782.1-676s1c1 Il21 
TRCN0000067399 CCGGCCCTGGAAACAATAAGACATTCTCGAGAATGTCTTATTGTTTCCAGGGTTTTTG NM_021782.1-296s1c1 Il21 
TRCN0000067400 CCGGGCCATCAAACCCTGGAAACAACTCGAGTTGTTTCCAGGGTTTGATGGCTTTTTG NM_021782.1-287s1c1 Il21 
TRCN0000067013 CCGGAGTGGAGAGATCAAGGCGATTCTCGAGAATCGCCTTGATCTCTCCACTTTTTTG NM_016971.1-525s1c1 Il22 
TRCN0000067014 CCGGGCTGTTTATGTCTCTGAGAAACTCGAGTTTCTCAGAGACATAAACAGCTTTTTG NM_016971.1-560s1c1 Il22 
TRCN0000067015 CCGGCGACCAGAACATCCAGAAGAACTCGAGTTCTTCTGGATGTTCTGGTCGTTTTTG NM_016971.1-464s1c1 Il22 
TRCN0000067120 CCGGCTTCTCCGTTCCAAGATCCTTCTCGAGAAGGATCTTGGAACGGAGAAGTTTTTG NM_031252.1-593s1c1 Il23a 
TRCN0000067121 CCGGTCTCGGAATCTCTGCATGCTACTCGAGTAGCATGCAGAGATTCCGAGATTTTTG NM_031252.1-221s1c1 Il23a 
TRCN0000065943 CCGGCCGCAGAGCATTCAAACAGTTCTCGAGAACTGTTTGAATGCTCTGCGGTTTTTG NM_053095.1-699s1c1 Il24 
TRCN0000065944 CCGGCTGAGCCTAATCCTTCTTCTTCTCGAGAAGAAGAAGGATTAGGCTCAGTTTTTG NM_053095.1-286s1c1 Il24 
TRCN0000065945 CCGGGTCGCTTTGGTGAAAGCCTTTCTCGAGAAAGGCTTTCACCAAAGCGACTTTTTG NM_053095.1-730s1c1 Il24 
TRCN0000066968 CCGGGAGTTGGACAGGGACTTGAATCTCGAGATTCAAGTCCCTGTCCAACTCTTTTTG NM_080729.1-253s1c1 Il25 
TRCN0000066969 CCGGCCACAACCAGACGGTCTTCTACTCGAGTAGAAGACCGTCTGGTTGTGGTTTTTG NM_080729.1-378s1c1 Il25 
TRCN0000066970 CCGGCGTCCCACTTTACCACAACCACTCGAGTGGTTGTGGTAAAGTGGGACGTTTTTG NM_080729.1-366s1c1 Il25 
TRCN0000067088 CCGGGATACCATCTTCCCAATGTTTCTCGAGAAACATTGGGAAGATGGTATCTTTTTG NM_145636.1-239s1c1 Il27 
TRCN0000067089 CCGGTGCAGGATTCAAATGTTCAAACTCGAGTTTGAACATTTGAATCCTGCATTTTTG NM_145636.1-459s1c1 Il27 
TRCN0000067090 CCGGTGCTTCTGGTACAAGCTGGTTCTCGAGAACCAGCTTGTACCAGAAGCATTTTTG NM_145636.1-56s1c1 Il27 
TRCN0000077023 CCGGCGGAGAGTAAACCTGTCCAAACTCGAGTTTGGACAGGTTTACTCTCCGTTTTTG NM_010556.2-247s1c1 Il3 
TRCN0000077024 CCGGCCACCGTTTAACCAGAACGTTCTCGAGAACGTTCTGGTTAAACGGTGGTTTTTG NM_010556.2-129s1c1 Il3 
TRCN0000077025 CCGGGCTCTATTGTCAAGGAGATTACTCGAGTAATCTCCTTGACAATAGAGCTTTTTG NM_010556.2-158s1c1 Il3 
TRCN0000247082 CCGGACCGGCTTCAGTACATGAAACCTCGAGGTTTCATGTACTGAAGCCGGTTTTTTG NM_029646.2-708s21c1 Il34 
TRCN0000247083 CCGGATGCAATGTACAGCTACAAATCTCGAGATTTGTAGCTGTACATTGCATTTTTTG NM_029646.2-1293s21c1 Il34 
TRCN0000247084 CCGGATGGACTCTGACCCAAGATAACTCGAGTTATCTTGGGTCAGAGTCCATTTTTTG NM_029646.2-640s21c1 Il34 
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TRCN0000067448 CCGGGAAGAACTCTAGTGTTCTCATCTCGAGATGAGAACACTAGAGTTCTTCTTTTTG NM_021283.1-354s1c1 Il4 
TRCN0000067449 CCGGGCACCATGAATGAGTCCAAGTCTCGAGACTTGGACTCATTCATGGTGCTTTTTG NM_021283.1-428s1c1 Il4 
TRCN0000067450 CCGGGCTTCCAAGGTGCTTCGCATACTCGAGTATGCGAAGCACCTTGGAAGCTTTTTG NM_021283.1-298s1c1 Il4 
TRCN0000067503 CCGGGCCAAGGATAACCTTGAATTTCTCGAGAAATTCAAGGTTATCCTTGGCTTTTTG NM_010558.1-679s1c1 Il5 
TRCN0000067504 CCGGAGAAATACATTGACCGCCAAACTCGAGTTTGGCGGTCAATGTATTTCTTTTTTG NM_010558.1-324s1c1 Il5 
TRCN0000067505 CCGGGCTATGCATTGGAGAAATCTTCTCGAGAAGATTTCTCCAATGCATAGCTTTTTG NM_010558.1-223s1c1 Il5 
TRCN0000067603 CCGGGCTCGCAAGTTGAAGCAATTTCTCGAGAAATTGCTTCAACTTGCGAGCTTTTTG NM_008371.2-498s1c1 Il7 
TRCN0000067604 CCGGGCATGTTTCCTAAAGAGACTACTCGAGTAGTCTCTTTAGGAAACATGCTTTTTG NM_008371.2-642s1c1 Il7 
TRCN0000067643 CCGGCCGTCCCAACTGATGATTGTACTCGAGTACAATCATCAGTTGGGACGGTTTTTG NM_008373.1-188s1c1 Il9 
TRCN0000067644 CCGGGCAGGCAACACACTGTCATTTCTCGAGAAATGACAGTGTGTTGCCTGCTTTTTG NM_008373.1-367s1c1 Il9 
TRCN0000067645 CCGGGACACCAATTACCTTATTGAACTCGAGTTCAATAAGGTAATTGGTGTCTTTTTG NM_008373.1-100s1c1 Il9 
TRCN0000067058 CCGGAGGCTGAAGGAGACAGTGAAACTCGAGTTTCACTGTCTCCTTCAGCCTTTTTTG NM_054079.1-488s1c1 Iltifb 
TRCN0000067059 CCGGCATCGTCAACCGCACCTTTATCTCGAGATAAAGGTGCGGTTGACGATGTTTTTG NM_054079.1-202s1c1 Iltifb 
TRCN0000067060 CCGGCAGTGCTAAGGATCAGTGCTACTCGAGTAGCACTGATCCTTAGCACTGTTTTTG NM_054079.1-298s1c1 Iltifb 
TRCN0000067871 CCGGCTACGAGATATGGTAATACAACTCGAGTTGTATTACCATATCTCGTAGTTTTTG NM_013598.1-405s1c1 Kitl 
TRCN0000067872 CCGGGCCTTATACTGGAAGAAGAAACTCGAGTTTCTTCTTCCAGTATAAGGCTTTTTG NM_013598.1-897s1c1 Kitl 
TRCN0000067908 CCGGGCCCTGCTACAACACAGCCATCTCGAGATGGCTGTGTTGTAGCAGGGCTTTTTG NM_010094.2-238s1c1 Lefty1 
TRCN0000067911 CCGGTCTGGGCACTGTCGCTGGTTACTCGAGTAACCAGCGACAGTGCCCAGATTTTTG NM_010094.2-80s1c1 Lefty1 
TRCN0000067909 CCGGCACCATTGAATGGCTGCGCTTCTCGAGAAGCGCAGCCATTCAATGGTGTTTTTG NM_010094.2-486s1c1 Lefty1 
TRCN0000066113 CCGGCACCATTGAATGGCTGAGAGTCTCGAGACTCTCAGCCATTCAATGGTGTTTTTG NM_177099.3-500s1c1 Lefty2 
TRCN0000066114 CCGGGCCCATGATTGTCAGTGTGAACTCGAGTTCACACTGACAATCATGGGCTTTTTG NM_177099.3-1043s1c1 Lefty2 
TRCN0000066115 CCGGGAACAGGTCCTGAGCAGTCTACTCGAGTAGACTGCTCAGGACCTGTTCTTTTTG NM_177099.3-138s1c1 Lefty2 
TRCN0000067993 CCGGGCGCCAATGCTCTCTTCATTTCTCGAGAAATGAAGAGAGCATTGGCGCTTTTTG NM_008501.1-347s1c1 Lif 
TRCN0000067996 CCGGCATGACAGACTTCCCATCTTTCTCGAGAAAGATGGGAAGTCTGTCATGTTTTTG NM_008501.1-429s1c1 Lif 
TRCN0000068038 CCGGTGGCTTCTCTTTGAGCAACAACTCGAGTTGTTGCTCAAAGAGAAGCCATTTTTG NM_010735.1-423s1c1 Lta 
TRCN0000068039 CCGGGCACACGAGGTCCAGCTCTTTCTCGAGAAAGAGCTGGACCTCGTGTGCTTTTTG NM_010735.1-547s1c1 Lta 
TRCN0000068040 CCGGTCTGTGTATCCGGGACTTCAACTCGAGTTGAAGTCCCGGATACACAGATTTTTG NM_010735.1-613s1c1 Lta 
TRCN0000068090 CCGGCGAGAGGGTCTACGTTAACATCTCGAGATGTTAACGTAGACCCTCTCGTTTTTG NM_008518.1-834s1c1 Ltb 
TRCN0000068091 CCGGGCCAAGAAGAAGCGTTTCTGACTCGAGTCAGAAACGCTTCTTCTTGGCTTTTTG NM_008518.1-518s1c1 Ltb 
TRCN0000067343 CCGGGCACCGCTGTTCTTTGAGCCTCTCGAGAGGCTCAAAGAACAGCGGTGCTTTTTG NM_010798.1-449s1c1 Mif 
TRCN0000067344 CCGGCCGGGTCTACATCAACTATTACTCGAGTAATAGTTGATGTAGACCCGGTTTTTG NM_010798.1-360s1c1 Mif 
TRCN0000067345 CCGGCCAGAACCGCAACTACAGTAACTCGAGTTACTGTAGTTGCGGTTCTGGTTTTTG NM_010798.1-294s1c1 Mif 
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TRCN0000068168 CCGGCCCAAGCAGTACAATGCCTATCTCGAGATAGGCATTGTACTGCTTGGGTTTTTG NM_013611.3-823s1c1 Nodal 
TRCN0000068169 CCGGCTGGACTTTCACGTTTGACTTCTCGAGAAGTCAAACGTGAAAGTCCAGTTTTTG NM_013611.3-219s1c1 Nodal 
TRCN0000068170 CCGGCAGGTGGACTTCAACCTGATTCTCGAGAATCAGGTTGAAGTCCACCTGTTTTTG NM_013611.3-778s1c1 Nodal 
TRCN0000065593 CCGGCGGCACAATATCCTCGGCATACTCGAGTATGCCGAGGATATTGTGCCGTTTTTG XM_137493.3-465s1c1 Osm 
TRCN0000065594 CCGGCAACACCAGATGTCTTTAATACTCGAGTATTAAAGACATCTGGTGTTGTTTTTG XM_137493.3-580s1c1 Osm 
TRCN0000065595 CCGGGAATCACTCTTGGAGCCCTATCTCGAGATAGGGCTCCAAGAGTGATTCTTTTTG XM_137493.3-234s1c1 Osm 
TRCN0000065598 CCGGGCTGCCCTAAATCTTCTGGAACTCGAGTTCCAGAAGATTTAGGGCAGCTTTTTG NM_009402.1-435s1c1 Pglyrp1 
TRCN0000065599 CCGGCCATCTGGAATCCCATGTCTACTCGAGTAGACATGGGATTCCAGATGGTTTTTG NM_009402.1-355s1c1 Pglyrp1 
TRCN0000301445 CCGGCCCACTTCATAACCTCCAGATCTCGAGATCTGGAGGTTATGAAGTGGGTTTTTG NM_023785.2-130s21c1 Ppbp 
TRCN0000301446 CCGGCCTGCAATTTATGGTCTATTTCTCGAGAAATAGACCATAAATTGCAGGTTTTTG NM_023785.2-636s21c1 Ppbp 
TRCN0000301448 CCGGCGTCAAGAGAATCGTCATGAACTCGAGTTCATGACGATTCTCTTGACGTTTTTG NM_023785.2-388s21c1 Ppbp 
TRCN0000201714 CCGGGACGAGTGGATGCGGATAATACTCGAGTATTATCCGCATCCACTCGTCTTTTTTG NM_009129.1-328s1c1 Scg2 
TRCN0000217809 CCGGCTATGATAGTGTTGGCTAATGCTCGAGCATTAGCCAACACTATCATAGTTTTTTG NM_009129.2-2244s1c1 Scg2 
TRCN0000219456 CCGGCTTAGCCAGGATGCTAGTTAACTCGAGTTAACTAGCATCCTGGCTAAGTTTTTG NM_009129.2-1670s1c1 Scg2 
TRCN0000190171 CCGGCTAGCCTACCATTAAGCCACTCTCGAGAGTGGCTTAATGGTAGGCTAGTTTTTTG NM_170727.1-305s1c1 Scgb3a1 
TRCN0000192491 CCGGCTCTGGTGTTGCTTTCTTCATCTCGAGATGAAGAAAGCAACACCAGAGTTTTTTG NM_054037.1-102s1c1 Scgb3a1 
TRCN0000202129 CCGGCCATTGGATCCTCTCATAGAGCTCGAGCTCTATGAGAGGATCCAATGGTTTTTTG NM_170727.1-364s1c1 Scgb3a1 
TRCN0000190210 CCGGCCTGTAAGACTGTACTGGAGACTCGAGTCTCCAGTACAGTCTTACAGGTTTTTTG NM_020519.1-174s1c1 Slurp1 
TRCN0000190254 CCGGCTTCCGATGCTATACCTGTGACTCGAGTCACAGGTATAGCATCGGAAGTTTTTTG NM_020519.1-94s1c1 Slurp1 
TRCN0000192879 CCGGGCCATTAACTCATGCAAGAATCTCGAGATTCTTGCATGAGTTAATGGCTTTTTTG NM_020519.1-125s1c1 Slurp1 
TRCN0000009602 CCGGGAGGTCAAAGTCTAGGAGTTTCTCGAGAAACTCCTAGACTTTGACCTCTTTTT NM_009263.1-678s1c1 Spp1 
TRCN0000054699 CCGGAGGATGACTTTAAGCAAGAAACTCGAGTTTCTTGCTTAAAGTCATCCTTTTTTG NM_009263.1-416s1c1 Spp1 
TRCN0000066843 CCGGCCCAGTCCAAATCTCTGGATACTCGAGTATCCAGAGATTTGGACTGGGTTTTTG NM_009379.2-1112s1c1 Thpo 
TRCN0000066846 CCGGCCCTTTGTCTATCCCTGTTCTCTCGAGAGAACAGGGATAGACAAAGGGTTTTTG NM_009379.2-554s1c1 Thpo 
TRCN0000066183 CCGGGCTATCTCATACCAGGAGAAACTCGAGTTTCTCCTGGTATGAGATAGCTTTTTG NM_013693.1-640s1c1 Tnf 
TRCN0000066184 CCGGCGATGGGTTGTACCTTGTCTACTCGAGTAGACAAGGTACAACCCATCGTTTTTG NM_013693.1-549s1c1 Tnf 
TRCN0000066186 CCGGCCTCCCTCTCATCAGTTCTATCTCGAGATAGAACTGATGAGAGGGAGGTTTTTG NM_013693.1-357s1c1 Tnf 
TRCN0000066234 CCGGCGGAGAAGCAACTCAGCTTTACTCGAGTAAAGCTGAGTTGCTTCTCCGTTTTTG NM_009425.1-449s1c1 Tnfsf10 
TRCN0000066235 CCGGCGCTTCCAAGATGGTCTCAAACTCGAGTTTGAGACCATCTTGGAAGCGTTTTTG NM_009425.1-649s1c1 Tnfsf10 
TRCN0000066236 CCGGGCTCATTGAAGAGGTGACTTTCTCGAGAAAGTCACCTCTTCAATGAGCTTTTTG NM_009425.1-316s1c1 Tnfsf10 
TRCN0000066284 CCGGCCCAAGTTCTCATAACCTGATCTCGAGATCAGGTTATGAGAACTTGGGTTTTTG NM_011613.2-913s1c1 Tnfsf11 
TRCN0000066285 CCGGCGCAGATGGATCCTAACAGAACTCGAGTTCTGTTAGGATCCATCTGCGTTTTTG NM_011613.2-387s1c1 Tnfsf11 
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TRCN0000066286 CCGGCATGACGTTAAGCAACGGAAACTCGAGTTTCCGTTGCTTAACGTCATGTTTTTG NM_011613.2-760s1c1 Tnfsf11 
TRCN0000066324 CCGGCCTAACCTACTTTGGACTCTTCTCGAGAAGAGTCCAAAGTAGGTTAGGTTTTTG NM_011614.1-717s1c1 Tnfsf12 
TRCN0000066325 CCGGCCTCGAAGAAGTGCTCCTAAACTCGAGTTTAGGAGCACTTCTTCGAGGTTTTTG NM_011614.1-271s1c1 Tnfsf12 
TRCN0000066326 CCGGGTACCTTTCTTGGAACAACTACTCGAGTAGTTGTTCCAAGAAAGGTACTTTTTG NM_011614.1-244s1c1 Tnfsf12 
TRCN0000076983 CCGGTGGCTAGACAAAGGACAAGGACTCGAGTCCTTGTCCTTTGTCTAGCCATTTTTG NM_023517.1-1334s1c1 Tnfsf13 
TRCN0000076984 CCGGCGGTTGCTCTTTGGTTGAGTTCTCGAGAACTCAACCAAAGAGCAACCGTTTTTG NM_023517.1-628s1c1 Tnfsf13 
TRCN0000076985 CCGGGCAGGTGTCTTTCATTTACATCTCGAGATGTAAATGAAAGACACCTGCTTTTTG NM_023517.1-1182s1c1 Tnfsf13 
TRCN0000066368 CCGGGCCATTCTCAACATGATGATACTCGAGTATCATCATGTTGAGAATGGCTTTTTG NM_033622.1-671s1c1 Tnfsf13b 
TRCN0000066369 CCGGGCTCCGAGAAAGGAGAAGATACTCGAGTATCTTCTCCTTTCTCGGAGCTTTTTG NM_033622.1-263s1c1 Tnfsf13b 
TRCN0000066370 CCGGCTCGGGAGAATGCACAGATTTCTCGAGAAATCTGTGCATTCTCCCGAGTTTTTG NM_033622.1-1079s1c1 Tnfsf13b 
TRCN0000066398 CCGGGCCCGGTTACTACTATGTGTACTCGAGTACACATAGTAGTAACCGGGCTTTTTG NM_019418.1-528s1c1 Tnfsf14 
TRCN0000066400 CCGGGAGAAGCTGATACAAGATCAACTCGAGTTGATCTTGTATCAGCTTCTCTTTTTG NM_019418.1-358s1c1 Tnfsf14 
TRCN0000066399 CCGGCAGGTCCTATTTCGGAGCTTTCTCGAGAAAGCTCCGAAATAGGACCTGTTTTTG NM_019418.1-813s1c1 Tnfsf14 
TRCN0000066434 CCGGCGAGAGCACACCTGACAATTACTCGAGTAATTGTCAGGTGTGCTCTCGTTTTTG NM_177371.1-287s1c1 Tnfsf15 
TRCN0000066435 CCGGCCCAGAGTCAGGAGACTATTTCTCGAGAAATAGTCTCCTGACTCTGGGTTTTTG NM_177371.1-426s1c1 Tnfsf15 
TRCN0000066436 CCGGCCGCCTACTAACAGGGTCCAACTCGAGTTGGACCCTGTTAGTAGGCGGTTTTTG NM_177371.1-579s1c1 Tnfsf15 
TRCN0000066529 CCGGGCAGAACAATTCGGTTGTCATCTCGAGATGACAACCGAATTGTTCTGCTTTTTG NM_009452.1-414s1c1 Tnfsf4 
TRCN0000066531 CCGGCGATGGTCGAAGGATTGTCTTCTCGAGAAGACAATCCTTCGACCATCGTTTTTG NM_009452.1-546s1c1 Tnfsf4 
TRCN0000066728 CCGGGCTGCATTACTTACAGGTCAACTCGAGTTGACCTGTAAGTAATGCAGCTTTTTG NM_009403.2-823s1c1 Tnfsf8 
TRCN0000066729 CCGGGCGATCATTCTGGTACTGGTACTCGAGTACCAGTACCAGAATGATCGCTTTTTG NM_009403.2-404s1c1 Tnfsf8 
TRCN0000066730 CCGGCCTGGCTTGTACTTCATCGTTCTCGAGAACGATGAAGTACAAGCCAGGTTTTTG NM_009403.2-647s1c1 Tnfsf8 
TRCN0000077039 CCGGCCTGCGGTTAATGTTCGGGATCTCGAGATCCCGAACATTAACCGCAGGTTTTTG NM_009404.1-175s1c1 Tnfsf9 
TRCN0000077040 CCGGAGAACAAGTTAGTGGACCGTTCTCGAGAACGGTCCACTAACTTGTTCTTTTTTG NM_009404.1-746s1c1 Tnfsf9 
TRCN0000077041 CCGGCGTTGTGCAATACAACTCTGACTCGAGTCAGAGTTGTATTGCACAACGTTTTTG NM_009404.1-473s1c1 Tnfsf9 
TRCN0000076993 CCGGCCACTGGTGTTTATTCTTTAACTCGAGTTAAAGAATAAACACCAGTGGTTTTTG NM_021367.1-521s1c1 Tslp 
TRCN0000076994 CCGGCCTTCATGCAATCTCCAGAATCTCGAGATTCTGGAGATTGCATGAAGGTTTTTG NM_021367.1-418s1c1 Tslp 
TRCN0000076995 CCGGGCTACCCTGAAACTGAGAGAACTCGAGTTCTCTCAGTTTCAGGGTAGCTTTTTG NM_021367.1-316s1c1 Tslp 
TRCN0000065448 CCGGGTGCTGATCCAGAAGCCAAATCTCGAGATTTGGCTTCTGGATCAGCACTTTTTG NM_008510.1-226s1c1 Xcl1 
TRCN0000065450 CCGGGCAGCGATCAAGACTGTGGATCTCGAGATCCACAGTCTTGATCGCTGCTTTTTG NM_008510.1-255s1c1 Xcl1 
TRCN0000065449 CCGGAGAAGAGAGTAGCTGTGTGAACTCGAGTTCACACAGCTACTCTCTTCTTTTTTG NM_008510.1-101s1c1 Xcl1 
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forward primer sequence reverse primer sequence 
Ccl8 150+ cacctgctgctttcatgtac Ccl8 260- ttggtctggaaaaccacagc 
Ccl9 335+ tgcctgtcctataactcacg Ccl9 471- tctctgaactctccgatcac 
Ccl17 127+ gagtgctgcctggattactt Ccl17 249- ggtctgcacagatgagcttg 
Ccl22 253+ ctctgccatcacgtttagtg Ccl22 389- atggagtagcttcttcaccc 
Cmtm2a 341+ gatcctgctcatctgtatgg Cmtm2a 480- caaggaacacacaggagaac 
Cmtm4 270+ ctgcatcgagactatcatgg Cmtm4 396- cctcatatgaaggttgaggc 
Cmtm5 264+ gacaagaccttcctgtcttc Cmtm5 380- gtgtgatgaggaactctagc 
Cmtm6 195+ tctgtgaagaggttgtgtcc Cmtm6 316- ttccagtatccactctgtcg 
Cmtm7 251+ gcgacctgataatgatcctc Cmtm7 400- tggaggctatcactatggag 
Cmtm8 278+ tcctttgcggagaacttctc Cmtm8 401- tgagagtccacaccagcag 
Ctf2 159+ agaagaacacgtcagcactg Ctf2 309- tctgcatcttccatggcatg 
Cx3cl1 531+ catctctctcaacttccgag Cx3cl1 652- attggtagacagcaggactc 
Cxcl2 140+ agtgaactgcgctgtcaatg Cxcl2 259- gagagtggctatgacttctg 
Cxcl5 145+ ttctgttgctgttcacgctg Cxcl5 286- gggatcacctccaaattagc 
Cxcl9 125+ atcatcttcctggagcagtg Cxcl9 303- tctccgttcttcagtgtagc 
Cxcl10 127+ ctgcaactgcatccatatcg Cxcl10 270- ggattcagacatctctgctc 
Cxcl12 244+ agccaacgtcaagcatctg Cxcl12 270- caggtactcttggatccac 
Cxcl14 441+ ggtccaagtgtaagtgttcc Cxcl14 571- cctggacatgctcttggtg 
Ebi3 545+ gctaaatgtcactgcagtgc Ebi3 725- cttgagagagaagatgtccg 
Fasl 432+ ccacaacacaaatctgtggc Fasl 566- ctttggttggtgaactcacg 
Flt3L 399+ gctggatagagcaactgaag Flt3I 639- gatgttggtctggacgaatc 
Gdf3 190+ cgagtttcaagactctgacc Gdf3 350- gctccttcacgtagcataag 
Gdf10 1443+ cctgaaggtggattttgcag Gdf10 1597- cagctctgacgatgctctg 
Gdf15 716+ agaggactcgaactcagaac Gdf15 879- tcagcaggagcagcgctc 
Grem1 121+ cacagcgaagaacctgagg Grem1 295- tctgctcagagtcattgtgc 
IL1f9 491+ ttgtgacagttccacgaagc IL1f9 650- ggtgtccattaacttccttac 
IL12b 199+ atcgttttgctggtgtctcc IL12b 344- gtccaggtgatgtcatcttc 
IL18 348+ cctgtgttcgaggatatgac IL18 491- ggagagggtagacattttac 
IL21 65+ ccttgtctgtctggtagtc IL21 223- ggagctgatagaagttcagg 
IL22 178+ ttgaggtgtccaacttccag IL22 333- tgcttcatcaggtagcactg 
Iltifb 171+ agcttgaggtgtccaacttc Iltifb 310- atccttagcactgactcctc 
Osm 106+ gaacactgctcagtttgacc Osm 230- gctccaagagtgattctgtg 
Pglyrp1 366+ cccatgtctattggcatcac Pglyrp1 490- tagttggatctcaggaagcc 
Spp1 390+ acagaatgctgtgtcctctg Spp1 551- tcagattcatccgagtccac 
Tnf 159+ gagcacagaaagcatgatcc Tnf 291- tcagtagacagaagagcgtg 
Tnfsf10 81+ tcagtcagcacttcaggatg Tnfsf10 240- tccgtctttgagaagcaagc 
Tnfsf14 151+ tttgtggtggatggacagac Tnfsf14 303- atgcagtctcaggagaaacc 
β-actin 848+ ttgctgacaggatgcagaag β-actin 992- atccacatctgctggaaggt 
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